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Abstract 
Ischaemia and reperfusion injury (IRI) in renal allografts is an important contributing 
factor to chronic allograft dysfunction. MicroRNAs (miRNA) have been shown to play 
important roles in cellular adaptation to pathological conditions, including IRI. This study 
aimed to evaluate changes in miRNA profile following IRI, and how the changes in particular 
miRNAs may influence renal proximal tubular epithelial cell (PTEC) morphology and 
function, potentially contributing to the development of chronic allograft dysfunction. To 
achieve this, several objectives were set. These included: (1) isolation and culture of primary 
human PTECs, (2) miRNA expression profiling following IRI and selection of candidate 
miRNA, and (3) in vitro and human pathology validation to explore the molecular mechanism 
of the candidate miRNA. 
Primary PTECs were isolated from normal renal tissue. These cells showed features of 
epithelial cells under light microscope and electron microscope. The cells were also 
characterised using immunofluorescent staining, which showed positive expression of 
epithelial cell markers, and negative expression for mesenchymal cell markers. MiRNA 
profiling using NanoString platform was performed on cell lines (HKC-8 and HK-2) and 
primary PTECs, which were exposed to either hypoxia or free radicals. Results revealed 
distinct miRNA signature changes following IRI in cells. However, only a small proportion of 
microRNAs were found to be significantly up/down-regulated in either cell lines or primary 
cells, which included miR-21, miR-376, miR-190b, miR-34a, miR-210, miR-363, miR-142 
and miR-130b. MiR-21 was shown to be up-regulated in all cells following both type of 
injuries. Online target prediction analysis also showed miR-21 to be involved in pathways 
relevant to cellular response to IRI and the development of fibrosis. 
The role of miR-21 was studied in detail. Up-regulation of miR-21 following ischaemia 
was shown to suppress SMAD7 and facilitate intra-nuclear localisation of SMAD3. In the 
presence of exogenous TGF-b1 or hypoxia, over-expression of miR-21 in cells led to an 
increase in SMAD3 activity. Over-expression of miR-21 also led to phenotypic shift in HKC-
8 cells, characterised as a decrease in E-cadherin and an increase in a-SMA and Collagen-1 
expression. Human pathology evaluation confirmed high expression of miR-21 in the tubular 
cells of severely ischaemic kidneys compared to non-ischaemic kidneys. 
In conclusion, changes in miRNA profile were observed in acute IRI in the kidney. One of the 
significantly affected miRNAs was miR-21. MiR-21 up-regulation resulted in sensitisation of 
tubular cells to TGF-b1, which may be essential in cellular repair processes, but may also 
contribute to deterioration of long-term organ function. 
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Chapter 1. Introduction 
1.1. Chronic Kidney Disease & Kidney Transplantation 
1.1.1. CKD: Overview & Epidemiology 
The universal definition of chronic kidney disease developed by the National Kidney 
Foundation, 2002, encompasses any structural or functional abnormalities of the kidney 
remittent for more than 3 months. CKD may be present with or without reduction in 
glomerular filtration rate (GFR) and manifest by either pathological abnormalities or detection 
of markers of kidney damage in blood or urine, or using available imaging tests (National 
Kidney Foundation, 2002). Based on the classification developed by the National Kidney 
Foundation-Kidney Disease Improving Global Outcomes team (NKF-KDIGO), CKD is 
classified into clinical stages, based on the severity of GFR loss and degree of albuminuria, 
which is associated with disease progression and prognosis. 
 
 
Figure 1-1 Classification and prognosis of CKD 
Clinical stages  and prognosis of CKD based on GFR and albuminuria according to the National 
Kidney Foundation (National Kidney Foundation-Kidney Disease Improving Global Outcomes, 2012)  
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As seen from Figure 1-1, CKD is a disease entity with a wide spectrum of severity. 
Although the classification and definition may appear to be robust and clear, it has been 
proven difficult to estimate the magnitude of problems related to CKD. CKD is not associated 
with the presence of pathognomonic signs and symptoms; thus, successful early detection of 
CKD relies largely on the availability of supplementary tests as well as on the identification of 
population at risk.   
Moreover, CKD is not a solitary disease entity, but is associated with many underlying 
diseases (e.g. glomerulonephritis, urinary tract stone disease, hypertension, and diabetes). In 
addition, it is associated with many complications (e.g. cardiovascular diseases, anaemia, 
mineral and bone disorders). The kidneys, through their involvement in regulation of blood 
pressure, acid-base and electrolyte balance, and other homeostatic functions, also play pivotal 
role in initiating or exacerbating systemic complications of a disease. The relationship 
between CKD with poor patient outcomes, especially with the incidence of end-stage renal 
disease, cardiovascular complications and early mortality highlights the importance of 
adequate and prompt management of CKD. Furthermore, recent reports have identified CKD 
as a growing global health problem. Analysis from 188 countries for the global burden of 
disease documented an increase in mortality related to CKD in 2013 compared to year 1990, 
regardless of the underlying cause. (GBD 2013 Mortality and Causes of Death Collaborators, 
2015). Regardless, it is likely that this rate is an underestimation, since it does not take into 
account the number of CKD-related cardiovascular events leading to mortality. 
1.1.2. The Role of Kidney Transplantation in Alleviating the Global Burden of CKD 
Since the first successful transplant performed by Dr. Joseph Murray in 1954, kidney 
transplantation has evolved from a therapeutic modality for a selected few to a routine 
procedure offered to wide spectrum of patients, aimed to not only enhance quality of life, but 
also to save life. Previously only considered as an adjunct to dialysis, kidney transplantation 
has currently emerged as a therapy of choice for end-stage renal diseases (ESRD). A series of 
studies describe the importance of kidney transplantation as an integral component of renal 
replacement therapy, both from medical perspective as well as from health economic 
standpoint. 
One of the earliest evidence highlighting the pivotal role of kidney transplantation was 
published by Wolfe et al., which reported a survival advantage in patients receiving a kidney 
transplant from a deceased donor compared to patients who remained on the waiting list 
(Wolfe et al., 1999). The benefit of transplantation is observed even in high-risk groups, such 
as elderly patients and patients with diabetes. Relative risk death is better in transplanted 
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patients, even after considering the risk of surgery, early complications, infections and 
cardiovascular events. The significance of transplantation is further emphasised by the 
negative effect of longer time in dialysis before transplantation on the post-transplant 
mortality rate, suggesting that dialysis is associated with more complication, such as infection 
and impaired cardiovascular dynamics (Cosio et al., 1998; Pesavento, 2009). 
Numerous studies on cost-analysis of kidney transplantation have also been published. 
Although results may vary between different countries and regions, it is generally accepted 
that kidney transplantation has a significantly higher first-year cost compared to maintenance 
dialysis. This initial higher cost, however, decreases significantly during subsequent years 
post-transplant and falls considerably below the cost of chronic maintenance dialysis. Overall, 
transplantation generally reduces overall cost associated with the management of ESRD.  
Despite global disparities in its uptake, kidney transplantation clearly plays a pivotal 
role in alleviating global burden of CKD, even more, considering its much-improved outcome 
and cost-effectiveness. With a steady increase in CKD prevalence worldwide, and limited 
health budgets, kidney transplantation should appeal as a therapeutic option for CKD, hence, 
the number is expected to continue to rise.   
1.1.3. Chronic Graft Loss in Kidney Transplantation; Magnitude of the Problem 
The literature uses interchangeable terminologies to describe chronic graft loss. 
Chronic allograft dysfunction is a terminology used to describe deterioration of function, 
primarily related to the development of fibrosis and glomerulosclerosis. The term chronic 
reflects the persistent and ongoing loss of function, and the late occurrence of a clinically 
detectable injury. The use of term chronic graft loss, however, is not always the same across 
different publications. Some literatures reserve the use of this term specifically for long-term 
functional loss, in which no clear aetiology could be identified, as in the cases related to initial 
IRI.  Others adopt the term more generally to include other causes, such as due to the use of 
nephrotoxic agents or chronic rejection. 
Successful efforts have been made to improve short-term allograft survival and patient 
survival through advancement in immunosuppressive therapy, better organ allocation and 
careful recipient selection. Despite the short-term improvement achieved, transplanted organs 
are still lost in the longer-term. This can be attributed to immunologic and non-immunologic 
events that occur from the time of the transplant procedure as well as de novo events arising at 
later time points post-transplant. Chronic graft loss affects all solid organ transplantation, with 
varying degrees of severity, regardless of the source of donor. Data from National Health 
Service Blood and Transplant (NHSBT) in the United Kingdom, documented a steady decline 
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in long-term graft survival in both adult and paediatric kidney transplant cohorts. There is 5-
15% reported graft loss at 10-year post-transplant in recipients receiving organs from living 
donors (NHSBT, 2017). The rate of graft loss increases to approximately 20-30% in 
transplantation from donors after brain death and circulatory death (NHSBT, 2017). Indeed, 
available data suggests that chronic graft loss remains one of the biggest hurdles in kidney 
transplantation.  
The rate of long-term graft loss is not expected to decrease unless the contributing 
factors are identified and prevention strategies developed. One of these contributing factors is 
ischaemia reperfusion injury (IRI) that leads to acute allograft injury. As the global burden of 
CKD steadily increases, the demand for kidney transplantation is also expected to rise. To 
meet this increasing demand and to overcome potential shortage of available donors, several 
strategies have been introduced, including the use of extended criteria donor. Inadvertently, 
however, this also means increasing the use of organs with more severe IRI, and therefore 
escalates the likelihood of earlier deterioration of function, increasing the prospect of 
developing chronic allograft dysfunction. 
1.1.4. Chronic Graft Loss as a Consequence of Acute Kidney Injury 
An increasing number of clinical epidemiology studies have reported an association 
between acute kidney injury (AKI) and the development of CKD. One of the clearest finding 
is described by Mammen et al. in a large paediatric intensive care unit cohort, in which only 1 
of 126 patients had CKD at immediately post discharge. However, the percentage of patients 
developing CKD increased to 10.3% during 1-3 years follow-up period. In addition, 46.8% of 
patients in this study developed hypertension, microalbuminuria or mildly decreased GFR, 
which are considered risk factors for CKD (Mammen et al., 2012; Heung and Chawla, 2014).  
In the context of IRI, a transplant cohort serves as an ideal model to investigate the link 
between acute ischaemic injury and development of late organ dysfunction. Acute ischaemic 
injury in kidney transplantation manifests clinically as delayed graft function (DGF). DGF is 
associated with prolonged hospitalisation and the need for renal replacement therapy post-
transplant. Nevertheless, recovery of organ function is usually achieved in patients with DGF, 
indicating a degree of resolution of acute ischaemic injury. Interestingly, regardless of this 
short-term resolution of function, DGF is still associated with increased risk of long-term 
graft loss, earlier functional deterioration and higher probability of rejection. This indicates an 
apparent association between acute events caused by ischaemia and persistent cellular 
damage, which impacts long-term function. Despite the well-established epidemiological link 
between AKI and CKD, available evidence to explain the causative relationship between the 
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two clinical entities is still lacking (Rifkin et al., 2012). This is one of the reasons that 
highlights the significance of my work.  
1.2. Delayed Graft Function; the Clinical Hallmark of IRI in Transplantation 
1.2.1. Definition of Delayed Graft Function; Consensus and Controversies 
Delayed graft function (DGF) in kidney transplantation is best defined as the inability 
of a transplanted kidney to function immediately after transplantation. DGF has been closely 
associated with IRI and the homeostatic dysregulation and immunological injury associated 
with IRI. It is considered as a form of AKI unique to the transplant setting. 
Although the term DGF has been adopted globally, the specific clinical criteria used to 
define DGF may vary between centres. A systematic review by Yarlagadda et al. has 
addressed this issue, concluding that current utilisation of heterogeneous clinical criteria used 
to define DGF may have certain limitations and lead to unreliable, delayed and inaccurate 
identification of DGF cases (Yarlagadda et al., 2008). The review highlighted the three most 
common diagnostic criteria used to define DGF; (1) the need for renal replacement therapy 
(RRT) after transplantation, (2) failure of serum creatinine to decrease or (3) the combination 
of criteria (1) and (2). Yaralagadda et al. reviewed the available literature and listed over 10 
definitions of DGF, as shown in Table 1-1. 
The most commonly found definition of DGF in the literature; the need for RRT after 
transplantation is associated with several problems, which are mainly due to the subjectivity 
(clinician-dependent) of the decisions made in initiating RRT. In addition, there is a marked 
variation in the time frame used, ranging from the first 4 days to 10 days after the transplant 
procedure. Defining DGF based on the requirement of RRT alone may also potentially 
include patients undergoing post-transplant RRT for a specific indication, such as volume 
overload or hyperkalaemia, despite a functioning graft. On the other hand, this definition may 
exclude patients with poor allograft function and low GFR who still have significant residual 
renal function (such as pre-emptively transplanted patients).   
Although serum creatinine is clinically still valued as the gold standard measurement of 
renal function, there have been several publications highlighting its inadequacy in reflecting 
the actual severity of tubular injury (Bosch, 1995; Herrera and Rodriguez-Iturbe, 1998; 
Malyszko et al., 2015), especially considering that creatinine level may be influenced by 
many factors, including muscle mass, diet, drugs and hydration status. Moreover, transplant 
patients may undergo dialysis to optimise their condition prior to transplantation, which may 
also mask a high creatinine level caused by DGF (Yarlagadda et al., 2008).  
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Table 1-1. Various clinical criteria used to define DGF 
Dialysis-based definitions 
§ Need for dialysis in the first week after transplantation 
§ Need for dialysis in the first week after transplantation once hyperacute rejection, vascular and 
urinary tract complications were ruled out 
§ Need for dialysis after transplant 
§ Need for dialysis in the first 10 days after transplant 
§ Absence of life-sustaining renal function that requires dialysis performed for hyperkalaemia 
§ Need for dialysis in the first 7 days after transplant with specific exclusion of single early post-
operative dialysis performed for hyperkalaemia 
§ Return to maintenance haemodialysis within the first 4 days after transplantation 
Creatinine-based definitions 
§ Serum creatinine increased or remained unchanged or decreased <10%/day during 3 consecutive 
days after transplant 
§ Creatinine (Cr) reduction ratio <30% and /or urine creatinine on day 2 <1000 mg 
§ Serum Cr >2.5 mg/dL on Day 7 or the need for post-transplant hemodialysis 
§ Time required for the kidney to reach Cr clearance >10 mL/min greater than 1 week. 
§ Failure of creatinine to decline in the first 48 h in the absence of rejection 
Combination of dialysis and creatinine based definitions 
§ Failure of serum creatinine to fall below pre-transplant levels, within 1 week regardless of the 
urine output 
§ Rise in serum Cr at 6–8 h post-operatively or <300cc of urine despite adequate volume and 
diuretics 
§ Dialysis requirement after transplant or a serum Cr >150µmol/L at day 8 
§ Urine output <1L in 24h and <25% fall in serum Cr from baseline in first 24 h post-transplant 
§ Urine output <75 mL/h in first 48 h or failure of serum Cr to decrease by 10% in the first 48 h 
§ Need for dialysis in the first week after transplant or failure of serum Cr to decrease within 24 h 
after transplant 
Modified from (Yarlagadda et al., 2008) 
Despite the existing heterogeneity in the clinical criteria used to define DGF, no current 
development has been reported to homogenise or improve our diagnosis of DGF. Several 
novel biomarkers, such as kidney injury molecule (KIM)-1 or neutrophil gelatin-associated 
lipocalin (NGAL) have been proposed, on the basis that they show better correlation with the 
degree of actual tubular injury occurring after IRI. However, the validation and uptake of their 
use clinically use is still limited, especially compared to the already widely accepted serum 
creatinine.  
In addition, DGF is used to describe lack of immediate function due to IRI. In reality, 
this functional delay may be the result of several conditions distinct from IRI (such as 
antibody-mediated rejection, thrombotic microangiopathy, acute calcineurin inhibitor toxicity 
and primary non-function), which may present independently of, or coexist with, IRI 
(Yarlagadda et al., 2008). Hence, a true diagnosis of DGF can only be made after excluding 
the presence of these other conditions, which is not always be straightforward. Considering 
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the aforementioned problems, it is still a challenge to reach a universal consensus on the 
definition of DGF.  
1.2.2. Delayed Graft Function: Incidence and Risk Factors 
Reports on DGF incidence vary greatly between different centres. Disparity in clinical 
criteria used to identify DGF is the main reason for such variation. In general, DGF has been 
reported to affect 3-16% of recipients receiving a living donor kidney (Senel et al., 1998; 
Yarlagadda et al., 2008; Sharma et al., 2010; Healthcare Systems Bureau Division of 
Transplantation and United Network for Organ Sharing, 2012; Salamzadeh et al., 2012; 
Redfield et al., 2016). Predictably, the incidence is higher and varies more in deceased donor 
cohorts, ranging from 5-50% in all cases (Yarlagadda et al., 2008) to 18-35% in donation 
after brain death (DBD) cohorts and 35-43% in donation after circulatory death (DCD) 
cohorts (Healthcare Systems Bureau Division of Transplantation and United Network for 
Organ Sharing, 2012). The wide range of incidence reported suggests a difference in DGF 
definition used. Interestingly, none of the definitions used is superior in predicting graft 
failure at 1 year in the DBD cohort.   
Inconsistency in defining DGF also affects the way the literature reports causes and risk 
factors for DGF. Generally, when DGF is viewed as a clinical entity, per se, and not 
considered as a specific pathological consequence of IRI, risk factors of DGF can be 
classified into two groups; (1) risk factors related to procurement and pre-existing donor 
characteristics and (2) risk factors associated with the recipients as listed in Table 1-2 below. 
Table 1-2 Risk factors of the development of DGF  
Procurement / Donor Associated Recipient Associated 
§ Non-heart-beating (DCD) donor 
§ Inotropic use 
§ Extensive ischaemia time 
§ Older age donor (>55 years) 
§ Increased BMI 
§ Marginal donor (diabetic or hypertensive 
disorders) 
§ Hypovolaemia 
§ Increased BMI 
§ Intra-operative albumin administration 
§ Allosensitisation (number of previous 
transplants) 
§ Inherited thrombophilia 
§ Pre-formed antidonor antibodies 
§ Cyclosporine nephrotoxicity 
§ Ureteral leakage 
§ Ureteral obstruction 
Modified from (Perico et al., 2004). 
When a more stringent definition of DGF is used, which designates DGF uniquely as a 
consequence of IRI, then the risks are limited to only the factors which contribute to a 
significant increase in IRI severity, such as prolonged ischaemia time and non-heart beating 
 
 
8 
donor. Clinical data analysis obtained from various cohorts strongly supports ischaemia time 
as a strong risk factor of DGF (Ojo et al., 1997; Senel et al., 1998; Lebranchu et al., 2005; 
Jeldres et al., 2009; Jung et al., 2010; Sharma et al., 2010; Salamzadeh et al., 2012; Ounissi et 
al., 2013; Redfield et al., 2016).  
1.2.3. Delayed Graft Function; Early Consequences and Its Implication to Long-term Graft 
Survival 
The most apparent early consequences of DGF are related to a more complex post-
operative clinical course for the recipient, such as utilisation of RRT, requirement for 
additional intensive/high level care and medications, all of which result in prolonged 
hospitalisation and increased cost. Currently available data suggests an increase hospital 
length of stay of up to 8 days for patients with DGF (Miglinas et al., 2013; Redfield et al., 
2016). An interesting approach to address the question of cost analysis related to DGF was 
made in the study by Snyder et al. Using a developed hypothetical analysis model, the study 
acknowledged a higher cost associated with an increased DGF incidence as a potential short-
term complication of adding DCD kidneys to the donor pool. However, it also concluded that 
the cost is acceptable when compared to keeping the patients on dialysis (Snyder et al., 2013). 
DGF has also been shown to influence graft survival, patient survival and rejection 
rates. During shorter-term follow-up (within 1-year post-transplantation), DGF patients are 
reported to have poorer graft survival and significantly higher acute rejection rates 
(Dominguez et al., 2004; Yarlagadda et al., 2009; Miglinas et al., 2013). During longer-term 
follow-up, however, the deleterious effect of DGF on graft and patient survival is less 
consistent. This may partly be attributable to the differences in the degree of the initial insult 
suffered by the allograft, hence producing either reversible or irreversible degrees of injury. It 
is plausible that the graft lost by the 1-year time point had suffered significantly more severe 
IRI, and thus underwent irreversible changes compared to the grafts that survived. Grafts that 
survived past the 1-year point may not have been as severely injured, thus regaining more 
normal function, resulting in a less clear cut link between DGF and graft survival.  
Nevertheless, a systematic analysis of currently available evidence compiled by 
Yarlagadda et al. clearly suggests detrimental effect of DGF on acute rejection and long-term 
renal function. The result of this meta-analysis of 33 studies showed that the DGF cohort had 
a 41% increased risk of graft loss at 3.2 years follow-up, significantly higher serum creatinine 
level at 1 year and 3.5 years follow-up, and DGF was associated with 38% relative increase in 
the risk of acute rejection (Bronzatto et al., 2009; Yarlagadda et al., 2009). However, the 
study did not find any significant difference in 5-year patient survival between the DGF and 
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non-DGF group. Taken together, this analysis has provided a clear link between acute 
ischaemic kidney injury and long-term deterioration in function, despite a period of relatively 
“normal” function during earlier stages. Identification and validation of a mechanistic link 
between acute IRI and progression to chronic organ dysfunction has been gaining a lot of 
research interest. Several mechanisms have been proposed for the development of chronic 
dysfunction, which involves the role of cellular changes during ischaemia (oxygen and energy 
deprivation, pH alteration and ion re-distribution), the role of inflammatory mediators, the 
role of oxidative stress, the role of cellular components within the kidney (endothelial, 
epithelial and immune cells), and the role of epigenetics. It is important to consider these 
mechanisms not as separate pathophysiologic entities, rather as components of an intricate 
mechanistic network, which much overlap and cross-talk. The detailed mechanisms of which 
IRI leads to tissue injury and delayed function will be discussed in the following section on 
the biology of IRI.  
1.3. Biological Basis of Ischaemia Reperfusion Injury 
1.3.1. Organ Specific response to IRI 
The cascade of responses subsequent to cessation and restoration of blood in different 
organs will generally follow a common and fundamental pattern, which will be discussed in 
detail in following subsections. The universal use of cold preservation in organ transplant 
procedures is based upon the knowledge that cellular damage can be delayed at low 
temperature in all organs. Nevertheless, the capacity of different organs to tolerate ischaemia, 
the threshold of injury reversibility, and the capability to limit the injury may vary 
significantly. Reports have shown that the time required to induce irreversible damage is 
different for different organs. This may partly be attributed to organ specific basal energy 
requirements, but also determined by tissue variation in the structure and function of 
microvascular beds and other cellular components within the organ (Kalogeris et al., 2012). In 
the kidney, normothermic ischaemia of 30 minutes or less has been found to be well tolerated 
and caused no irreversible organ damage (Kalogeris et al., 2012). 
1.3.2. The Kidney; Anatomical & Physiological Considerations 
The anatomy of the nephron and renal microcirculation plays a crucial role in 
understanding the effect of ischaemia on the kidney. In physiological conditions, kidneys 
receive approximately 20% of cardiac output. This blood flow is primarily channelled to the 
cortex, whereas a small proportion supplies the medullary region. This creates a gradient of 
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oxygen tension within the kidney, with the cortex being the most oxygenated region, the 
medulla being relatively hypoxic, and the papillae being the least oxygenated. Blood flow to 
the medulla is supplied by an intricate microvasculature network, which arises from the vasa 
recta, the continuation of efferent arterioles of the juxtamedullary glomeruli. Studies in rats 
have shown that pre- and post-glomerular arterio-venous shunting creates a relatively hypoxic 
environment within the kidney (Ngo et al., 2014). In comparison to other parts of the body, 
the kidney operates at lower oxygen tensions, both during normoxia and hypoxia (Safran et 
al., 2006). Moreover, in response to hypoxia, kidney blood flow may alter dramatically, 
especially to the outer medullary region. Altogether, these factors predispose the kidney to 
hypoxic damage. To date there is substantial evidence describing how hypoxia induces acute 
kidney injury (Granger and Korthuis, 1995; Kosieradzki and Rowinski, 2008; Basile et al., 
2012). However, demonstrating the role of hypoxia in the progression of kidney injury in the 
longer-term, is more challenging. Several studies have shown an association of chronic 
hypoxia in the renal tubulointerstitium with oxidative stress and chronic inflammation, and 
that these factors are involved in the progression of CKD (Eckardt et al., 2005; Nangaku, 
2006; Fine and Norman, 2008; Heyman et al., 2008). A recent rodent study has shown the 
significance of hypoxia alone in the progression of CKD. The authors reported increased 
urinary protein excretion and tubular vimentin expression as well as infiltration of 
inflammatory cells, in rats treated with dinitrophenol, a mitochondrial uncoupler, which 
increased renal oxygen consumption without altering oxidative stress (Friederich-Persson et 
al., 2013) 
1.3.3. Cellular Response to Acute IRI and Pathways of Progression to Long-Term 
Functional Impairment 
1.3.3.1. ATP Depletion and Intracellular pH Alteration 
Cessation of an oxygen supply adequate to maintain normal cellular function is the 
main driver of ischaemic injury. This is immediately followed by a switch to an anaerobic 
pathway of energy production, which will only generate small amounts of high-energy 
phosphates and lead to decrease in intra-cellular pH due to the build-up of lactate, protons and 
nicotinamide adenine dinucleotide (NAD+). Conversion of pyruvate to lactic acid is necessary 
to regenerate the lost NAD+ in the anaerobic glycolysis pathway. This process acidifies the 
cytoplasm up to a point where the low pH starts to inhibit phosphofructokinase, a key enzyme 
of the glycolysis pathway. Insufficient blood flow to remove accumulating lactate will 
eventually stop energy production and further worsen the level of acidosis.   
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Ischaemic condition in cells results in metabolic substrate depletion. Ischaemic tissues 
contain much fewer glycogen granules than normal tissue (Kosieradzki and Rowinski, 2008). 
Exhaustion of cellular glycogen arrests anaerobic glycolysis. Unavailability of adequate 
adenosine tri-phosphate (ATP) to initiate glycolysis will also result in metabolic arrest, even if 
there is still glycogen available. Degradation of ATP to adenosine di-phosphate (ADP) and 
adenosine mono-phosphate (AMP) occurs very rapidly during ischaemia, aggravating energy 
source deprivation. AMP will be metabolised further to adenine nucleotides and 
hypoxanthine, which will contribute significantly to generation of reactive oxygen species 
during subsequent reperfusion (Devarajan, 2006).  
1.3.3.2. Altered Ion Exchange and its Consequences 
Intracellular accumulation of hydrogen ions will be compensated by increased Na+/H+ 
exchange resulting in the influx of sodium ions. In turn, the sodium ions will be exchanged 
for Ca2+ by the Na+/Ca+ exchanger.  ATP depletion causes the cell to inactivate ATPases, 
including Na+/K+ ATPase and Ca2+ ATPase, resulting in even more intracellular Ca2+. Some 
reports have suggested that this influx of extracellular Ca2+ only takes place during prolonged 
ischaemia and reperfusion, whilst during the initial phase of ischaemia, the increase in 
intracellular Ca2+ is primarily due to active redistribution of endoplasmic reticulum (ER) 
calcium (Schumacher et al., 1998; Kosieradzki and Rowinski, 2008). Reperfusion further 
increases intracellular Ca2+. As extracellular H+ is removed after the re-establishment of blood 
flow, the proton gradient will increase across cell membrane, leading to an increase in Na+/H+ 
exchanger function, which increases intracellular Ca2+  (Kalogeris et al., 2012).  
The overload of Ca2+ is an important underlying mechanism for subsequent cellular 
pathology following IRI, which may lead to cell death. Ca2+ overload is detrimental to cell 
survival by triggering mitochondrial permeability transition pore (mPTP/mPT) activity, 
activating pathological Ca2+/calmodulin-dependent protein kinases (CaMKs), stimulating 
calpains and generating danger signals (Kalogeris et al., 2012).  Opening of mTP allows H+ to 
move back into the mitochondrial matrix disrupting ATP synthesis. The opening of this non-
selective pore will also lead to sudden influx of water, which in turn may cause mitochondrial 
swelling and rupture. Danger signals, such as calcium pyrophosphate and uric acid exert their 
effects by binding to inflammasomes. Binding to inflammasomes initiates cytokine release, 
which in turn activates transcription factors (NFkB), stimulating even more cytokine and 
chemokine release eventually leading to exacerbation of IRI. 
The disruption in trans-membrane ion channels and the phospholipid bilayer due to 
ischaemic damage, eventually leads to accumulation of water in the intracellular 
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compartment. In addition, glycolysis pathway arrest and dephosphorylated ATP lead to 
continuous accumulation of metabolic intermediates and products (e.g. glucose-6-phosphate, 
a-glycerol phosphate, lactate, NADH, inorganic phosphatases, etc.), all of which cause an 
increase in intra-cellular osmolarity (Kosieradzki and Rowinski, 2008). Hyperosmolarity 
attracts water to the intracellular compartment, which leads to ischaemic oedema. In the 
transplantation setting, the use of hypertonic preservation solution was introduced to prevent 
ischaemic oedema, as introduction of isotonic fluid may generate a greater osmotic gradient.  
Furthermore, oedema can develop in the cytosol affecting the outer cellular membrane, 
as well as within the cell organelles, further compromising cellular function. Different 
organelles will be impaired by the state of altered ion exchange and ischaemic oedema in 
different ways. For instance, ER requires a carefully regulated milieu to perform its function. 
Ischaemia impairs this fine-tuned environment by altering ion concentration/gradient and pH, 
preventing ER from performing many important biochemical reactions important to the cell, 
such as the folding of proteins (Kalogeris et al., 2012). The state of accumulation of misfolded 
and unfolded proteins in ER is known as ER stress., which will activate the unfolded protein 
response (UPR), in an attempt to degrade the unfolded protein. Failure to eradicate the 
unfolded protein causes cells to undergo apoptosis (Minamino et al., 2010). 
1.3.3.3. The Role Hypoxia-Inducible Factor (HIF) 
Cellular adaptation to hypoxia is largely regulated by a heterodimeric transcription 
factor, hypoxia-inducible factor (HIF), which consists of two sub-units; a and β. Whereas the 
β sub-unit is relatively insensitive to alteration in oxygen levels, the cellular concentration of 
the sub-unit alpha (HIF-a) is highly dependent on cellular oxygen levels, a process that 
involves hydroxylation of conserved residues (Tanaka et al., 2014; Burslem et al., 2017). 
HIF-a has two major isoforms; HIF-1a, HIF-2a and one additional minor isoform HIF-3a 
(Tanaka et al., 2014; Tanaka, 2017). The main difference between HIF-1a and HIF-2a lies 
mostly in the variation of their N-terminal transactivation domain (N-TAD), which determine 
their binding to specific target genes (Loboda et al., 2012). The difference in their regulation 
and action is still not fully understood. HIF-1a is detectable after a short-term hypoxic period, 
whilst HIF-2a is known to be only activated in chronic hypoxia, thus is associated with the 
regulation and survival of cancer cells and cellular adaptation to hypoxia (Hu et al., 2003; 
Ratcliffe, 2007). Understanding of the role of HIF-3a is even less complete. Available 
literatures hypothesise that HIF-3a acts as negative regulator of HIF-mediated transcription 
(Loboda et al., 2012).  
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1.3.3.3.1. The Regulation of HIF 
HIF-1a is continuously expressed at low levels in the cell. In normoxia, HIF-1a levels 
are kept low by the action of HIF-prolyl hydroxylase domains (PHDs). In order to perform 
their catalytic function, the enzyme PHDs require O2, Fe, and 2-oxoglutarate (an intermediate 
in the Tri-carboxylic acid cycle) (Rabinowitz, 2013). PHDs hydroxylate two proline residues 
in HIF-1a, which enables recognition of HIF-1a by von Hippel-Lindau tumour suppressor 
(pVHL), leading to proteosomal degradation of HIF-1a . This degradation process occurs 
very rapidly, resulting in a very short half-life of HIF-1a, thus making it undetectable in 
normoxic conditions. During hypoxia, catalytic function of PHDs is reduced or diminished, 
leading to accumulation of HIF-1a in the cytoplasm. Existing HIF-1α will form complexes 
with the constitutively expressed HIF-1β, leading to subsequent binding of the complex to 
hypoxia-response element (HRE) region, initiating gene transcription. A co-activator protein 
p300/CBP (CREB-binding protein) has been identified in a stable complex with HIF-1a, 
which was closely linked with HIF activity in inducing several hypoxia responsive genes (e.g. 
erythropoietin enhancer and vascular endothelial growth factor) (Arany et al., 1996).  
 
 
Figure 1-2 Regulation of Hypoxia-Inducible Factor 
Schematic illustration of HIF-a regulation during normoxia and hypoxia. (HIF = hypoxia-inducible 
factor; PHD = prolyl hydroxylase domains; VHL = von Hippel Lindau; HRE = hypoxia-response 
element) 
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Study of ischaemic rat kidneys identified that HIF-1a was expressed predominantly in 
tubular epithelial cells, while HIF-2a was expressed mainly in vascular endothelial cells and 
interstitial fibroblasts (Rosenberger et al., 2002; Tanaka, 2017). HIF regulates the 
transcription of numerous genes to control haematopoiesis, angiogenesis and anaerobic 
metabolism in response to hypoxia (Mole et al., 2009). Conde et al. found that HIF-1a is 
expressed during ischaemia, but disappears 24 hour after hypoxia is reversed, then reappears 
in late reperfusion (Conde et al., 2012), suggesting recurrence of tissue hypoxia during the 
cell regenerative phase (Nangaku et al., 2013). In human kidney allograft biopsies, up-
regulation of HIF is detected immediately after engraftment, at 10-14 days post procedure, but 
not after 3 months (Rosenberger et al., 2007). From these findings, we can conclude that 
kidney hypoxia occurs not only during the acute phase of ischaemic injury but also during the 
recovery phase (Tanaka et al., 2014), presumably due to the activity of oxygen-consuming 
regenerative processes. 
1.3.3.3.2. HIF and the Development of Fibrosis 
The activation of HIF plays a pivotal role in both immediate cell responses to injury as 
well as long-term regulation of fibrosis. Current evidence is contradictory regarding the actual 
role of HIF in progression of CKD. Experiments using cobalt chloride (CoCl2) and 
dimethyloxalyglycine (DMGO) to stabilise HIF and increase expression of HIF target genes 
in a mouse model of renal fibrosis showed up-regulation of vascular endothelial growth factor 
(VEGF), glucose transporter 1 (GLUT1) and cell proliferation, indicating a reno-protective 
effect of HIF (Deng et al., 2010). Another study in mice assessed the relationship between 
HIF-1, ischaemic acute kidney injury (AKI) and the development of fibrosis by increasing 
HIF levels using pre-ischaemic pharmacological inhibition of PHD. Kobayashi et al. 
documented repression of fibrogenesis in mice subjected to unilateral ureteral obstruction 
(UUO) by global activation of HIF (Kobayashi et al., 2012). Using a murine model of IRI, 
Kapitsinou et al. showed a protective effect of pre-ischaemic PHD inhibition in mice 
subjected to acute ischaemic kidney injury. Pre-ischaemic increase in HIF level caused by 
PHD inhibition was associated with reduced fibrotic area and less alpha-smooth muscle actin 
(a-SMA) expression at 21-day post IRI (Kapitsinou et al., 2012). Interestingly, this anti-
fibrotic effect was not observed when PHD inhibition was given after IRI, or in PHD-
inhibitor treated animals lacking endothelial HIF-2a (Kapitsinou et al., 2012; Kapitsinou et 
al., 2014).  
Conversely, extensive evidence is available to support a pro-fibrotic role of HIF. Wang 
et al. showed decreased collagen and a-SMA induction by silencing HIF-1a gene in rats with 
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chronic renal ischaemia (Wang et al., 2014c). Moreover, HIF-1a knockout was shown to 
prevent transforming growth factor-β1 (TGF-β1) induced epithelial-to-mesenchymal 
transition (EMT) in mouse proximal tubular epithelial cells subjected to unilateral ureteral 
obstruction (UUO) (Higgins et al., 2007). Endothelial HIF-2a was also reported to play an 
important role in protection against ischaemic kidney injury. Despite some discrepancies, 
current findings clearly indicate an association between ischaemia, post-ischaemic increases 
in HIF levels and long-term pro-fibrotic changes. Post-ischaemic renal fibrogenesis occurs 
through several mechanisms, such as direct transcriptional regulation of pro-fibrotic genes, 
epithelial-to-mesenchymal transition (EMT) and induction of epigenetic changes, all of which 
may be driven by HIF activation, either through direct regulation or indirectly, involving 
crosstalk with multiple signalling pathways (Higgins et al., 2008; Liu et al., 2017). 
1.3.3.4. Mitochondrial Dysfunction and Oxidative Stress 
The role of mitochondria is central and very complex in the cellular response to IRI. 
Initially, to neutralise the continuous increase of intracellular Ca2+, cells will initiate the 
uptake of Ca2+ into the mitochondria using a mitochondrial Ca2+ uniporter. However, this 
mechanism alone will not be sufficient, especially if the initial ischaemic insult is severe or 
prolonged.  
There are several ways how mitochondria contribute to cell death after IRI. Firstly, 
ischaemia alone inhibits mitochondrial metabolism, resulting in rapid depletion of ATP. 
Secondly, during the initial phase of ischaemia, the relatively acidic intracellular milleu keeps 
the mitochondrial permeability transition pore (mTP) in the mithocondrial membrane inactive. 
However, upon reperfusion, mTP pores open, which in turn alters mitochondrial 
transmembrane potential significantly, allowing non-selective in/efflux of molecules leading 
to mitochondrial depolarisation (Kalogeris et al., 2012; Elshenawy et al., 2017).  Prolonged 
opening of mPTP leads to apoptosis, and has been used to differentiate between irreversible 
and reversible reperfusion injury. Moreover, the mitochondrial electrochemical gradient is 
also disrupted, interfering with mitochondrial capacity to generate ATP. Thirdly, 
mitochondria act as a source of reactive oxygen species (ROS) after an ischaemic insult, 
mainly attributed to the disturbance in the electron transport chain (e.t.c). Lastly, 
mitochondrial morphology may also be impaired following IRI. Conditions such as low ATP 
level and increased ROS generation can cause excessive mitochondrial fission, which also 
contributes to post-ischaemic cell death (Kalogeris et al., 2012).  
Tissue injury due to oxidative stress plays a role in the reperfusion component of IRI. 
However, it is important to understand that the severity of reperfusion injury is a result of the 
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severity of ischaemia. Various sources of ROS have been identified in different tissues; these 
include xanthine oxidase (XO), NADPH oxidase, nitric oxide synthase (NOS), 
lipoxygenase/cyclooxygenase, monoamine oxidase and the mitochondria. Similar sources of 
ROS have also been identified in kidney IRI (Granger and Kvietys, 2015).  
Degradation of ATP to ADP and AMP during ischaemia leads to accumulation of 
hypoxanthine, which acts as the main fuel for ROS formation. Availability of O2 and 
restoration of ATP in tissue upon reperfusion enables the conversion of hypoxanthine to 
xanthine, generating superoxide and hydrogen peroxide, which subsequently leads to 
production of more reactive secondary species. Moreover, altered redox status caused by the 
initial ischaemic injury means that there is higher level of NADH available relative to NAD+, 
which has been shown to be capable of enhancing production of O2- independent of XO.  
(Granger and Kvietys, 2015).  
There are two forms of superoxide-producing nitrous oxide (NOXs) known to be 
involved in tissue reperfusion injury. The main isoform is from macrophages and neutrophils 
(phagocyte NOXs), and the other isoform is produced by non-phagocytic cells of the vascular 
wall  (vascular NOXs) (Kalogeris et al., 2012). Phagocyte NOXs remain inactive until 
stimulated, and are responsible for ‘respiratory burst’ of oxidant production, characterised by 
sudden and marked increase of oxidant synthesis, immediately following phagocyte activation 
by inflammatory mediators (Kvietys and Granger, 2012; Raedschelders et al., 2012). 
Physiologically, this serves as a host defence mechanism, whereby the reactant species are 
released extracellularly or into phagolysosomes (Kalogeris et al., 2012). On the other hand, 
vascular NOX is present in a fully-active state, but at low-levels of constitutive activity and 
has subtle oxidant effects. A minor proportion of vascular NOX is maintained in a separate 
compartment in the cytosol, and behaves similar to phagocyte NOX (Kalogeris et al., 2012; 
Kvietys and Granger, 2012).  Although the generation of ROS from phagocyte NOX and 
vascular NOX are distinct, the activation of both cell types has been shown to be involved in 
the pathogenesis of IRI in most organs, including the kidney (Kvietys and Granger, 2012; 
Raedschelders et al., 2012). 
In conclusion, a high mitochondrial ROS level is a major feature of cellular reperfusion 
injury, which reflects increased ROS production and inadequate ROS disposal. This leads to 
further deleterious effect to the cells, such as alteration in mitochondrial oxidative 
phosphorylation, depletion of ATP, increase in intra-cellular calcium levels, activation of 
proteases and lipid peroxidation (Paller et al., 1984; Weinberg, 1991; Ratliff et al., 2016). 
Furthermore, oxidative stress may also damage cellular proteins and DNA, which may lead to 
apoptosis and cell death (Kehrer and Klotz, 2015).  
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1.3.3.5. Endothelial Injury and Vascular Rarefaction 
Depending on its severity, ischaemia alone may cause endothelial injury/dysfunction. 
As a consequence, dysfunctional endothelium will no longer able to serve as an adequate 
barrier between the interstitium and the vascular compartment, lose its ability to control 
adhesion and infiltration of immune/inflammatory cells and fail to regulate key haemostatic 
mechanisms (Kalogeris et al., 2012). Endothelial cells contribute to progression of IRI by two 
main mechanisms; (1) increased permeability and (2) vasomotor dysregulation. 
Increased endothelial permeability can be attributed to direct injury to the endothelial 
cells, actin cytoskeleton alterations, cell-to-cell junctional dissociation and enhanced 
leukocyte-endothelial interactions (Sutton, 2009; Verma and Molitoris, 2015). In normal 
conditions, the endothelium is maintained as a monolayer, which requires the formation of 
junctional complexes. These junctional complexes are highly sensitive to physiological or 
pathophysiological stimuli, such as ROS, cytokines, lipid mediators and proteases (Kalogeris 
et al., 2012). The release of pro-inflammatory mediators and ROS during IRI will induce 
phosphorylation, internalisation and degradation of junctional complex proteins resulting in 
endothelium structural damage (Kumar et al., 2009). Disruption of glycocalyx and up-
regulation of cellular adhesion molecules, such as ICAM, VCAM and selectins that will 
promote accumulation of leukocytes (Bonventre and Yang, 2011).  
Increased level of prostaglandin H2, leukotrienes C4 and D4 and increased sympathetic 
nerve stimulation have all been documented to follow endothelial injury, leading to excessive 
vasoconstriction. As the result of increased sympathetic activity, there is a reduction in 
circulating NO, which will further amplify the degree of vasoconstriction (Bonventre and 
Yang, 2011). The injured endothelium will also release chemotactic cytokines, increasing 
leukocyte-endothelial adhesion during reperfusion. Increased leukocyte activation and 
leukocyte-endothelial adhesion stimulates the release of vasoactive cytokines, including TNF-
a, IL-1b, IL-6, IL-12, IL-15, IL-18 and IL-32, which in turn amplify the vasoconstriction that 
occurs (Bonventre and Yang, 2011). As a consequence, a greater degree of ischaemia will 
ensue, adding more injury to the initial insult as well as affecting subsequent repair processes. 
A significant reduction in peritubular capillary (PTC) density has been suggested as a 
possible factor that makes the post-ischaemic kidney susceptible to further deterioration of 
function. Using the bilateral ischaemia reperfusion rat model, Basile et al. showed a 30-50% 
permanent reduction in PTC in the outer medullary region despite normal tubular 
morphology. The ischaemic group was also reported to develop subsequent tubulointerstitial 
fibrosis after longer follow-up (Basile et al., 2001). Similar findings were also reported in a 
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kidney transplant cohort. Loss of PTC after during the first 3 months post-transplant was 
associated with increased interstitial fibrosis, tubular atrophy and reduced renal function 
(Steegh et al., 2011).  
Basile et al. (Basile and Yoder, 2014) summarised three possible mechanisms in which 
post-ischaemic PTC loss could contribute to  the development of long-term fibrosis; (1) 
exacerbation of pre-existing hypoxia, (2) changes in outer medullary haemodynamics and (3) 
endothelial-to-mesenchymal transition (EndoMT), which promotes proliferation of new 
fibroblasts. Exacerbation of hypoxia is mainly the result of increased intra-renal 
microvascular resistance due to vasoactive cytokine activity, as discussed previously. This is 
also closely tied to alteration in medullary haemodynamics. It is hypothesised that hypoxia 
and medullary haemodynamic alterations lead to apoptosis, which perpetuates PTC loss. 
EndoMT was proposed as an alternative explanation of PTC loss. A study on bilateral 
ischaemic kidney mouse model showed co-existing staining of endothelium (CD31 or cablin) 
and mesenchymal marker (S100A4) (Basile et al., 2011). The role of EndoMT is still not 
clearly understood, but recently has been gaining increasing interest. 
Moreover, IRI induced inflammatory conditions reduces naturally occurring anti-
coagulant activity (Verma and Molitoris, 2015). The combination of excessive 
vasoconstriction, leukocyte activation and subsequent coagulation system activation may lead 
to mechanical obstruction of the renal micro-capillary network and reduction in blood vessel 
patency, which further compromises regional microcirculation, especially in the outer renal 
medulla. 
1.3.3.6. Role of Damaged Tubular Epithelial Cells, Failed Tubular Recovery & Tubular 
Maladaptive Repair 
The proximal tubular epithelial cells (PTECs) are the main site of injury in the acutely 
ischaemic kidney. Consequently, the severity and recurrence of injury at this site acts as an 
important factor in determining reversibility of the damage and progression to long-term 
organ failure. Tubular injury induced by diphtheria toxin showed that tubular injury alone can 
initiate interstitial fibrosis, which primarily developed around proximal tubules (Takaori et 
al., 2016). Further experiments utilising toxin receptor-mediated cell knock-out (TRECK) 
enabled selective injury only to proximal tubules, which again induced transition of 
fibroblasts to myofibroblats, leading to fibrosis. Repeated and more severe selective injury 
was reported to induce interstitial fibrosis, distal tubular injury and glomerulosclerosis and 
atubular glomeruli (Takaori et al., 2016; Takaori and Yanagita, 2016). 
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Ischaemic tubular injury is most evidently found in the S3 segment of the proximal 
tubule (Heyman et al., 2010), and recent studies have highlighted the significant role of 
PTECs in renal IRI (Han et al., 2002; Chevalier, 2016). Ischaemic injury to TEC initially 
results in loss of cytoskeletal integrity. The degree of cytoskeletal alteration depends on the 
severity and duration of ischaemia. This loss of cytoskeletal integrity further modifies cellular 
polarity, cell-to-cell interactions as well as cell-to-matrix interactions, and loss of function 
(Sutton and Molitoris, 1998). 
Kidney tubular epithelial cells (TECs) have been shown to play active roles in 
progression of post-ischaemic tissue damage.  There is substantial evidence that TECs release 
pro-inflammatory and chemotactic cytokines in response to IRI (Sutton and Molitoris, 1998; 
Kapper et al., 2002; Moll et al., 2013), which includes TNF-α, IL-6, IL-1β and TGF-β in 
addition to chemokines, such as MCP-1, IL-8, RANTES and ENA-78 (Kapper et al., 2002). 
This leads to recruitment of immune cells, important for repair following IRI, but also 
involved in the damage that occurs. In addition, damaged epithelial cells produce damage-
associated molecular patterns (DAMPs), which act as warning signals by activating a series of 
pattern recognition receptors (PRRs), known as Toll-like receptors (TLR2, TLR3 and TLR4), 
express complement receptors and other co-stimulatory molecules which regulate T 
lymphocyte activity (Leemans et al., 2005; Wu et al., 2007; Bonventre and Yang, 2011). 
Down-regulating the expression of TLR-2 on kidney parenchymal cells were also shown to 
reduce the level of pro-inflammatory cytokines (IL-1β, IL-6, MCP-1) produced by the kidney, 
thus providing functional and structural protection against IRI progression (Leemans et al., 
2005). Wu et al. demonstrated up-regulation of TLR4 post IRI in TECs and inhibiting TLR4 
effectively prevented progression of IRI (Wu et al., 2007). Futhermore, TLR4 knockout mice 
also showed reduced tubular injury with better preservation of renal function after induction 
of IRI compared with wild type mice (Pulskens et al., 2008). 
Dedifferentiation of proximal tubule cells caused by IRI may not always be followed 
by complete re-differentiation and resolution of injury. Rodent kidneys subjected to IRI still 
had a proportion of abnormal tubules with flat epithelium without brush borders after 14 days. 
These cells were morphologically abnormal, atrophic and growth arrested. As well as 
showing strong TGF-β signalling, these abnormal cells also showed persistent loss of 
phosphate and tension homologue (PTEN) associated with increased expression of vimentin, 
pro-fibrotic c-Jun N-terminal kinase (JNK) activation and platelet-derived growth factor 
(PDGF)-B production (Lan et al., 2012a).  
Tubular cell secretion of cytokines and growth factors is important for cell survival and 
repair, however, this should halt once complete regeneration is achieved (Bonventre, 2010; 
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Venkatachalam et al., 2015). Study of five different murine models of acute kidney injury 
revealed large numbers of proximal tubule were arrested in the G2/M phase of the cell cycle, 
which is associated with persistent activation of JNK signalling and higher production of 
COL4A1 and ACTA2 mRNA levels (Yang et al., 2010). A number of studies by 
Venkatachalam et al. also showed that tubular cell arrest and atrophy is linked with increased 
secretion of fibrogenic peptides, which accelerates proliferation of interstitial 
pericytes/fibroblasts  through multiple pathways, including PI3K-Akt-mTOR, ERK-MAPK, 
JNK-MAPK and previously mentioned TGF-β pathways (Suzuki et al., 2001; Canaud and 
Bonventre, 2015; Venkatachalam et al., 2015), eventually resulting in nephron loss. These 
findings are the basis of validating several cell cycle arrest biomarkers in the detection of 
acute kidney injury (Kashani et al., 2013).  
Tubular cells maladaptive repair is also associated with activation of several other pro-
fibrotic pathways, such as Notch and Wnt signalling. Recent work using a mouse model with 
inducible proximal tubule Wnt1 secretion displayed interstitial myofibroblast activation and 
proliferation and increased matrix protein production (Maarouf et al., 2016). Interestingly, no 
evidence of inflammatory cytokine expression, leukocyte infiltration, or epithelial injury were 
detected in these fibrotic kidneys, demonstrating direct paracrine Wnt1 activity in initiating 
interstitial fibrosis through tubulointerstitial crosstalk (Maarouf et al., 2016). 
1.3.4. IRI and Immune System Activation 
IRI is a result of various mechanisms, including the host inflammatory/immune 
response. The immune system activation exerts its effect largely upon reperfusion of an 
ischaemic kidney. However, it is important to recognise that the initiation of inflammation 
occurs during ischaemia, whilst post-ischaemic events contribute to its amplification. These 
reperfusion events include oxygen re-fuelling, ROS generation, endothelial dysfunction, 
leukocyte recruitment, chemokine and cytokine synthesis and complement activation (Jang et 
al., 2009; Kvietys and Granger, 2012). The ischaemic kidney is not merely the target of 
immune activation. Instead, it plays an active role in promoting immune activation.  
An acute inflammatory component of IRI involves the expression of cell surface 
adhesion molecules. To evaluate the effect of IRI on the expression of these adhesion 
molecules, rat renal grafts were cold preserved for 2, 4, 6, 12, 24 and 48 hours, before being 
transplanted into syngeneic recipients (Dragun et al., 2001). This study revealed that longer 
duration of cold-ischaemia led to loss of endothelial integrity and increased expression of 
VCAM-1. Ischaemic grafts also displayed enhanced intra-graft pro-coagulant capacity and a 
worse tubular necrosis score (Dragun et al., 2001). Unexpectedly, renal functions measured 
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by creatinine and urea was not different between grafts with shorter ischaemia and grafts with 
longer ischaemia time. This implies that there are potentially injurious processes occurring 
after moderate IRI that are clinically undetectable. Whether the same can be extrapolated to 
the effects of IRI on long-term allograft function in patients receiving ischaemic allografts but 
who do not develop DGF remains an important research question.  
1.3.4.1. The Role of Neutrophils and Macrophages 
Neutrophil adhesion to dysfunctional endothelial cells is a rapid and important 
component in the initiation of damage to the ischaemic kidney. Recruitment of neutrophils by 
endothelial cells requires the expression of ICAM1, E and P selectin, which cross-talk with 
integrins and L-selectin on polymorphonuclear (PMN) cells (Thornton et al., 1989; 
Kosieradzki and Rowinski, 2008; Yago et al., 2015), however the exact mechanism and 
trafficking of neutrophils in renal IRI is not yet clear. Neutrophils have been shown to migrate 
into the transplanted organ within 6 hours of reperfusion and are attracted by chemokines, 
such as CXCL8, CXCL10, IL-17 and MCP-I (Neto et al., 2004; Kosieradzki and Rowinski, 
2008; Chaturvedi et al., 2013; Kolaczkowska and Kubes, 2013). Damaged cells will be killed 
by neutrophils by direct phagocytosis or degranulation, releasing proteases, myeloperoxidase, 
nitrogen species, antimicrobial peptides and cytokines (Kinsey et al., 2008). The presence of 
neutrophils in the glomeruli after reperfusion was reported to have a deleterious consequence 
to long-term kidney outcomes, with higher serum creatinine levels at 3 and 6 months after 
transplantation (Koo et al., 1998; Friedewald and Rabb, 2004). Inhibiting the accumulation of 
neutrophils in the kidney or blocking neutrophils-endothelial interactions may prevent acute 
kidney injury (Haug et al., 1993; Kelly et al., 1994; Kelly et al., 1996; Jang and Rabb, 2009; 
Chaturvedi et al., 2013; Yago et al., 2015). In contrast, others have failed to reproduce the 
beneficial effects of neutrophil depletion and reported neutrophil independent mechanisms in 
the pathophysiology of acute tubular injury (Thornton et al., 1989; Salmela et al., 1999; 
Melnikov et al., 2002). Nevertheless, the majority of evidence supports a role of neutrophils 
in the development of post-ischaemic injury, by mechanisms including obstruction of renal 
microvasculature and the releasing free radicals and proteases (Friedewald and Rabb, 2004).     
The role of macrophages in renal response to IRI is complex. Macrophages has been 
shown to promote tubular injury during the initial phase of IRI. On the other hand, 
suppressing macrophage function during the repair process (at later time points post 
reperfusion) has been shown to suppress tubular proliferation, thus impairing the normal 
recovery process. Studies have described the involvement of macrophages in the early 
inflammatory response, during cellular regeneration and tissue repair as well as the 
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development of fibrosis. These diverse roles are played by different sub-types of macrophages 
based on their activation and functional states. Classical activation of macrophages is driven 
by interferon gamma (IFNg). Ischaemia induced cellular injury also produces DAMPs, which 
will contribute to macrophage activation. These classically activated M1 macrophages are 
pro-inflammatory in nature, thus associated with tissue damage. However, they also play an 
important role in clearing apoptotic cells and debris, thereby initiating the repair process 
(Huen and Cantley, 2015). Alternatively activated macrophages include M2a macrophages, 
which are responsible for wound healing and M2b macrophages, also known as 
immunoregulatory macrophages. Generally, M2 macrophages activate regulatory T-cells 
(TReg) and restore renal tissue homeostasis (Huen and Cantley, 2017), by promoting tubular 
proliferation and limiting renal injury. M2a macrophages are activated through IL-4/IL-13 
binding to IL-4 receptor, which leads to production of growth factors, collagen precursor 
synthesis and generation of extracellular matrix. M2b macrophages regulate inflammatory 
response by producing immunosuppressive cytokines, IL-10 and TGF-b. Production of TGF-
b is to limit inflammatory cytokine production, but at the same time may contribute to 
activation of pro-fibrotic pathways. When injury persists, chemokines, macrophage colony 
stimulating factors (M-CSF) and IL-34, are secreted to sustain monocyte recruitment and 
retention of macrophages (Huen and Cantley, 2017). Blockade of M-CSF receptor has 
protective effects following transplantation (Jose et al., 2003). Retention of M2b macrophages 
in the injured tissue will produce macrophages-derived factors, which subsequently activate 
and support myofibroblasts, inducing extracellular matrix deposition and fibrosis. The signals 
responsible for retaining pro-fibrotic macrophages in the kidney remain unclear, but studies 
using unilateral ureteral obstructive (UUO) rodent model suggest a role for the chemokine 
receptors CCR1, CCR2, CX3CR1 (Huen and Cantley, 2017). 
1.3.4.2. The Role of Complement System 
The complement system plays an important role in the post-ischaemic inflammatory 
process. The importance of complement in the kidney transplantation setting was highlighted 
in several studies, primarily linking complement allotype and complement gene expression to 
transplant outcome (Brown et al., 2006; Naesens et al., 2009). In IRI, complement has been 
identified as an important mediator (Zhou et al., 2000; Sheerin et al., 2008; Danobeitia et al., 
2014).  
Complement activation in the kidney occurs predominantly through the alternative 
pathway. A murine study of renal IRI identified the re-distribution of the complement 
inhibitor, complement receptor 1-related protein (Crry) from the tubular basolateral surface 
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prior to complement activation and C3 deposition (Thurman et al., 2006). Interestingly, in a 
non-ischaemic milieu, the deposition of C3 on the basolateral surface was not correlated with 
any apparent abnormality. Mice deficient in Crry showed worse renal injury, which was 
correlated with increased mononuclear phagocyte infiltration and TEC apoptosis (Miao et al., 
2014). In addition, injured peritubular endothelium may allow plasma C3 into the 
tubulointerstitial space, providing sufficient C3 to exceed local complement regulation (Brar 
and Quigg, 2014).  
A number of studies have also investigated the role of C5 in the response to renal IRI 
and kidney transplantation. Ischaemic insult to the kidney has been shown to involve both 
C3a and C5a with up-regulation of their respective receptors (C3aR and C5aR). C3a and C5a 
generated during IRI were shown to increase pro-inflammatory cytokine/chemokine 
production by macrophages, and was associated with increased kidney injury molecule 
(KIM)-1 expression by proximal TECs (Peng et al., 2012). A comparison between the two 
complement components, however, showed a predominant role of C5 (Peng et al., 2012). 
Moreover, the membrane attack complex C5b-9 has been linked to up-regulation of collagen 
gene expression in renal TECs, and suggested as a potential target for IRI prevention (Zhou et 
al., 2000; Abe et al., 2004). 
1.3.4.3. The Role of Lymphocytes 
Several lymphocyte sub-populations have been identified as important components of 
the renal response to IRI. This includes; natural killer (NK) and NKT cells, renal dendritic 
cells (DCs), T cells and B cells. Substantial evidence is available to link all of these sub-types 
to the renal response to IRI, mainly linking their actions to direct targeting of injured tubular 
and endothelial cells, activation of neutrophils and macrophages, and secretion of pro-
inflammatory cytokines, such as IFN-γ, TNF-α, IL-4 and IL-10.  
Although initially regarded as by-standers, current evidence suggests that T cells are 
involved in the pathogenesis of IRI. Depletion of CD4 and CD8 T cells in mice with renal IRI 
has been shown to improve renal function and reduce neutrophil infiltration and tubular 
atrophy (Rabb et al., 2000). Furthermore, reconstitution of T cells in these T cell-deficient 
mice restored the level of injury (Burne et al., 2001). Pre- and post-ischaemic adoptive 
transfer of regulatory T cells (Tregs) has been shown to protect the kidney from ischaemic 
injury, reduce TNF-α and IFN-γ production and accelerate repair (Kinsey et al., 2009; 
Monteiro et al., 2009; Kinsey et al., 2013; Kinsey and Okusa, 2014).  
B cells are involved in the adaptive immune response to IRI by releasing antibody. To 
date, available studies showed a predominantly harmful effect of post-ischaemic B cell 
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activation (Linfert et al., 2009). Depleting B cells in mice improves renal function and 
reduces tubular injury after ischaemia (Burne-Taney et al., 2003). A study by Jang et al. 
reported that B cell-deficient mice subjected to ischaemia showed more tubular proliferation, 
less tubular atrophy and higher expression of IL-10 and VEGF (Jang et al., 2010). Further 
adoptive transfer of B cells into these mice exerted the opposite effect, suggesting that B cells 
may interfere with the post-ischaemic repair processes in the kidney. In contrast, another 
study found worse post-ischaemic renal injury in mice lacking all mature B cells (Renner et 
al., 2010), suggesting a more complex and divergent role for B cells in the progression of IRI.       
1.4. MicroRNA; an Overview of Structure, Biology and Function 
1.4.1. Introduction to MicroRNA 
A microRNA (miRNA) is a small non-coding RNA consisting of only ~20-30 
nucleotides in length. miRNA was first discovered in the nematode Caenorhabdtis elegans by 
the joint work of Victor Ambros, Rosalind Lee and Rhonda Feinbaum in 1993 (Lee et al., 
1993). Their initial work identified Lin-4 as a small non-coding RNAs, which acts as an 
endogenous regulator of various genes that control developmental timing in C. elegans 
(Carthew and Sontheimer, 2009). This finding led to a series of important discoveries, which 
have shaped our current understanding of the complexity and regulation of the transcriptome. 
MiRNAs are highly conserved across different mammalian species and play a pivotal role in 
cellular functions in normal conditions, such as cellular proliferation, cell cycle and 
developmental processes, cellular differentiation and apoptosis, as well as in a range of 
pathological processes, including cancer, degenerative diseases, auto-immune diseases, 
fibrogenic processes and IRI (Friedman et al., 2009; Bernardo et al., 2012). A miRNA can 
play its regulatory function by targeting several messenger RNAs (mRNAs), and may 
influence one or more pathways involved in cellular function. This ability to regulate multiple 
genes in a pathophysiological network is an attractive feature for the use of miRNA as 
biomarkers and therapeutic targets. The effect of a stimulus, such as ischaemia and 
reperfusion injury is exerted not only by one distinct mechanism, but through several 
synergistic pathways. Identification and targeting key miRNAs involved in this process would 
allow more comprehensive monitoring of a pathologic process and potentially enable a 
greater therapeutic effect. 
MiRNA is not the only post-transcriptional regulatory mechanism identified in cells. 
Evidence is available on the role of other non-coding RNAs, such as long non-coding RNA 
(lncRNA) and short interfering RNA (siRNA), in the regulation of various cellular functions. 
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As the name implies, the nucleotide length is the main difference between lncRNA (more than 
200nt) and short non-coding RNAs (i.e. siRNA and miRNA). LncRNA affects both RNA 
processing and protein function by complementary binding to its target RNA or directly 
interacting with target protein and facilitating riboprotein complex formation (Wilusz et al., 
2009). In principle, siRNA and miRNA function through similar mechanisms, thus cannot be 
distinguished based on their function alone. However, differences exist in their nature, 
structure, precursor and function as described in Table 1-3.  
Table 1-3 Distinction between the main features of siRNA and miRNA 
Characteristics miRNA siRNA 
Occurrence Naturally occurs across all species 
(plants, animals, human) 
Occurs in plants and lower animal 
species. Presence in mammals is 
questioned 
Structure Single stranded, 19-25nt Double stranded, 21-22nt 
Interaction to target 
and Mode of action 
No exact complementarity to target 
mRNA required. 
Result: mRNA decay, translational 
repression of many target mRNAs 
Exact match to target mRNA needed 
Result: mRNA endonucleolytic 
cleavage, specific genes knock-down, 
minor off-target effects 
Biogenesis Expressed by miRNA encoding genes 
(different from genes that they 
regulate) 
Expressed by the same genes that 
they regulate 
Precursors Precursor miRNA (pre-miRNA); 
hairpin structure containing 70-100nt 
with interspersed mismatches 
Double stranded RNA containing 30 
to >100nt 
Clinical applications Diagnostic tool / biomarker 
Therapeutic target 
Therapeutic target 
  
Increasing evidence links miRNAs to various physiological and pathological processes 
positioning miRNA as an attractive candidate for a diagnostic tool or therapeutic target 
(Schena et al., 2014; Wilflingseder et al., 2014). Moreover, unlike mRNA, the short nature of 
miRNA and its resistance to cleavage make miRNA very stable (Bhatt et al., 2011; Scian et 
al., 2013a; Wilflingseder et al., 2014). MiRNAs are reliably detected in body fluids or tissues. 
To compensate their diminutive size and lack of exact homology to target mRNA sequence 
miRNAs are present in high copy number, which facilitates in situ detection of miRNAs in 
blood, urine and fresh frozen and formalin fixed paraffin embedded tissues (Nuovo, 2010).     
1.4.2. MicroRNA Biology and Function 
MicroRNAs are found intracellularly in protein complexes and extracellularly in 
microvesicles in body fluids, such as urine or plasma (Bhatt et al., 2011; Maluf et al., 2014; 
Wilflingseder et al., 2014). MicroRNA biosynthesis involves a relatively complex pathway 
(Figure 1-3). Pri-miRNA, which is several kilobases in length, is derived from transcription of 
miRNA genes. Pri-miRNA has a distinct hairpin structure, which is recognised by a nuclear 
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protein, DiGeorge syndrome critical region 8 (DGRC8). The DGRC8 pri-miRNA complex 
recruits the RNAse Drosha to form the Microprocessor complex. This process leads to the 
cleavage pri-miRNA at the base of stem-loop, producing pre-miRNAs containing 
approximately 70 nucleotides. Pre-miRNA is transferred to the cytoplasm by exportin 5. In 
the cytoplasm, pre-miRNA is further cleaved to mature miRNA, which consists of 21-25 
nuclotides by the enzyme Dicer. The mature miRNA will interact with members of the 
argonaute protein (AGO) family to form the RNA-induce silencing complex (RISC), which is 
the effector complex of miRNA. MiRNA then plays its role by either blocking protein 
translation or degradation of target messenger RNA (mRNA) (Bhatt et al., 2011). The RISC 
is directed to target mRNA based on the complementary sequences in the miRNA and mRNA 
(Bhatt et al., 2011). The biology of miRNA can be modified by the introduction of miRNA 
mimic to over-express a certain miRNA, or by miRNA inhibitor or anti-miR (Figure 1-3). The 
modification of miRNA expression has the potential to be exploited in miRNA research and 
future therapies.  
 
Figure 1-3 Illustration of miRNA biology and mechanism of action 
Primary miRNAs (Pri-miRNA) are transcribed from a miRNA gene. This is followed by Drosha 
processing, which cleaved Pri-miRNAs into precursor miRNA (Pre-miRNA). Following export of 
Pre-miRNA into the cytoplasm, Dicer processes Pre-miRNAs into mature miRNA, which will be 
assembled into RNA-induce silencing complex (RISC) to perform its function (Bernardo et al., 2012) 
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1.4.3. MiRNA Nomenclature 
MiRNA nomenclature begins with the species of its origin; ‘hsa’ for homo sapiens, 
‘mmu’ for mouse, ‘rno’ for rat, ‘d’ for drosophilia, and many others. Description of whether it 
is a mature sequence or a precursor follows the description of the species. Precursor hairpins 
are written as ‘mir’, the gene that encodes a particular miRNA is written as ‘MIR’, whilst 
mature sequence is written as ‘miR’. This is then followed by number(s) as the actual name of 
the miRNA, which usually, but not always indicate the order of naming or timing of 
discovery relative to other miRNAs. Closely related miRNA with nearly identical sequences 
are annotated with an additional lower case after the number set (for example, miR-34a). In 
addition, identical miRNA sequences may be excised from opposite arms of the same 
precursor. These miRNAs will be labelled by adding ‘5p’ or ‘3p’ at the end of their 
annotations, indicating excision from either the 5’- or 3’- arm respectively (for example, miR-
21-5p or miR-21-3p). Addition of asterisk is given to indicate the “passenger” strand of the 
mature miRNA, which is usually thought to be degraded, except in a small number of 
miRNAs where it may also be functional. 
1.5. MicroRNAs; Their Relevance to Normal Cellular Function and Disease Processes  
Studies have identified specific miRNAs involved in regulating distinct cellular 
functions, such as cellular division, apoptosis, cellular metabolism, intra-cellular signalling, 
immunity and cellular movement. Abnormalities in the level of miRNAs, therefore, will also 
affect specific cellular functions leading to pathological outcomes. A role for miRNAs in the 
pathogenesis of human diseases have been identified in developmental disorders, cancer, 
autoimmune, infectious and inflammatory diseases involving almost all human organs.  
1.5.1. MicroRNAs in Human Developments and Diseases 
MiRNAs are involved in regulating at least 60% of transcripts of the human genome, 
and therefore play a part in diverse cellular functions and disease processes.  The roles of 
miRNAs in human diseases are complex and diverse. The apparent connection between 
miRNAs and the development of disease is supported by substantial miRNA profiling data 
showing altered expression of certain miRNAs in various disease processes. In some diseases, 
the degree of miRNA up-/down-regulation has also been associated with disease sub-types, 
severity and progression, highlighting the potential of miRNA as a meaningful diagnostic and 
prognostic marker.  
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MiRNAs play a role in the pathogenesis of cancer through two possible mechanisms; 
(1) by suppressing translation of tumour suppressor genes, or (2) by inhibiting important 
cellular regulatory processes such as apoptosis and cell differentiation (Waldman and Terzic, 
2009). The link between miRNAs and various form of cancer is well established, largely 
based on the abundant profiling studies available. This includes cancer of the lung, head and 
neck, gastrointestinal tract (oesophageal, gastric, colon), reproductive organs (breast, ovary, 
endometrium, and cervix), kidney and various haematological malignancies (Waldman and 
Terzic, 2009; Li and Kowdley, 2012). Because miRNA is tissue specific, the up-/down-
regulation of a miRNA is often unique for different type of cancer and organs involved, which 
is crucial for their use as screening tool, prognostic indicator or potential therapeutic target.  
Cardiovascular research is one of the earliest fields where the role of miRNA was 
recognised. MiRNAs play important role in the regulation of the cardiovascular system 
through several components, including endothelial cells, myocardium and the regulation of 
angiogenesis and vascular regression. So far, changes in miRNA expression level has been 
linked with cardiac hypertrophy, cardiac failure and cardiac development, primarily through 
miR-1, miR-133 and miR-208, which are expressed at a high level in the heart (Ardekani and 
Naeini, 2010; Li and Kowdley, 2012).  
MiRNA has also been demonstrated to play a very important role in the development of 
the brain and pathogenesis of various diseases involving the nervous system. Interestingly, the 
level of expression of several miRNAs was shown to be specific not only to different cell 
types of the nervous system, but also to certain neurodevelopmental phases (Ardekani and 
Naeini, 2010). Changes in the level of a distinct miRNA, therefore, may indicate an 
abnormality in a specific developmental stage. More importantly, this provides a strong 
support that miRNAs play a pivotal role in determining the fate of cellular lineage, as well as 
in cellular division, cellular programming and apoptosis (Ardekani and Naeini, 2010).  
Recent studies have demonstrated regulatory function of several miRNAs in 
inflammatory and immunological pathways. A recent study on cultured human endothelial 
cells identified the role of miR-126 in preventing leukocyte adherence to endothelial cells by 
inhibiting the expression of an adhesion molecule VCAM-1 (Harris et al., 2008). Another 
study using murine macrophages showed that secretion of cytokines, such as TNF-a and IFN-
b induces miR-155 expression, which has been linked to activation of immunological 
pathways through several actions, including granulocyte/monocyte expansion and B- and T-
cell activation (O'Connell et al., 2007). The role of miRNAs in cellular differentiation was 
also found in the development of inflammatory cells. Several studies have identified key 
miRNAs, such as miR-17 and miR-150, involved in B-cell maturation (Zhou et al., 2007; 
 
 
29 
Ventura et al., 2008), miR-424 in monocyte differentiation (Rosa et al., 2007) and miR-223 in 
granulocyte differentiation and activation (Johnnidis et al., 2008). The link between miRNAs 
and the immune system is further highlighted by significant changes in the expression profile 
of several miRNAs in inflammatory and autoimmune diseases, such as rheumatoid arthritis 
(Stanczyk et al., 2008; Tili et al., 2008) and systemic lupus erythematosus (Dai et al., 2007). 
The evidence mentioned above is only a small part of the abundant literature on the role 
of miRNAs in various human disease processes, which clearly reflects the biological 
importance and potential clinical utilisation of miRNAs.  
1.5.2. MicroRNAs in Kidney Physiology and Disease 
Early studies involving Dicer-knock-out mice highlighted the importance of miRNAs 
in maintaining structural and functional integrity of various components of the kidney, 
including renal endothelium, the glomerular barrier and tubular epithelial cells. The 
abnormalities observed suggest that miRNAs play a vital role in kidney development and 
kidney physiology. Conditional knock-out of Dicer in the ureteric bud epithelium of mice 
resulted in hydronephrosis and parenchymal cyst formation (Pastorelli et al., 2009). Selective 
deletion of Dicer in mouse podocytes induce cytoskeletal changes, which in turn causes 
proteinuria and glomerulosclerosis, leading to rapidly progressing chronic kidney disease 
(Harvey et al., 2008; Shi et al., 2008). Removal of Dicer from renin secreting cells of mice 
was also shown to deplete the number of juxtaglomerular cells, decrease renin gene 
expression and renin concentration in the plasma, and most importantly lowered systemic 
blood pressure (Sequeira-Lopez et al., 2010). The resulting pathologies included marked 
vascular deformity and fibrosis. In mouse proximal tubular epithelial cells, inhibition of Dicer 
resulted in global down-regulation of miRNAs, especially in the renal cortex (Wei et al., 
2010). However, this abnormal miRNAs expression level was not followed by histological 
changes or abnormal renal function. Interestingly, this change made the tubular cells more 
resistant to IRI, with improved renal function, less tissue damage, reduced apoptosis and 
better survival (Wei et al., 2010).  
The link between miRNA with various renal pathologies, such as acute kidney injury, 
fibrosis, polycystic kidney and neoplasm has been extensively studied (Spiegel et al., 2011; 
Chung et al., 2013; Hou and Zhao, 2013; Amrouche et al., 2014; Schena et al., 2014; 
Wilflingseder et al., 2014). As the leading cause of CKD, the association between diabetic 
nephropathy and miRNAs has been a major focus of research. Several miRNAs have been 
identified as important in the pathogenesis and progression of diabetic nephropathy, mainly 
based on studies using animal models.  
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The expression of a miR-192 was shown to be significantly higher in the mesangial 
cells of diabetic mice. MiR-192 targets SMAD-interacting protein 1 (SIP1), which regulates 
the expression of TGF-b induced Collagen type 1 and type 2. This is crucial in the 
progression of diabetic nephropathy (Kato et al., 2007). Based on this study, it is plausible 
that miR-192 acts as an effector of the TGF-b pathway. In contrast, another study 
demonstrated that treatment of tubular epithelial cells with TGF-b down-regulates the 
expression of miR-192, which correlated with increased fibrosis and decreased estimated 
GFR in diabetic nephropathy patients (Krupa et al., 2010). The results of both studies imply 
that the same miRNA may respond differently to the same stimulus (i.e. TGF-b stimulation) 
in different cell types, which makes interpreting and obtaining a comprehensive picture of a 
miRNA’s role more complex and challenging.  
The expression of a miRNA may fluctuate throughout the course of a disease. An 
animal study highlighting the role of miR-21 in diabetic nephropathy showed initial down-
regulation of miR-21 in early phase of the disease (Zhang et al., 2009). MiR-21 provides a 
degree of protection by preventing renal mesangial cell hypertrophy through inhibition of 
PI3K/Akt pathway (Zhang et al., 2009). However, other studies have shown that higher levels 
of miR-21 in renal biopsy specimens of diabetic nephropathy patients, and this is associated 
with more advanced renal pathology, including higher degrees of fibrosis (McClelland et al., 
2015). In addition, miR-216a and miR-217 have also been linked to the progression of 
diabetic nephropathy, primarily through PTEN inhibition, which in turn activates the Akt 
kinase pathway (Kato et al., 2009). 
The association between miRNAs and other kidney diseases were largely made by 
comparing miRNAs expression in affected patients to a normal cohort. Some of the kidney 
diseases associated with abnormal miRNA expression include; IgA nephropathy (miR-148b, 
miR-200c, miR-141, miR-205 and miR-192) (Wang et al., 2010; Szeto and Li, 2014), 
autosomal dominant polycystic kidney disease (down-regulation of miR-15a) (Lee et al., 
2008), lupus nephritis, hypertension (loss of down-regulation of angiotensin receptor-1 
(AGTR1) by miR-155) (Sethupathy et al., 2007), and renal-cell carcinoma, which is 
associated with dysregulation of a hypoxia-regulated miRNA, miR-210 (Jung et al., 2009).  
The role of miRNAs in the progression of acute kidney injury to chronic kidney disease 
is especially interesting. Epithelial-to-mesenchymal transition (EMT) has been proposed as an 
important contributor to the long-term development of fibrosis following acute injury in the 
kidney, and substantial evidence is available to link changes in miRNA profile to the 
development of EMT. The miR-200 family is among the most extensively studied miRNAs, 
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and they are involved in the regulation of EMT. Down-regulation of the miR-200 family 
induces EMT in a TGF-β dependent manner, which is implicated in progression of fibrosis 
and also in tumour metastasis (Gregory et al., 2008). In addition, induction of EMT was 
associated with a decrease in the expression level of miR-205. Inhibition of mature miR-205 
in Madin-Darby canine kidney epithelial cells lead to changes in cell phenotype including 
elongated cell morphology, loss of plasma membrane E-cadherin and ZO-1 expression and 
increased cytoskeletal stress-fibre formation (Gregory et al., 2008). Other miRNAs have also 
been examined in the context of fibrogenesis, among many are; miR-363, miR-192, miR-200, 
miR-21-, miR-34a, miR-155 and miR-127 (Goodwin et al., 2010; Shapiro et al., 2011; 
Aguado-Fraile et al., 2012; Chau et al., 2012; Saikumar et al., 2012; Li et al., 2013; van den 
Akker et al., 2015).  
1.5.3. MicroRNA in Kidney Transplantation and Ischaemia/Reperfusion Injury; Current 
Knowledge 
In the kidney transplantation setting, miRNA expression has been profiled in 
association with rejection, interstitial fibrosis, tubular atrophy as well as ischaemia and 
reperfusion injury. Correlation between intrarenal miRNAs, clinical and histological profile of 
a kidney transplant cohort revealed a set of differentially expressed miRNAs in acute rejection 
cases compared to normal allograft tissues (Anglicheau et al., 2009). The study identified 
overexpression of miR-142-5p, miR-155 and miR-223 during acute rejection, and highlights 
the potential for these miRNAs to predict acute rejection episodes (Anglicheau et al., 2009). 
Another profiling study detected down-regulation of 12 miRNAs (including miR-324-3p, 
miR-611, miR-654) and up-regulation of 8 miRNAs (including miR-658, miR-320, miR-381) 
in acute rejection cases (Sui et al., 2008). Interestingly, despite a very similar approach used, 
the changes in miRNAs listed were distinct and there was a lack of overlap between the two 
studies. This may be attributed to differences in patient characteristics or disparity in the 
technology of the profiling platform used. Moreover, it is important to acknowledge the 
contribution of potential confounding factors in these studies. These factors may be related to 
the renal function, presence of viral infection, effect of immunosuppressive drugs in the 
kidney and time since transplantation, all of which may affect the level of expression of 
miRNAs.  
Several authors have published the expression profiles of miRNA following IRI in the 
kidney. Numerous studies have been published, with most of the work performed in rodents. 
There is very little data to validate the observations made in rodent models to human cells or 
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diseases. Currently available studies on miRNA profile in kidney performed using ischaemia 
or reperfusion model are listed in Table 1-4. 
 
Table 1-4. Existing evidence in the involvement of various miRNAs in the renal response to IRI 
miRNA Model Treatment Expression / 
Results 
Effect / 
Target 
Ref. 
miR-10a Rat 45 min. bilateral 
renal pedicle 
clamping 
followed by 
reperfusion. 
Microarray 
profiling 
Up-regulated within 
1hr 
Not stated (Wang et 
al., 2014a) 
miR-18a Wistar rats 30 min. renal 
bilateral IRI 
Up-regulated in 
kidney tissue 
Blood: Down-
regulated 
Urine: Undetectable 
Not stated (Saikumar 
et al., 
2012) 
miR-20a C57BL/6 
mice 
30min. unilateral 
warm ischaemia 
Rapidly up-
regulated 
Not stated (Goodwin 
et al., 
2010) 
(Shapiro et 
al., 2011) 
miR-21 C57BL/6 
mice 
30min. unilateral 
warm ischaemia 
Rapidly up-
regulated 
Not stated (Goodwin 
et al., 
2010) 
(Shapiro et 
al., 2011) 
Mice 30 min. unilateral 
warm ischaemia 
Rapidly up-
regulated 
 (Chau et 
al., 2012) 
Mice miR-21+/+ vs 
mir-21-/- 
More Mpv17l in 
mir-21-/- 
amplifies ROS 
generation by 
targeting 
Mpv171 
(Chau et 
al., 2012) 
Mice miR-21-/- Higher serum 
creatinine after IRI 
Not stated (Jia et al., 
2013) 
Mice Xenon pre-
conditioning 
(protection for 
IRI) 
Up-regulated Not stated (Jia et al., 
2013) 
Wistar rats 30 min. renal 
bilateral IRI 
Up-regulated in 
kidney tissue 
Down-regulated in 
blood 
Down-regulated 
initially, modestly 
elevated within 72h 
in urine 
Not stated (Saikumar 
et al., 
2012) 
Mice IPC (ischaemic 
pre-conditioning) 
vs Sham 
Up-regulated in IPC Not stated (Xu et al., 
2014) 
Mice miR-21-/- and 
IPC 
Exacerbate IRI Up-regulate 
PDCD4 
(increase 
apoptosis) 
(Xu et al., 
2014) 
Mice miR-21-/-, no IPC No effect on IRI N/A (Xu et al., 
2014) 
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BALB/c 
mice 
Bilateral renal 
ischaemia 
(45min.) followed 
by reperfusion. 
Sham vs IRI 
assigned to: pre-
miR-21, 
antagomiR-21, 
PBS 
Pre-miR-21 + IRI: 
lower plasma BUN, 
creatinine, 
histological scores. 
Decreased PDCD4 
mRNA and active 
caspase-3, caspase-
8 protein 
expressions. 
Anti-apoptotic 
properties by 
supressing 
expression of 
PDCD4 gene 
and active 
caspase-3, 
caspase-8. 
(Hu et al., 
2014) 
miR-24 Human Observation on 
kidney transplant 
biopsy specimens 
with prolonged 
cold ischemic 
time 
Up-regulated Regulating H2A 
histone family, 
member X, 
heme 
oxygenase1 
(Lorenzen 
et al., 
2014) 
 Mice 
 
Unilateral I/R 
injury 
Up-regulated 
 
(Lorenzen 
et al., 
2014) 
 HK2 cells ATP depletion 
(chemical anoxia) 
for 1hr + ATP 
repletion for 
30min. 
Transfection with 
miR-24 
precursors  
miR-24 silencing 
Increased apoptosis 
Increased ROS 
production 
Altered functional 
parameters 
Ameliorate 
apoptosis, rescued 
functional 
parameters 
(Lorenzen 
et al., 
2014) 
miR-34 HK-2 cells 1% O2 Down-regulated Promote EMT (Du et al., 
2012) 
miR-126 Mice Bilateral renal 
pedicle clamping 
in control vs miR-
126 
overexpressed 
mice 
N/A Increase 
circulating Lin-
/Sca-1+/cKit+ 
haematopoietic 
stem and 
progenitor cells, 
thus promotes 
vascular 
integrity and 
supports 
recovery 
(Bijkerk et 
al., 2014) 
miR-127 Rat (NRK-
52E) 
HK2 cells 
Ischaemia / 
reperfusion 
 
Up-regulated Mediated by 
HIF-1α 
Target KIF3B, 
involved in cell 
trafficking. 
Involved in cell-
matrix and cell-
to-cell adhesion 
maintenance 
(Aguado-
Fraile et 
al., 2012) 
miR-
146a 
C57BL/6 
mice 
30min. unilateral 
warm ischaemia 
Up-regulated after 
day 3 
Not stated (Goodwin 
et al., 
2010) 
(Shapiro et 
al., 2011) 
miR-155 Wistar rats 30 min. renal 
bilateral IRI 
Up-regulated in 
kidney tissue 
Down-regulated in 
blood 
Unchanged (slight 
non-significant 
decrease) in urine 
 
Not stated (Saikumar 
et al., 
2012) 
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miR-187 C57BL/6 
mice 
30min. unilateral 
warm ischaemia 
Rapidly down-
regulated, continue 
to decrease 
Not stated (Goodwin 
et al., 
2010) 
(Shapiro et 
al., 2011) 
miR-192 C57BL/6 
mice 
30min. unilateral 
warm ischaemia 
Rapidly down-
regulated, continue 
to decrease 
Not stated (Goodwin 
et al., 
2010) 
(Shapiro et 
al., 2011) 
Rat 45 min. bilateral 
renal pedicle 
clamping 
followed by 
reperfusion. 
Microarray 
profiling 
Up-regulated after 
6hr 
Not stated (Wang et 
al., 2014a) 
miR-194 C57BL/6 
mice 
30min. unilateral 
warm ischaemia 
Down-regulated, 
remain at level ≈ 
control 
Not stated (Goodwin 
et al., 
2010) 
(Shapiro et 
al., 2011) 
Rat 45 min. bilateral 
renal pedicle 
clamping 
followed by 
reperfusion. 
Microarray 
profiling 
Up-regulated after 
6hr 
Not stated (Wang et 
al., 2014a) 
miR-
199a-3p 
C57BL/6 
mice 
30min. unilateral 
warm ischaemia 
Up-regulated after 
day 3  
Not stated (Goodwin 
et al., 
2010) 
(Shapiro et 
al., 2011) 
miR-210 Human  Urinary miRNA 
profile of stable 
transplant patients 
vs acute rejection 
Low miR-210 
associated with 
higher decline in 
GFR 1 year post-
transplant 
Not stated (Lorenzen 
et al., 
2011b) 
 Human Plasma miRNA of 
AKI patients vs 
healthy control 
Up-regulated Not stated (Lorenzen 
et al., 
2011a) 
 BALB/c 
mice 
30min. bilateral 
clamping of renal 
pedicle, followed 
by de-clamping 
Up-regulated, most 
prominent at 4hr 
and 24hr after 
reperfusion 
Targeting VEGF 
signalling 
pathway to 
regulate 
angiogenesis 
post IRI. 
(Liu et al., 
2012) 
miR-214 C57BL/6 
mice 
30min. unilateral 
warm ischaemia 
Up-regulated after 
day 3, wane by day 
21 
Not stated (Goodwin 
et al., 
2010) 
(Shapiro et 
al., 2011) 
miR-494 Mice Not stated Up-regulated 
rapidly (within 1 
hr) 
Reduce 
overexpression 
of ATF3  
(Lan et al., 
2012b) 
miR-714 C57BL/6 
mice 
27min. bilateral 
renal pedicle 
clamping 
Up-regulated at 3, 6 
and 24hr. 
Not stated (Bellinger 
et al., 
2014) 
miR-805 C57BL/6 
mice 
30min. unilateral 
warm ischaemia 
Down-regulated, 
remain at level ≈ 
control 
Not stated (Goodwin 
et al., 
2010) 
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(Shapiro et 
al., 2011) 
miR-
877* 
C57BL/6 
mice 
27min. bilateral 
renal pedicle 
clamping 
Up-regulated at 3, 6 
and 24hr. 
Not stated (Bellinger 
et al., 
2014) 
miR-
1188 
C57BL/6 
mice 
27min. bilateral 
renal pedicle 
clamping 
Up-regulated at 3, 6 
and 24hr. 
Not stated (Bellinger 
et al., 
2014) 
miR-
1224 
C57BL/6 
mice 
27min. bilateral 
renal pedicle 
clamping 
Up-regulated at 3, 6 
and 24hr. 
Not stated (Bellinger 
et al., 
2014) 
miR-
1897-3p 
C57BL/6 
mice 
27min. bilateral 
renal pedicle 
clamping 
Up-regulated at 3, 6 
and 24hr. 
Closely 
associated with 
Nucks1 gene 
expression, 
which putative 
downstream 
targets include 
genes linked to 
renal injury, 
inflammation 
and apoptosis 
(Bellinger 
et al., 
2014) 
 
Although there have been a lot of studies performed to identify which miRNAs are 
involved in the renal response to IRI, little has been done to elucidate their actual mechanism 
of action to. Furthermore, as described in Table 1-4, most published reports conducted their 
experiments on immortalised cell lines or animal models, and only a small number of studies 
have attempted to correlate these observations with results from clinically available tissues or 
perform experimental validation on primary human cells.  
Published data have suggested the potential of microRNAs to be utilised as biomarkers, 
therapeutic targets or to provide additional insights to the mechanisms of ischaemia and 
reperfusion injury in the kidney, especially in the transplantation setting. However, at present, 
this potential has not yet being fulfilled as results have been inconclusive and in some cases 
contradictory due to differences in study design and the technology platform used (van den 
Akker et al., 2015). 
1.6. Introduction to Methodology in MicroRNA Research 
A growing interest in understanding the physiological role of miRNAs has led to the 
development and modification of novel molecular genetic techniques. Principally, 
methodologies in miRNA include five major components; (1) small RNA isolation, (2) 
miRNA detection or profiling, (3) target determination and validation, (4) miRNA regulation 
and (5) clinical correlation. 
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1.6.1. Isolation of Small RNAs 
Developments in RNA isolation techniques have enabled researchers to capture small 
RNAs with <200nt either using specifically optimised kits for small RNA isolation or by 
isolating total RNA using a phenol-based reagent such as TRIzol® or TRI Reagent®, without 
the need for a small RNA enrichment step. Recovery of small RNA, including miRNAs has 
been performed successfully using Phenol based isolation techniques, and is the 
recommended procedure for isolating total RNA for miRNA profiling using microarray 
platforms. 
1.6.2. MicroRNA Detection and Profiling 
There are various methods available commercially to profile and detect expression of 
miRNAs. However, their technical development has not come without challenges. Bernardo 
et al. attributed these challenges to several miRNA features; (1) the short nature and lack of 
common sequence (e.g. poly(A) tail) in mature miRNAs, (2) the presence of target sequence 
in not only mature miRNA, but also in pri- and pre-miRNAs and (3) the sequence similarities 
between miRNAs of the same family, which may differ by only one nucleotide (Bernardo et 
al., 2012). Principally, microarray or deep sequencing platforms and real-time quantitative 
polymerase chain reaction (qPCR) are the most common instruments utilised in miRNA 
profiling.  
Microarray and deep sequencing enable researchers to simultaneously determine the 
relative change in expression level, rather than the absolute abundance, of a large set of 
miRNAs. The use of pre-designed microarray probes, which rely on available databases and 
prior knowledge of known miRNAs, limit the ability of this method to find new miRNA 
sequences. The introduction of deep sequencing platforms (or next generation 
sequencing/RNA-seq) overcomes this problem by its ability to provide absolute quantification 
of all RNA species in a sample. The technology provides opportunity for novel miRNA 
discovery. Predictably, this leads to the generation of a very large and complex dataset, which 
require new methods of data interpretation, bioinformatic analysis, validation and functional 
experiments (Koshiol et al., 2010; Bernardo et al., 2012).  
qPCR is a method commonly used to validate the results obtained from microarray or 
deep sequencing. The quantification step is preceded by reverse transcription of the miRNA 
of interest, which can be performed either by adding a stem-loop primer specific to a 
particular miRNA or by adding a universal sequence (poly(A) tail) to all miRNAs. The first 
method is quantified using TaqMan® assays, while the latter utilises SYBR based qPCR. The 
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use of miRNA specific primers provides more efficient and specific amplification, as well as 
allowing discrimination between mature miRNA and pre-miRNA. However, the technique is 
more expensive and requires separate reverse transcription reaction for each miRNA of 
interest. On the other hand, despite being more cost effective and less laborious, the use of a 
universal primer would not be able to differentiate mature from pre-miRNA sequence. 
In situ hybridisation (ISH) is the only technique available to visualise and localise 
miRNA in cells or tissue. Knowing the distribution of a particular miRNA is important in 
understanding its biological role. However, the steps involved in this technique require 
thorough and lengthy optimisation. Short probes used in ISH are less specific and may yield 
inconsistent and false negative results, especially when detecting low copy number miRNAs. 
Northern blotting is the least commonly used method, due to the time required, and the 
technical challenges involved in working with small and low copy number miRNAs. This 
technique requires high concentration of RNA in a sample to start with. Nonetheless, it is the 
only technique capable to detect both miRNA and its precursor. Both ISH and northern 
blotting have benefited from recent development of locked-nucleic acid (LNA) probes. LNA 
is formed by addition of a methylene bridge to nucleic acid analogues to “lock” the RNA 
conformation, resulting in higher binding affinity to complementary RNA, enhanced single 
nucleotide discrimination and better resistance to exo- and endonucleases, thus improving 
overall assay sensitivity and specificity (Vester and Wengel, 2004).  
1.6.3. Target Prediction and Validation 
The miRNA – mRNA interaction is determined by the seed region of miRNA, which 
contains a short nucleotide sequence. This property enables miRNA to bind with multiple 
mRNA targets, at the same time allowing a single mRNA to be regulated by multiple 
miRNAs. Using prediction databases that match miRNA seed region sequences to that of 
mRNAs, it is possible to predict potential target genes of a particular miRNA, which justifies 
further experimental validation. Currently, there are a number of miRNA prediction 
programmes freely accessible online, each relying on its own unique algorithm based on 
knowledge on miRNA behaviour. Target prediction of a miRNA is not recommended based 
on only a single database, due to differences in the criteria used by each algorithm. Available 
comparative studies failed to identify a single database that is consistently superior to the 
others. To combine the strengths of each programme, it is recommended to use three to four 
computational approaches in predicting miRNA targets or a single algorithm that combines 
several prediction databases (Li et al., 2010; Witkos et al., 2011; Bernardo et al., 2012).  
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To further verify miRNA targets, several experimental validation methods have been 
proposed. Reporter assays are amongst the most commonly used method. In principle, cell 
lines need to be transfected with plasmid containing luciferase reporter vector incorporated 
with the 3’ UTR of the predicted miRNA target. MiRNA-mRNA binding is confirmed by co-
transfecting the cells with either miRNA mimic or inhibitor. A change in luciferase 
expression is expected if miRNA-mRNA binding occurs. Alternatively, qPCR and Western 
blotting can be used to quantify the predicted targets of a miRNA, thus indirectly identifying 
potential miRNA-mRNA interactions. The same methodologies may also be applied to 
evaluate regulation and functionality of a miRNA of interest. Transfection of miRNA mimic 
or inhibitor to cultured cells may lead to a change in protein expression and consequently 
phenotypic alteration. Introduction of double-stranded miRNA mimic will complement 
endogenous mature miRNA leading to further protein inhibition. On the other hand, a miRNA 
inhibitor, which is single-stranded oligonucleotide, will block endogenous miRNA binding, 
increasing protein synthesis. These changes can then be assessed by several methods 
including immunofluorescence studies and Western blotting. 
In vitro validation of miRNA target is often followed by determination of its regulation 
and function in vivo. This is most commonly achieved by administering miRNA inhibitor in 
vivo to reduce the level of mature miRNA, thus increasing target mRNA and protein levels. In 
contrast, in vivo application of miRNA mimics in miRNA research is very limited, largely due 
to their significant off-target effects. Both miRNA inhibitors and miRNA mimics used in vivo 
must be chemically modified in a way to facilitate permeability into cells, delay excretion and 
enhance in vivo stability. However, these requirements can be problematic especially for 
miRNA mimics, as they will result in miRNA uptake by tissues that do not normally express 
the miRNA of interest, resulting in unwanted side effects (Rooij, 2011). A number of 
developments have been made to address this issue, including the use of viral vectors for 
miRNA mimic delivery. The use of adeno-associated viruses (AAVs) also enables continuous 
expression of miRNA, thus ensuring more effective replacement of down-regulated miRNAs. 
Different AAVs serotypes have different tissue specificity which can also be exploited to 
facilitate more directed delivery (Rooij, 2011).  
1.7. Aims and Hypothesis 
The aims of this study are to: 
1. Profile microRNA in kidney proximal tubular epithelial cell lines and human primary 
proximal tubular epithelial cells following ischaemia and reperfusion injury. 
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2. Identify key potential microRNAs which are involved in the renal response to 
ischaemia and reperfusion injury. 
3. Analyse functional aspects of those key microRNAs in vitro to try to explain their 
potential role in cellular response to injury. 
4. Validation of key microRNAs profile in vivo. 
 
This study hypothesises that ischaemia – reperfusion injury will result in changes in 
microRNA expression in renal proximal tubular epithelial cells, which will affect their 
morphology and function. 
 
 
 
40 
Chapter 2. General Methods and Reagents 
2.1. Risk Assessment 
All experiments conducted are in compliance with Biological Control of Substances 
Hazardous to Health (BIOCOSH) and Control of Substances Hazardous to Health (COSHH) 
regulations. Risk assessment form was submitted and approved by the University Biological 
Committee. All laboratory work was conducted in accordance with Institutional rules and 
regulations.  
2.2. Project Overview 
This project is divided into three main experimental steps as illustrated in Figure 2-1. 
The first part of the project was focused on the generation of primary PTECs, which involved 
optimisation of the isolation protocol and characterisation of the cells isolated. The second 
part of the project was directed at generating protocols for inducing ischaemia and reperfusion 
injury in the cells and evaluating the changes induced by these injuries. More importantly, the 
second part of the project concentrated in profiling the changes of miRNAs, selection of 
candidate miRNAs, and prediction and validation of their target genes. The last part of the 
project was aimed at interrogating the biomolecular role of specific miRNAs in vitro and 
validating their expression and distribution in human tissues.  
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Figure 2-1. Project flowchart  
Summary of the overall experimental steps involved in the study. Numbers indicate the sequence in 
which these experimental steps were conducted. 
2.3. Tissue Culture; HKC-8 & HK-2 Cells 
2.3.1. Cells Lines Used 
HKC-8 is an immortalised human cortical kidney tubular epithelial cell developed in 
the National Cancer Institute, Bethesda, US. The cell line was immortalised by transfection 
with an Adenovirus-12 SV40 vector. HKC-8 has been well characterised and demonstrated to 
have a profile of cell integrins typical of the proximal tubule (Thraves et al., 1990). Its 
biochemical properties were also found comparable to other established cell lines, including 
LLC-RK1, OK and HK-2 cells (Racusen et al., 1996). HKC-8 has been used in several 
studies, including those focusing on the role of epithelial cells in renal fibrosis (Moll et al., 
2013). 
HK-2 is an immortalised proximal tubular epithelial cell line from normal adult human 
kidney developed in the Fred Hutchinson Cancer Research Centre, USA. It is derived from a 
primary proximal tubular epithelial cell culture of normal adult human renal cortex. The cells 
were immortalised by recombinant retrovirus containing HPV 16 E6/E7 genes (Ryan et al., 
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1994). It has been shown to retain functional characteristics of primary tubular epithelium and 
demonstrated reproducible experimental results compared with freshly isolated proximal 
tubular epithelial cells (Ryan et al., 1994). 
2.3.2. Culture & Maintenance of HKC-8 and HK-2 Cells 
HKC-8 and HK-2 cells were cultured in specified growth medium as described in Table 
2-1. The cells were grown in a humidified incubator at 37°C with 5% CO2 until they reached 
approximately 80% confluence. To passage, the culture medium was removed and replaced 
with 4 mL of sterile Dulbecco’s Phosphate Buffer Saline (DPBS; Sigma-Aldrich, USA). 
DBPS was removed prior to incubation with 0.5 gram/L Trypsin – 0.2 gram/L EDTA (Lonza, 
Switzerland) for 5 minutes. Trypsin-EDTA will break cell adhesion to the culture dish and 
cell-to-cell adhesion. Detached cells were recovered by adding culture medium before 
centrifugation for 5 minutes at room temperature. The supernatant was discarded. Cells were 
seeded onto a plastic flask. For experimental purposes, the cells were seeded in 6-well plates 
at 100,000 cells/mL/well, with 2mL cells suspension in each well.  
Table 2-1 Specification of culture media, media supplementation, centrifugation and seeding 
protocol for cell line 
Cells Base Culture Medium 
Medium 
supplementation 
Rotor 
speed 
(G) 
Seeding 
vessel 
Seeding 
density 
HKC-8 DMEM / HAM 
F-12 (Lonza) 
5% FBS (Sigma)  
100 U/mL Penicillin 
100 µg/ml Streptomycin 
(Sigma) 
1,000 g 75cm2 flask 
 
6-wells plate 
2 x 105 
cells/mL 
0.5 x 105 
cells/mL/well 
HK-2 DMEM – high 
glucose (4.5 
gram/L)  
(Lonza)  
5% FBS (Sigma) 
100U/mL Penicillin 
100µg/ml Streptomycin 
(Sigma) 
300 g 25cm2 flask 
 
6-wells plate 
1.5 x 105 
cells/mL 
0.5 x 105 
cells/mL/well 
2.3.3. Cell Counting 
Cells were counted manually using a haemocytometer. The pellet was re-suspended in 
1 mL culture media. 10 µL of cell suspension was mixed with 10 µL of 0.4% Trypan blue 
(Sigma-Aldrich, USA) to estimate cell count per millilitre. The mixture placed in a 
haemocytometer and a bright field inverted microscope was used to count the number of cells. 
Viable cells should exclude the blue dye, thus will appear clear against the blue background.  
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2.3.4. Cryopreservation, Recovery & Passage Selection 
Alternatively, cells were cryopreserved by re-suspending the cell pellet in foetal bovine 
serum (FBS) containing 10% Dimethylsulfoxide (DMSO; Sigma-Aldrich). The suspension 
was stored in a 1.5 mL cryovial which was frozen gradually at -80°C before transferring to 
liquid nitrogen for long-term storage. If required, cryopreserved cells were thawed slowly to 
37°C. Once thawed, complete culture media was added to the suspension. The mixture was 
centrifuged for 5 minutes (centrifuge speed is described in Table 2-1) at room temperature 
and cells re-suspended in media. Subsequent culture and propagation were performed as 
described previously. To ensure reproducibility, I only used cells with passage number 38-40 
for HKC-8 cells, and passage number 10-15 for HK-2 cells. 
2.4. Isolation of Primary Proximal Tubular Epithelial Cells 
2.4.1. Tissue Origin and Ethical Approval 
Ethical approval was obtained from National Research Ethics Committee, East 
Midland, UK for works on gene and protein expression in the kidney (REC reference number 
13/EM/0311). Kidney tissue was derived from macroscopically normal parts of nephrectomy 
specimens removed for oncological indications. The tissue was collected in sterile RPMI 
1640 media (isolation media; Sigma-Aldrich, USA) supplemented with 5% FBS and 
Penicillin (100 U/mL) / Streptomycin (100 µg/ml), and was immediately transported at 4°C 
for cell isolation.  
2.4.2. Isolation Protocol 
All isolation steps were conducted in a sterile environment dedicated to human primary 
cell work. The renal fibrous capsule and medulla (if present) were removed, leaving only the 
renal cortex. Tissue was inspected for any macroscopic pathology, which if evident would 
exclude the sample from further isolation steps. Gross weight of the specimen should be at 
least 1.5 gram wet weight. Renal cortex was minced into approximately 1 mm3 pieces. 
Collagenase-4 (Sigma-Aldrich, USA) was added to isolation medium to make the final 
concentration of 0.67 mg/ml and tissue was incubated at 37°C for 2 hours on an automated 
rocker.  The suspension then passed through a 40 µm cell strainer. Discontinuous Percoll 
(Sigma-Aldrich, USA) gradients were made up in two densities; 1.04 gram/mL in isolation 
medium and 1.07 gram/mL in PBS. The sieved suspension was loaded onto the gradient and 
spun down at 900 g for 25 minutes at 4°C. A band containing tubular epithelial cells should 
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be visible after the centrifugation. This population was recovered by careful aspiration and 
was seeded into a 25 cm2 flask for further culture.  The seeding density in a 25 cm2 flask 
should not exceed approximately 1.5 x 105 cell/mL. This seeding density should reach 80-
90% confluency in 5-7 days. Culture media was replaced every 2-3 days by mixing the new 
media with 1mL of conditioned media. The detail of media used and their respective 
supplementation can be found in Table 2-2.  
Table 2-2 Type and composition of media used in isolation and culture of human primary 
PTECs 
Cells Base Culture Medium Medium supplementation 
Isolation 
medium 
RPMI 1640  
(Sigma)  
5% FBS (Sigma) 
100 U/mL Penicillin 100 µg/ml Streptomycin (Sigma) 
Culture 
medium 
DMEM / HAM F-12 
(Lonza) 
REGM SingleQuot Kit + growth factors (Lonza), 
containing: 
   0.5 mL Insulin 
   0.5 mL Hydrocortisone 
   0.5 mL GA-1000 
   0.5 mL Adrenaline 
   0.5 mL T3 
   0.5 mL Transferrin 
   2.5 mL FBS 
   Human epithelial growth  
   factor 
2.4.3. Passaging Cells 
Cells were passaged once they reached 80% confluency. Confluent cells were washed 
and detached using trypsin EDTA as previously described in section 2.3.2. Trypsin was 
neutralised by adding growth media before pelleting the cells by centrifugation at 500 g for 5 
minute. To maintain subsequent passages, 25 cm2 flask was used with 1.5 x 105 cell/mL 
seeding density. For use in specific experiments, cells were seeded in accordance to the 
experimental protocol, using multi-well plates.  
2.4.4. Cryopreservation, Recovery & Passage Selection 
Cryopreservation was performed by re-suspending the cell pellet in freezing medium 
containing FBS and 10% DMSO (Sigma-Aldrich, USA). The suspension was transferred to 
1.5 mL cryovials. Cell cooling was performed gradually at a rate of approximately 1°C per 
minute using a cryo-freezing container until reaching -80°C. Cryovials were placed in liquid 
nitrogen for long-term storage.  Recovery was performed as described for HKC-8 and HK-2 
cells. 
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2.5. RNA Isolation and Quality Control 
2.5.1. Protocol 
Cells were harvested from flasks or plates by trypsinisation and centrifugation. 
Remaining growth medium was replaced with DPBS (Sigma-Aldrich, USA), and samples 
were kept on ice (4°C). RNA was isolated using miRvana microRNA isolation kit (Ambion, 
Life Technologies, USA). Briefly, DPBS was removed followed by disruption of cells using 
lysis buffer and denaturing solution in 1:1 ratio, using 300 µL of lysis buffer for every 1 
million cells. Purification and DNA removal were performed by adding Acid-Phenol: 
Chloroform extraction mixture, followed by 5 minute centrifugation at 12,000 g at room 
temperature. The mixture should separate into aqueous and organic phases after 
centrifugation. Using 100 µL pipette, the upper aqueous phase was carefully transferred into a 
fresh micro-centrifuge tube. The volume of aqueous phase collected should be recorded at this 
step, in order to accurately determine the volume of 100% ethanol to be added subsequently. 
Pure ethanol was added to the sample, and the mixture was passed through the filter cartridge. 
Samples were washed and centrifuged three times using two types of Washing Solutions 
provided in the kit (once with Was Solution 1, and twice with Wash Solution 2/3). The flow-
through was discarded after each washing step. To ensure complete removal of organic 
compunds, the filter cartridge, was centrifuged at 11,000 g for 2 minutes at room temperature. 
The filter cartridge was transferred into a new collection tube. 100 µL of nuclease-free water 
was heated at 60°C, and then added to the centre of the filter cartridge. The tube was 
centrifuged at 12,000 g to elute the final RNA product. The product was immediately placed 
on ice for analysis or quality control, or stored in -80°C.  
2.5.2. RNA Quality Control 
RNA quality was evaluated by spectrophotometry (NanoDrop ND-1000: Thermo 
Scientific, USA) and agarose gel electrophoresis.  Purity of RNA was assessed from the ratio 
of absorbance of a sample at 260 nm and 280 nm, as well as 260 nm and 230 nm. A ratio 
equivalent to 1.8 – 2.0 was considered acceptable for RNA. Lower than acceptable ratio 
indicates possibility of protein or other contaminants with absorption close to 280 nm.  An 
acceptable ratio value of 260/230 nm absorbance was 2.0-2.2. Lower absorbance value may 
be a sign of carbohydrate, phenol or other contaminants, which absorb at 230 nm. Each RNA 
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sample was validated individually before being used in downstream gene expression analysis 
assay.  
Based on absorbance measurements the RNA was free of significant contamination. 
Figure 2-2 shows the spectrophotometry results of RNA isolated from human primary PTEC, 
HKC-8 and HK-2 cells. Absorbance ratios at 230 nm, 260 nm and 280 nm were all within 
acceptable range (Figure 2-2). The isolation method was also proven to yield a good RNA 
concentration. In summary, the spectrophotometry results indicated that relatively pure RNA 
was isolated from cells. Consistent RNA concentration obtained from each cell line indicated 
consistent cell seeding density and reproducibility of the RNA isolation methods used. 
 
 
Figure 2-2 Spectrophotometry results of RNA isolated from different cell types  
The figures demonstrate absorbance at 280 nm, 260 nm and 230 nm. Results were randomly selected 
representative of RNA isolation result from (a) HKC-8 cell, (b) HK-2 cell and  (c,d) human primary 
PTECs obtained from two different patients  
 
In addition, RNA integrity was evaluated using agarose gel electrophoresis. A 1.2% 
agarose gel was prepared in 1x TBE buffer (Table 2-3) containing 0.5 µg/mL Ethidium 
Bromide.  The mixture of RNA and loading dye was heated at 65°C for 5 minutes before 
loading. Electrophoresis was performed in 1x TBE buffer at 10 V/cm.  
 
 
a b 
c d 
HKC8 HK2 
pPTEC pPTEC 
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Table 2-3 1x TBE buffer composition 
Reagents Weight Concentration 
Tris Base 10.8 gram 89mM 
Boric Acid 5.5 gram 89mM 
Na2EDTA 0.93 gram 2mM 
 
Subsequently, the gel was imaged under UV light (Syngene G:Box gel dock and 
software) to detect the presence RNA bands. 1 kb DNA ladder (Promega, USA) was used as 
reference and positive control. Visible and intact 28s rRNA and 18s rRNA bands indicates 
good RNA integrity. Figure 2-3 illustrated the integrity of RNA isolated from HKC8 cells, 
with two distinct bands (18s and 28s rRNA) visible on RNA gel electrophoresis. 
 
 
Figure 2-3. RNA gel electrophoresis 
Gel electrophoresis of RNA isolated from HKC-8 cells. 1 µg of total RNA was loaded into a lane 
(denoted as RNA). 1 kb DNA ladder (denoted as LAD) was used as a reference and positive control. 
2.6. Gene Expression Analysis 
2.6.1. Reverse Transcription 
First strand cDNA was synthesised using TaqMan® Small RNA Assays - Reverse 
Transcription Kit (Life Technologies, USA). This is a commercially available kit, with pre-
formulated primer and probe sets designed to detect and quantify mature microRNAs 
(miRNAs). Principally, the assay consists of two main steps; (1) hybridisation of a miRNA 
specific stem-loop reverse transcription (RT) primer to a single-stranded miRNA, and (2) 
addition of reverse-transcriptase enzyme, which extends the cDNA (Figure 2-4). 
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Figure 2-4 Reverse transcription of a miRNA 
Illustration of the first step in quantifying miRNA expression using real-time PCR, which involved 
addition of a specific stem-loop RT primer followed by reverse-transcriptase enzyme. Source: 
(Bernardo et al., 2012)  
Briefly, a master-mix containing the components listed in Table 2-4 was made in 
accordance to the assay protocol. The master mix was then added to the mixture of 5x miRNA 
specific reverse-transcription primer and the RNA sample. The composition of each RT 
reaction is summarised in Table 2-4. 
Table 2-4 Components of RT Reaction 
RT master mix Component Vol. (µL) / reaction 
100mM dNTPs (with dTTP) 0.15 
MultiSCribe™ RTase, 50U/uL 1.00 
10x RT Buffer 1.50 
RNase Inhibitor, 20U/uL 0.19 
Nuclease-free water 4.16 
Master mix volume 7.00 
     +  5x RT primer 3.00 
     +  RNA sample 5.00 
Total volume 15.00 
 
Each reaction was performed in a 0.2 mL nuclease-free microtube which was 
centrifuged for 2 minute at 2,000 g at room temperature. After a 5-minute incubation period 
on ice, the samples were placed in a thermal-cycler (TC-512, Techne Bibby Scientific). The 
thermal cycler settings shown in Table 2-5 were used. 
Table 2-5 Reverse transcription thermal cycler setting 
Step Time Temperature 
Hold 30 minutes 16°C 
Hold 30 minutes 42°C 
Hold 5 minutes 85°C 
Hold ∞ 4°C 
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2.6.2. Real-time PCR 
2.6.2.1. Materials & Protocol 
TaqMan qPCR Assay kits (Life Technologies, USA) were used to quantify miRNA 
expression. Each PCR reaction contained the components shown in Table 2-6. The initial 
phase of the assay denatured the double-stranded cDNA by increasing temperature. TaqMan 
oligonucleotide probes contain a reporter fluorescent dye on the 5’ end and quencher dye on 
3’ end. When target sequence is detected, the probe anneals, allowing it to be cleaved by the 
5’ nuclease activity of Taq DNA polymerase. This cleavage separates the reporter dye from 
the quencher, increasing emission (Figure 2-5).  The increase in fluorescence intensity will be 
proportional to the number of amplicons produced, as more reporter dye molecules are 
cleaved with each PCR cycle. This method permits specific hybridization between probe and 
target, and measurement of multiple targets in one reaction. Primers used in this study are 
listed in Table 2-7 
Table 2-6 Components of PCR Reaction 
Component Vol. (µL) / reaction 
TaqMan Small RNA Assay (20x) 1.00 
Product from RT Reaction 1.33 
SensiFAST™ Probe-HiROX mix 10.00 
Nuclease-free water 7.67 
Total volume 20.00 
 
 
 
Figure 2-5 Amplification and miRNA detection by TaqMan probe 
MiRNA sequence was amplified using forward and reverse primer, and TaqMan probe specific for the 
miRNA. TaqMan probe is dual labelled with a fluorophore (F) and a quencher (Q). Source: (Bernardo 
et al., 2012)   
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Table 2-7 PCR Primers 
Primer Name Nucleotide sequence Source 
hsa-miR-21-5p UAGCUUAUCAGACUGAUGUUGA Life Technologies, USA 
hsa-miR-34a-5p UGGCAGUGUCUUAGCUGGUUGUU Life Technologies, USA 
hsa-miR-363-3p AAUUGCACGGUAUCCAUCUGUA Life Technologies, USA 
hsa-miR-210-5p AGCCCCUGCCCACCGCACACUG Life Technologies, USA 
hsa-miR-142-3p UGUAGUGUUUCCUACUUUAUGGA Life Technologies, USA 
hsa-miR-130b CAGUGCAAUGAUGAAAGGGCAU Life Technologies, USA 
 
Each reaction was loaded into a 96-well plate. The real-time PCR system (7500 Fast 
real Time PCR System, Applied Biosystem, USA) was set in accordance to the 
manufacturer’s protocol (Table 2-8) 
Table 2-8 PCR Setup for MicroRNA 
Step 
Enzyme Activation PCR 
Hold Cycle (40 cycles) Denature Anneal/extend 
Temperature 95°C 95°C 60°C 
Time 10 minutes 15 seconds 60 seconds 
Run mode: standard 
Sample volume = 20µL 
 
2.6.2.2. Data Analysis 
During the initial phases of a PCR, little change in fluorescent signal should be 
detected. This is regarded as baseline. A fixed fluorescence threshold was set above the 
baseline for each PCR amplification plot. The cycle number at which the fluorescence 
detection passes the fixed threshold was recorded (CT or threshold cycle) for each reaction.  
Comparative quantification (ΔΔCT) was used to determine the fold difference in gene 
expression. This method of qPCR analysis allows comparison between a given sample with a 
control sample (control / calibrator) and a reference gene (normaliser / endogenous control). 
The calculation for this analysis is summarized below (tar C = target gene in control; ref C = 
reference gene in control; tar S = target gene in sample; ref S = reference gene in sample). 
CT tar C - CT ref C = ΔCT calibrator 
CT tar S - CT ref S = ΔCT sample 
ΔCT sample - ΔCT calibrator = ΔΔCT 
Fold difference = 2 –ΔΔCT 
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2.6.2.3. Reference Gene Selection 
An ideal reference gene should be expressed constantly and with high abundance 
across the cell lines of interest and under different conditions. Several human endogenous 
controls have been identified, with RNU48, among others, reported as the most highly 
abundant across a selection of 38 human tissues (CT = 22.2 ± 0.8) (Biosystems, 2007). 
RNU48 also showed relatively stable expression in National Cancer Institute-60 human cell-
lines (CT = 22.2 ± 1.4) (Biosystems, 2007). I confirmed this abundance and stability of 
expression by analysing CT values of RNU48 across the cell lines used in this study as well as 
across different treatment conditions (Figure 2-6). Threshold cycle of RNU48 was similar in 
HKC-8 and HK-2 cells. This is the basis of selecting RNU48 as reference gene in our study. 
 
 
Figure 2-6 RNU48 threshold cycle in HKC-8 and HK-2 cells in various treatment conditions 
CT values of RNU48 in HKC-8 and HK-2 cells. Comparison was made between the cells incubated in 
1% O2 for 24-hour, the cells treated in H2O2 and untreated cells. Each point represents the mean of CT 
values + SD of three samples. Detection of the difference between the mean was performed using one-
way ANOVA test. 
 
2.6.2.4. Primer Efficiency 
The efficiency of both the reference and target primers were measured by performing 
PCR for reference and target gene on serial dilutions of cDNA (1:10, 1:100, 1:1,000 and 
1:10,000). The CT values of each dilution were used to generate a standard curve. The slope 
(y) was obtained from the standard curve and was used to calculate percentage amplification 
efficiency (E) using the formula below: 
E = [(10–1/slope)-1] × 100% 
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The acceptable percentage amplification efficiency result should be between 85% - 
110% (Biosystems, 2014). Experiments to validate primer efficiency were performed for three 
genes of interests (miR-21, miR-34a and RNU48), which were used in the initial phase of this 
study. Through serial dilutions of cDNA, each primer set showed an increase in CT values 
(Figure 2-7). The efficiency for all primers was close or within the accepted range. 
 
 
Figure 2-7 Primer efficiency validation of RNU48, miR-21 and miR-34a 
Primer efficiency validation of (a) RNU48 as reference gene, (b) miR-21 and (c) miR-34a. Three 
replicates were for each cDNA dilution of a primer. The experiments were performed using RNA 
isolated from untreated HKC-8 cells. Percentage efficiency (E) was calculated from the slope (y) 
generated from each standard curve, using the formula E = [(10–1/slope)-1] × 100%. The acceptable 
range is between 85%-110% 
 
2.7. Luciferase Assays 
2.7.1. Materials and Protocol 
Reagents and buffers used in all luciferase assays were performed using a Luciferase 
Assay System kit (Promega, USA). The system required lysis of the cells containing the 
luciferase, which was followed by addition of luciferase assay reagent that generates nearly 
 
 
53 
constant light for at least 1 minute. The amount of light generated reflects the activity of 
firefly luciferase present.  
Briefly, cells containing the luciferase reporter under the control of a promoter of 
interest were used for this assay. After removal of growth medium, cells were washed gently 
with sterile PBS. Cells were lysed by dispensing 100 µL of 1x Lysis Reagent provided in the 
kit, into each well used in a 24-well plate. Samples underwent a freeze-thaw cycle at 37°C for 
10 minutes followed by -80°C for 10 minutes before mechanically detached from plate using 
a cell scraper. The cell suspension was mixed well and centrifuged at 2,000 g for 15-30 
seconds. 30 µL of each cell suspension was transferred into a designated well in a 96-well 
white opaque plate. 70 µL of luciferin reagent was added to each 30 µL sample immediately 
prior to luciferase activity measurement. Luciferase activity was measured using a multimode 
microplate reader (Molecular Devices, USA). The remaining 50 µL of cell suspension was 
used for protein quantification. Luciferase activity was normalised to the total protein 
concentration of the sample. Normalised values were analysed to detect differences in 
luciferase activity between samples.  
The cells containing the luciferase reporter used in this study include SMAD3-
luciferase HKC-8 cells, HRE-luciferase HKC-8 cells, and pGL3-luciferase HKC-8 cells. The 
details of these cells will be discussed under sub-sections describing their use in specific 
experiments.  
2.8. Western Blotting 
2.8.1. Materials 
Buffers and reagents used for Western blotting (WB) are listed in Table 2-9. Western 
blot technique was used in various experimental steps of this project. Primary and secondary 
antibodies used are listed in Table 2-10 and Table 2-11 respectively. 
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Table 2-9 General buffers, washing solutions and other reagents used in Western blotting 
Buffers / Reagents Contents Source 
RIPA buffer 150 mM NaCl 
50 mM Tris (pH 7.5) 
0.1% sodium dodecyl sulfate (SDS) 
1% Triton x-100 
0.5% deoxycholic acid 
10 µL/mL phosphatase inhibitor 
protease inhibitor  
made up to 50 mL with nanopure water 
Sigma 
Sigma 
Sigma 
Sigma 
Sigma 
Abcam 
Thermo Scientific 
4X Laemmli sample 
buffer 
355 mM 2-mercaptoethanol (50 µL) + 
950 µL of 4X Laemmli buffer 
Sigma 
Bio-Rad, USA 
10X MOPS running 
buffer 
MOPS 52.3 gram 
Tris (base) 30.3 gram 
SDS 5 gram 
EDTA 1.5 gram 
Make up to 1 L with distilled water 
Sigma 
Sigma 
Sigma 
Sigma 
10X Transfer buffer Tris (base) 30.2 gram 
Glycine 144 gram 
Make up to 1 L with distilled water 
Sigma 
Sigma 
 
10X Tris-buffered 
saline (TBS) 
NaCl 87.6 gram 
Tris (base) 12.1 gram 
pH 8.0 
Make up to 1 L with distilled water 
Sigma 
Sigma 
 
TBS Tween (TBST) 9 volumes of distilled water 
1 volume of 10X TBS 
0.05% w/v Tween-20 
 
 
Sigma 
Blocking solution 5% w/v non-fat dry milk in 1X TBST Not applicable 
General diluent for 
antibodies (see Table 
2-10 and Table 2-11 
for exception) 
1% w/v non-fat dry milkin 1X TBST Not applicable 
Developing substrates Pierce ECL Western blotting substrates Thermo Scientific 
Film developer RG X-ray developer solution Champion Photochemistry 
Film fixer RG X-ray fixer solution Champion Photochemistry 
 
2.8.2. General Protocol 
Protein lysates for Western blotting were prepared by mixing cells with a pre-made cell 
disruption (RIPA) buffer. From here on, cells were kept at 4°C. 100 µL of RIPA buffer was 
added to every well in a 6-well plate. Cells were scraped and transferred into a 
microcentrifuge tube and sonified twice for 10 second with approximately a 5-10 second 
interval. Lysates were centrifuged at 4°C, at maximum speed (12,000 g) for 15 minutes. 
Supernatant was aspirated without disturbing the debris at the bottom of the tube, and 
transferred into a clean tube. Protein concentration was measured using the BCA protein 
assay. Lysates were diluted to 1 µg/µL in 4X Laemmli sample buffer containing 2-
mercaptoethanol. Samples were heated to 95°C for 5 minutes.  
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Protein electrophoresis was performed using pre-cast 4-12% Acrylamide protein gel, 
1.0 mm (Invitrogen, USA), immersed in 1X MOPS running buffer. Protein gels were run at 
120 constant voltage for approximately 2 hours. Proteins were transferred to a 0.2 µm-pore 
PVDF membrane (Amersham, USA) using a semi-dry transfer method for 30 minutes at 1 A; 
25 V. The membrane was washed and blocked using blocking solution at room temperature 
for 1 hour.  Subsequently, the membrane was incubated in the diluted primary antibody at 4°C 
overnight. The antibody was diluted in the diluent listed in Table 2-10. Diluted secondary 
antibody was applied after the membrane was adequately washed (four times 10 minutes 
washing time) using 1X TBS. Diluent for secondary antibody is listed in Table 2-11. The 
membrane was incubated in secondary antibody for 2 hours at room temperature. Prior to film 
exposure, Pierce enhanced chemiluminescent (ECL) substrates were applied onto the 
membrane for 1 minute. Protein bands were visualised by exposing the membrane to a film 
for a designated exposure time, followed by film development and fixing.   
2.8.3. Protein Band Intensity Analysis 
Protein band intensity was quantified using image analysis software, ImageJ 
(Schindelin et al., 2015). The band intensity of a particular protein was normalised to the 
intensity of a loading reference protein (GAPDH) band of the respective sample. The 
normalised intensity measurements were compared to identify the effect of a particular 
treatment given.  
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Table 2-10 Primary Antibodies 
Protein Antibody Source Host Target Application Clonality Dilution Diluent Secondary Antibody 
ZO-1 Anti-ZO-: sc-10804 Santa Cruz Bio, Inc. Rabbit Human IF Polyclonal 1 : 100 PBS 1 
E-Cadherin  Anti-E-Cadherin BD Transduction 
Lab. 
Mouse Human IF 
WB 
Monoclonal 1 : 100 
1 : 2000 
PBS 
General 
2 
5 
K-Cadherin  Anti-K-Cadherin: sc-1503 Santa Cruz Bio, Inc. Goat Human IF Polyclonal 1 : 100 PBS 4 
Cytokeratin  Anti-Cytokeratin 19 Abcam Rabbit Human IF Polyclonal 1 : 100 PBS 1 
α-SMA Anti- α-Actin: sc-32251 Santa Cruz Bio, Inc.  Mouse Human IF 
WB 
Monoclonal 1 : 100 
1 : 1000 
PBS 
General 
2 
5 
Vimentin Anti-Vimentin Abcam Rabbit Human IF Polyclonal 1 : 100 PBS 1 
Collagen I Anti-Collagen I Abcam Rabbit Human IF Polyclonal 1 : 100 PBS 3 
Collagen I Anti-Collagen I alpha 1 Novus Bio Rabbit Human WB Polyclonal 1 : 1000 Blocking sol. 6 
SMAD3 Anti-SMAD3 Abcam Rabbit Human IF Polyclonal 1 : 100 PBS 3 
SMAD7 Anti-SMAD7 Invitroge Rabbit Human WB Polyclonal 1 : 1000 Blocking sol. 6 
HIF-1α Anti-HIF-1α Santa Cruz Bio, Inc Mouse Human IF Monoclonal 1 : 100 PBS 2 
GAPDH Anti-GAPDH Sigma Mouse Human WB Monoclonal 1 : 2000 General 5 
GAPDH Anti-GAPDH Sigma Rabbit Human WB Polyclonal 1 : 2000 General 6 
Table 2-11 Secondary Antibodies 
Number Antibody Source Host Target Application Dilution Diluent 
1 Alexa Fluor 488 AbCam Goat Rabbit IF 1 : 200 Pure water 
2  Alexa Fluor 488 Invitrogen Goat Mouse IF 1 : 200 Pure water 
3 Alexa Fluor 546 Invitrogen Goat Rabbit IF 1 : 200 Pure water 
4 FITC Abcam Rabbit Goat IF 1 : 200 Pure water 
5 HRP-conjugate Dako Goat Mouse WB 1 : 2000 General 
6 HRP-conjugate Dako Goat Rabbit WB 1 : 2000 General 
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2.9. Immunofluorescence 
2.9.1. Materials 
For immunofluorescent (IF) staining, the buffers/reagents are used (Table 2-12). 
Immunofluorescent staining technique was used in various experimental steps of this project. 
Primary and secondary antibodies used are listed in Table 2-10 and Table 2-11 respectively. 
Table 2-12 General buffers and reagents used in immunofluorescence technique 
Buffers / Reagents Contents Source 
Phosphate buffered saline 
(PBS) 
1.15 gram Na2HPO4 
8.0 gram NaCl 
0.2 gram KCl 
0.2 gram KH2PO4 
in 1000 mL distilled water, pH 
adjusted to 7.4 
Sigma 
 
Blocking solution 5% goat serum  
in PBS 
Sigma 
Mounting medium Anti-fading agent 
0.015 mol/L sodium azide 
Dako 
2.9.2. General Protocol 
Briefly, cultured cells were grown on 13 mm diameter sterile coverslips in 6-well plates 
until a visible monolayer of cells was formed. Cells were fixed with ice-cold methanol for 10 
minutes, followed by three washes with PBS, each for approximately 3 minutes. Coverslips 
were incubated in 5% serum from the secondary antibody host to block non-specific binding. 
The blocking solution was removed and coverslips were incubated overnight at 4°C with 
primary antibody. Residual unbound primary antibody was removed by washing the 
coverslips with PBS three-times, each for approximately 3 minutes. This was followed by 
incubating the coverslips in secondary antibody for 2 hours at room temperature. Nuclei were 
counter-stained with 100 µL DAPI (4',6-diamidino-2-phenylindole; Sigma-Aldrich) 1 : 3,000 
dilution in PBS for 10 minutes at room temperature. Coverslips were washed with PBS before 
mounting onto microscopy slides using fluorescence mounting medium. Visualisation was 
performed using Zeiss AxioImager fluorescent microscope available in BioImaging Core 
Facility, Newcastle University and Leica Fluorescent microscope at the Biobank Imaging 
Service Unit, Newcastle University, UK. For each immunofluorescent experiment performed, 
the expression of a protein of interest in the treatment group was compared to its expression in 
a non-treated group (control). Negative control using cells fixed onto a slide, which were 
given primary antibody or secondary antibody only were used to detect possible non-specific 
signal.  
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2.9.3. Quantitation of Fluorescence Staining 
Area of fluorescence (µm2) indicates the level of expression of a protein of interest in 
one field of view.  Area of fluorescence was quantified using image analysis software, ImageJ 
(Schindelin et al., 2015). Mean area of fluorescence were calculated from three different 
slides. Data analysis was performed as mentioned in subsequent statistical analyses section. 
2.10. Protein Quantification – Bicinchoninic Acid (BCA) Protein Assay 
Total protein concentration was quantified using the colorimetric based BCA protein 
assay (Pierce™ BCA Protein Assay, Thermo Scientific™, USA). Briefly, 25 µL of each 
sample was added to 200 µL of a mixture of reagents containing BCA and 4% cupric 
sulphate. Reduction of Cu2+ to Cu1+ by protein will chelate BCA molecules, producing a 
purple-coloured product, which exhibits a strong absorbance at 562 nm. A multimode micro-
plate reader was used to detect absorbance of standards and samples arranged in a clear-
bottom 96-well plate. Using a set of protein standards with known concentration (20-2000 
µg/mL), a standard curve was generated (Figure 2-8), which was used to calculate protein 
concentration in test samples.  
 
 
Figure 2-8. Standard curve of BCA method 
An example of a BSA curve generated by linear regression used in protein quantification. The graph 
was produced from serial protein standards provided in the assay kit.  
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2.11. Characterisation of Human Primary Proximal Tubular Epithelial Cells  
2.11.1. Light Microscopy 
Inverted bright-field microscopy was used to visualise cellular morphology. Isolated 
cells from different patients were imaged at each passage from passage 1 to passage 5. The 
main objective was to evaluate morphological resemblance of the isolated cells to the known 
features of human PTECs. In addition, light microscopy would also identify reproducibility of 
the isolation technique, to find potential variation in cellular morphology that may exist 
between different samples and to determine potential morphological changes occurring after 
passaging cells. Qualitative comparisons were made between different passages of the same 
cell lineage and between different cell lineages at the same passage number. 
2.11.2. Immunofluorescent staining 
Immunofluorescence allows qualitative evaluation of the presence of membrane and 
cytosolic proteins specific for epithelial and mesenchymal cells. Preparation of slides is 
described in section 2.9.2. To characterise primary PTEC, I used several epithelial cell protein 
markers; ZO-1, E-Cadherin, K-Cadherin and Cytokeratin. To detect potential cellular 
contamination, the isolated cells were also stained for the presence of mesenchymal cell 
markers; α-SMA, Vimentin and Collagen I. The details of primary antibodies used are listed 
in Table 2-10. Characterisation of primary PTECs was performed using cells at passage 2.  
2.11.3. Scanning Electron Microscopy 
Scanning electron microscopy was used to assess the presence of microvilli as a typical 
feature of renal tubular epithelial cells. Two different cell isolates were randomly selected for 
electron microscopy. Cells were grown on 13mm diameter coverslips until a monolayer of 
cells was formed. To remove contaminants cells were washed with PBS. Fixation of cells was 
performed using 2% glutaraldehyde in Sorenson’s phosphate buffer at 4°C for at least 
overnight. This was followed by removal of excess fixative by PBS washes 2 times 15 
minutes. Cells underwent step-wise dehydration by immersion in a graded series of ethanol 
concentrations. Subsequent mounting, plating and imaging were performed in the Electron 
Microscopy Research Facilities, Newcastle University. Briefly, the specimens were dried 
using a Critical Point Drying (CPD) procedure, whereby carbon dioxide was removed after 
transition from the liquid to the gas phase. This step is critical to ensure the integrity of 
specimen surface in the SEM chamber. The dried specimen was mounted on a metallic stub to 
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be later inserted into the SEM. Before visualisation, the specimen was coated with 20-30 nm 
of gold-palladium to increase its conductivity as well as to prevent the build-up of high 
voltage charges (Bozzola, 2007). The preparation of SEM slides and image acquisition were 
performed with the assistance of the Electron Microscopy Research Services Unit, Newcastle 
University, United Kingdom. 
2.12. Methods to Induce Hypoxia or Simulating the Effect of Hypoxia 
To induce hypoxia or mimicking the effect of hypoxia, several methods were used. 
These include the use of 1% O2 chamber, increasing HIF-1α expression by transient 
transfection of HIF-1α plasmid, or stabilisation of HIF-1α by cobalt chloride (CoCl2) 
treatment.  
2.12.1. Hypoxic Chamber 
Hypoxia was induced by incubating cells in a 1% O2 incubator available in the Institute 
of Cellular and Molecular Biology, Newcastle University, United Kingdom. The incubator is 
equipped with airtight ports to maintain relatively constant internal O2 concentration, even 
during sample placement into the chamber or removal from the chamber.  
2.12.2. HIF-1a Plasmid Transfection 
A HIF-1a plasmid with pcDNA3 backbone vector (William Kaelin; Addgene, USA, 
see Figure 2-9) was used (Kondo et al., 2002). Bacteria (Dh5-alpha strain Escherichia coli) 
containing the plasmid was transferred onto a culture petri dish containing solidified LB agar 
supplemented with ampicillin, and incubated overnight at 37°C. 100 mL LB broth solution 
containing 50 µg/mL ampicillin was prepared. One colony of plasmid-containing bacteria 
from the agar plate was added to the broth and incubated at 37°C overnight with continuous 
mixing. The bacteria were harvested by centrifugation at 2,000 g for 5 minutes at room 
temperature. Chargeswitch-Pro® filter plasmid Maxiprep Kit (Invitrogen, UK) was used to 
isolate the plasmid. Briefly, the bacterial cell pellet was re-suspended in 7 mL resuspension 
buffer. The suspension was mixed gently with 7 mL lysis buffer, before incubating it at room 
temperature for 5 minutes. An equal volume of precipitation buffer was added to the cells 
until a white precipitate was visible. Plasmid DNA was filtered by running the lysate through 
a filter column, which was centrifuged at 4,000 g for 2 minutes at room temperature. After 
centrifugation, the flow-through collected was discarded. Wash Buffer was added to the 
column, followed by centrifugation at 4,000 g for 2 minutes. To elute the purified plasmid 
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DNA, Elution Buffer was added to the column before centrifugation at 4,000 g for 1 minute. 
The DNA quality was assessed using a Nanodrop® spectrophotometer. Isolated DNA could 
be used directly or stored at -20°C. 
HIF-1a plasmid DNA was transfected into HKC-8 cells using a reverse transfection 
method. Transfection mixture containing 50 µL basal media for HKC-8, without antibiotic or 
serum supplementation, 1.5 µL transfection reagent (Lipofectamine LTX reagent, Invitrogen, 
USA) and 500 ng of plasmid DNA was prepared inside each well prior to seeding the well 
with approximately 30,000 HKC-8. For experiments using the HIF-1a plasmid, the backbone 
vector pcDNA3 (AddGene, USA, see Figure 2-10) was transfected to HKC-8 cells as the 
control plasmid. 
 
 
Figure 2-9 Map of the HIF-1a plasmid 
Genetic sequence mapping of the HIF-1a plasmid Source: AddGene, USA 
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Figure 2-10 Plasmid map of pcDNA 
Genetic sequence mapping of the pcDNA backbone vector Source: AddGene, USA 
2.12.3. Cobalt Chloride Treatment 
Treating cells with CoCl2 will replace Fe in the enzyme HIF-prolyl hydroxylase 
domains (PHDs), responsible for degrading HIF-1α. This will inhibit their ability to recognise 
HIF-1α. Thus, CoCl2 has been widely used as a method to simulate hypoxic effect in cells. A 
10mM stock solution of CoCl2 was prepared by dissolving 0.024 gram of CoCl2 powder 
(237.93 gram/mL; molecular weight = 237.93, Sigma, USA) in 10mL of complete media. The 
stock solution was sterile filtered and diluted to a working solution of 100 µM using complete 
media.  
2.13. Assessment of the Effect of Hypoxia 
The effect of Hypoxia on the cells was validated using immunofluorescent staining for 
hypoxia-induced factor 1 – alpha (HIF-1α) and using HKC-8 cells transfected with hypoxia 
responsive element (HRE) luciferase. HKC-8 cells were used to assess hypoxia and findings 
with HKC-8 extrapolated to other cells, on the basis that all these cells possess common renal 
tubular epithelial features and therefore should behave in a similar pattern under a given 
condition.  
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2.13.1. Immunofluorescence for HIF-1a 
HKC-8 cells were grown on 13 mm diameter coverslips in 6-well plate until reaching 
90% confluency. Cells were serum starved 24 hours prior to hypoxia at in 1%O2 for 24 hours. 
HKC-8 cells treated with 100 µM cobalt chloride (CoCl2; Sigma-Aldrich) for 72 hours were 
used as positive control. Slides were prepared as described in section 2.9.2. To assess the 
effect of hypoxia, HKC-8 cells were stained for HIF-1a protein. In hypoxic conditions, HIF-
1a stabilisation is expected, indicated by intra-nuclear localisation of HIF-1a staining.  
2.13.2. Hypoxia Response Element – Luciferase Reporter Assay 
A luciferase reporter containing three hypoxia response elements (HRE) from the Pgk-
1 gene (Navdeep Chandel; AddGene, USA, see Figure 2-11) was used (Emerling et al., 
2008). The HRE-luciferase is contained in a pGL3 vector plasmid. DNA isolation from the 
bacteria containing the plasmid were performed as for the HIF-1a plasmid described in 
2.12.2.  
HRE-luciferase plasmid DNA was transfected into HKC-8 cells using a reverse 
transfection method. Briefly, approximately 30,000 HKC-8 cells were seeded in each well of 
a 24-well plate. Each well contained 50 µL basal media for HKC-8, without antibiotic or 
serum supplementation, 1.5 µL transfection reagent (Lipofectamine LTX reagent, Invitrogen, 
USA) and 500 ng of plasmid DNA. Transfected HKC-8 cells were incubated in standard 
incubator to serve as control, and in a 1% O2 incubator for 12 and 24 hours as treated groups. 
HRE-luciferase transfected HKC-8 cells were also treated with 100 µM of CoCl2 for 48 hours 
as positive control. 
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Figure 2-11 Plasmid map of HRE-luciferase 
Genetic sequence mapping of HRE-luciferase plasmid developed by Navdeep Chandel. Source: 
AddGene, USA 
The pGL3 plasmid (see Figure 2-12) was also transfected to HKC-8 cells as a vector 
control. At each designated time points, cells were harvested for the measurement of 
luciferase activity, according to luciferase assay preparation protocol described in section 
2.7.1. 
 
Figure 2-12 Plasmid map of pGL3 vector 
Genetic sequence of pGL3 basic plasmid, as a vector control for HRE-luciferase plasmid. Source: 
Addgene, USA 
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2.14. Inducing Oxidative Stress 
Treatment with hydrogen peroxide (H2O2) has been widely used as a method to induce 
oxidative stress in cells. H2O2 stock solution of 1,000 µM was prepared by adding 11.33 µL of 
H2O2 (30% w/w; 8.82 M, Sigma) into 10mL complete media. Working concentration of 100-
800 µM was diluted in sterile working environment from the stock solution. Preliminary 
viability study was performed on each cell line to determine the optimal concentration of 
H2O2. HKC-8, HK-2 or primary cells were grown to 80% confluency in 6-well plates. Cells 
were serum starved for 24 hours before treatment. 
2.14.1. Viability Assay 
Varying concentrations of hydrogen peroxide (from 100 µM to 1,000 µM in 100 µM 
intervals) in complete culture media was used to recreate reperfusion injury. Cells were kept 
in H2O2 treated media for 4 hours before the media was replaced with normal complete 
media. The cells remained in the fresh media for the following 20 hours. Cell viability was 
calculated by dividing the number of live cells (non-stained cells in Trypan blue exclusion 
assay) by the total number of cells recovered. The H2O2 concentration which showed 
evidence of cell injury with a sufficient number of surviving cells to permit analysis was 
regarded as optimal. This concentration would then be used to induce oxidative stress in that 
particular cell line. 
2.14.2. Reactive Oxygen Species Detection 
To qualitatively analyse oxidative stress in a cell population, a molecular probe 
detection reagent was used. Measurement of dichlorofluorescein (DCF) oxidation is a 
commonly used method to detect reactive oxygen species (ROS). In its reduced and 
acetylated form, 2’,7’-di-chlorofluorescein (DCF) is non-fluorescent. Intracellular esterase 
will cleave the lipophilic blocking groups, which yield a charged form of the dye (Jakubowski 
and Bartosz, 2000). Carboxy-H2DCFDA is the carboxy derivative of fluorescein, which 
carries additional negative charge, allowing greater stability. Oxidation of these molecular 
probes can be quantified by measuring the increase in fluorescence using flow cytometry. For 
this experiment, a H2DCFDA derivative with a thiol-reactive chloromethyl group, 5-(and-6)-
chloromethyl-2,7-dichlorodihydrofluorescein diacetate, acetyl ester (CM-H2DCFDA) was 
used. H2O2 treated HKC-8 cells were re-suspended in PBS containing 1 µM H2DCFDA dye 
and incubated for 30 minutes at 37°C.  The suspension was centrifuged at 1,000 g for 5 
minutes at room temperature. The pellet formed was re-suspended in PBS. Cell fluorescence 
 
 
66 
was assessed using a FACS Canto II flow cytometer (BD Biosciences, UK). HKC-8 cells 
without exposure to dye was also analysed to measure cell auto-fluorescence. Results were 
analysed using FACS Diva Clinical Software (BD Biosciences). 
2.15. MicroRNA Profiling using NanoString® nCounter Platform 
2.15.1. Assay Principle 
NanoString® nCounter is a direct digital detection platform for individual target 
molecules (i.e. microRNA) by utilising fluorescent spots that are spatially ordered (also 
known as molecular probes). Each colour arrangement represents a different type of target 
molecules, creating a huge diversity of colour barcodes. The assay colour barcodes bind to 
target miRNAs in one-to-one ratio, allowing the targets to be added directly without the need 
of amplification or enzymatic reaction. Each code will be sorted, individually counted, and 
cross-referenced to a target identity. This will give digital count of target molecules present in 
a sample. The assay involves three main steps; ligation and hybridisation, purification / 
immobilisation and counting.  
In ligation and hybridisation step, unique miRNA tag (miRtag) was added to the 
sample. This enables extension of a miRNA for downstream detection. This ligation process 
is assisted by a temporary binding to a bridge sequence with partial complementarity to both 
the miRNA and the miRtag (see Figure 2-13). The ligated target miRNA is then hybridised to 
reporter and capture probes, forming a target-probe complex (see Figure 2-14). 
 
 
Figure 2-13 Target miRNA ligation by NanoString system 
Illustration of ligation of a target mature miRNA sequence by miRTag sequence with temporary 
binding to a bridge sequence unique to both the target miRNA and miRtag. Source: NanoString 
Technologies, Inc. (NanoString Technologies Inc, 2014) 
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Figure 2-14 Hybridisation of miRNA in NanoString system 
Illustration of miRNA hybridisation to capture and target probes to form target-probe complex. 
Source: NanoString Technologies, Inc. (NanoString Technologies Inc, 2014) 
Excess probes are then washed, before the purified complexes are inserted to a sample 
cartridge (see Figure 2-15). Electrical current will immobilise, arrange and fix these 
complexes onto the cartridge surface. Using the Digital Analyser (DA) unit of the NanoString 
system, the target-probe complexes were captured using a microscopic CCD camera, and then 
counted. The count of each barcode is the count of a target miRNA it refers to (see Figure 
2-16). The binding of the colour barcodes to the target miRNA is performed occurred in one-
to-one ratio. In addition, no amplification step is performed in this system, limiting the 
possibility of amplification bias.  
 
Figure 2-15 Purification and immobilisation step in NanoString system 
Illustration of the removal of the excess of probes and immobilisation of target-probe complexes to the 
assay cartridge. Source: NanoString Technologies, Inc. (NanoString Technologies Inc, 2014) 
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Figure 2-16 Image capture and counting of molecular barcode in NanoString System 
Illustration of target-probe complexes being captured and counted in the Digital Analyser (DA) unit of 
a NanosString system. Counted molecules may be in the form of mRNA (as illustrated) or miRNA. 
Source: NanoString Technologies, Inc. (NanoString Technologies Inc, 2014) 
2.15.2. Assay Preparation and Setup 
The preparation for NanoString assay was performed in NanoString core facility, the 
Department of Academic Haematology, Newcastle University, United Kingdom by a 
specialised technician. The nCounter Human v3 microRNAs Expression Assay CodeSet was 
used to profile miRNAs in the samples. All experiments performed in NanoString system 
should be designed in sets of a maximum of twelve assays. In this experiment, four cell types 
were used: HKC-8, HK-2, and two primary PTECs isolated from two different patients. Each 
cell type was treated with either hypoxia or H2O2 for 2 and 12 hours. Each cell type has a 
corresponding non-treated control, which were kept in standard normoxic incubator for 12 
hours. In total, 24 samples were arranged for this profiling assay as illustrated in Figure 2-17.  
The nCounter assay platform consists of two instruments; the Prep Station and the 
Digital Analyser (DA). Assay protocol provided by the manufacturer has been previously 
tested using the same miRNA CodeSet as was used in this experiment, and therefore, was 
directly applied without further modification. The following description is only a summary of 
the procedures performed prior to NanoString data analysis. The complete protocol was 
described in detail in the Appendix, as also described in the manufacturer’s protocol 
(NanoString Technologies Inc., 2010). 
Prior to preparation, total RNA samples were normalised to 33 ng/mL using RNAse-
free water. Firstly, samples were annealed by mixing each normalised sample with previously 
prepared mixture of diluted miRNA Assay Controls, Annealing Buffer and miRNA Tag 
Reagent provided in the assay kit. Annealing step was performed using a thermocycler 
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programmed according to the assay recommendation. Ligation of miRNA targets was 
initiated after annealing by the addition of Ligation Master mix provided in the assay kit. 
After ligation, samples were hybridised to form target-probe complex. Each hybridisation 
reaction contains the following components; reporter CodeSet, hybridisation buffer, Capture 
ProbeSet, and an aliquot of the ligated miRNA. Once the hybridisation reaction is completed, 
the samples were placed in the Prep Station. Purification and immobilisation of the hybridised 
complexes onto the surface of a specialised cartridge was performed automatically in the Prep 
Station. The Prep Station allows a maximum of 12 samples per run, which are loaded into a 
12-lane cartridge. The cartridge was then analysed in the Digital Analyser to identify and 
count the barcodes captured for each sample.  
 
 
Figure 2-17 Samples setup for miRNAs profiling using Nanostring® nCounter platform 
2.15.3. Quality Control Metrics, Normalisation and Background Elimination 
The output of Nanostring® nCounter assay is presented in form of a number of counts 
for each molecular probe. Several quality control measures were applied to screen possible 
errors related to technical issues of the assay (problems related to cartridge, capture camera, 
etc.). These measures include field of view count (FOV), binding density (BD) and internal 
controls (positive ligation controls and negative controls). 
Each lane in the cartridge was imaged by the DA in discrete units, known as fields of 
view (FOV). Imaging problems can be detected by comparing the ratio of successfully 
imaged FOVs (FOV Counted) to the total number of imaging attempts (FOV Count). A large 
disparity between the FOV Count and FOV Counted reflects potential technical issues related 
to inability of the camera to focus, presence of bubbles or insufficient oiling of the cartridge.  
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The DA maintains its accuracy in capturing colour barcodes (miRNA probes) by 
excluding any code overlap that may exist in an image. This ensures accuracy of the assay, 
and provides assurance that the molecular counts provided were in fact a set of truly 
recognisable codes. However, the data could be compromised if the image captured is 
saturated, causing a large proportion of the data to be excluded due to codes overlap. To 
prevent this, the nCounter platform provides a measurement of the number of optical features 
per square micron, known as the binding density. Binding density includes many system 
controls that are not affected by samples, and therefore act as an imaging quality control 
rather than sample performance quality control. In a specific range of binding density (0.05-
2.25), the DA can detect and count each reporter barcode accurately. Binding density greater 
than 2.25 means larger number of reporter overlaps and code exclusions, which may 
potentially affect data interpretation. 
The platform utilises several probes for positive and negative control. These probes 
were designed against a set of target transcript sequences derived from the External RNA 
Control Consortium (ERCC), which are of similar size to a miRNA. The positive control 
transcript sequences were ligated and hybridised in the same manner as endogenous miRNAs. 
This enables them to act as controls for the entire miRNA analysis process, from sample 
preparation through hybridisation. In addition, these positive controls were also used in data 
normalisation step. Positive control counts are used to normalise all platform associated 
sources of variation (e.g. purification, hybridisation, conditions, etc.), which may indicate 
under-performance of a lane/lanes. The nCounter platform calculates geometric mean of 
positive control counts of each lane. The average of these calculated values across all lanes is 
used as the reference against which each lane is normalised. A scaling factor is then 
calculated for each of the lanes based on the calculated value for the positive control in each 
lane relative to the average of this value for the positive controls across all lanes. This scaling 
factor may then be used to adjust the counts for each gene target and negative controls in the 
associated lane. The typical range of this positive control normalisation scale is between 0.3 
to 3. This normalisation using positive control, however, will not account for differences in 
sample input between technical/biological replicates. To account for differences between 
sample inputs, normalisation using either a set of reference genes or large numbers of 
reporters (known as global normalisation i.e. 100 microRNAs that are highly expressed across 
all samples) was used. The assay also uses several negative control probes, for which no 
transcript is supplied. These can be used to estimate systematic background counts within any 
single hybridisation reaction. 
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2.16. Profiling Analysis and Target Prediction 
2.16.1. Selection Criteria 
Several microRNAs were chosen from the NanoString® output based on their degree 
of expression after ischaemia or reperfusion injury. Up/down-regulation of the level of 
expression of 2-fold or greater was considered significant. As mentioned previously, only 
those microRNAs which were consistently up/down-regulated in either HKC-8 and HK-2 
cells or both primary PTECs were included in the subsequent functional analysis works.  
2.16.2. MiRNA Functionalitiy and Target Gene Prediction 
A selection of miRNAs which fulfil the selection criteria were analysed to identify their 
potential role in specific biological pathways. Analysis of miRNA functionality and 
prediction of target genes were performed in two steps as illustrated in Figure 2-18. MiRNAs, 
that fulfilled the selection criteria were firstly analysed for their association with specific 
genes and biological pathways using DIANA-MirPath v.3.0 (Vlachos et al., 2015). This 
database enables combinatorial prediction of multiple miRNA targets in a specific biological 
pathway derived from the Kyoto Encyclopedia of Genes and Genomes (Kanehisa and Goto, 
2000). I opted to use the a priori method provided by DIANA-MirPath v3.0 to identify all 
genes targeted by at least one of the selected miRNAs (known as the gene union approach). 
DIANA-MirPath identified potential target genes of these miRNAs in three different indexes; 
DIANA-microT-CDS (Vlachos et al., 2015), Tarbase v7.0 (Sethupathy et al., 2006) and 
TargetScan (Agarwal et al., 2015). KEGG biological pathways associated with these genes 
were listed. Only biological pathways which were identified by all three indexes were 
selected. 
Secondly, I selected a specific miRNA from the MiRPath analysis result, which is 
associated with a pathway relevant to cellular response to IRI. Using MiRWalk 2.0 database 
(Dweep and al., 2015), I identified potential target genes of individual miRNA of interest with 
respect to the certainty of its miRNA-mRNA interactions. The results only include target sites 
for miRNAs at the 3’UTR with three types of canonical sites; the 7mer1A (adenine in 
position 1 at the 5’ end of miRNA), the 8mer (matched adenine in position 1 and an additional 
match in position 8) and the 7mer-m8 (match in position 8). MiRWalk allows simultaneous 
prediction using several established target prediction algorithms. For the purpose of this 
study, four target predictor algorithms were chosen, which includes MiRWalk’s own 
database, DIANA-MirPath, TargetScan, and MiRanda (John et al., 2004; Betel et al., 2008). 
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Only those targets that were predicted by all four programs were regarded as candidates for 
further in vitro validation experiments. 
 
 
Figure 2-18 MiRNAs functionalities and miRNA target prediction steps  
Flow-chart of steps performed in the analyses of miRNA functionality and miRNA target prediction. 
The steps include identification of relevant pathways involved using MiRPath. Subsequently, the 
miRNAs identified in the relevant pathways were imported into MirWalk to predict potential target 
genes   
2.17. Transfection of MicroRNA Mimic and Inhibitors 
2.17.1. Materials and Protocol 
Transfection of miRNA mimic and inhibitor was performed using the transfection 
reagent Lipofectamine® RNAiMAX (Life Technologies™, USA) using the reverse 
transfection method, in accordance to the manufacturer’s protocol. Briefly, transfection 
complexes containing serum-deprived medium (Opti-MEM® medium, Gibco®, Life 
Technologies™, USA), RNAiMAX transfection reagent and the desired miRNA mimic or 
inhibitor were added into each well. The final transfection complex contained 25 pmol of 
miRNA mimic/inhibitor and 7.5 µL of RNAiMAX in one well of a 6-well plate or 5 pmol of 
miRNA mimic/inhibitor and 1.5 µL of RNAiMAX in a one well of a 24-well plate. HKC-8 
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cell suspension was then added to the well and incubated in 5%CO2 incubator at 37°C for 24 
hours to allow the cells to incorporate the mimic and inhibitor molecules. 
2.17.2. Assessing Transfection Efficiency 
2.17.2.1. Fluorescent-labelled microRNA mimic transfection control 
The effectiveness of the transfection protocol was evaluated using a fluorescence-
labelled (miRIDIAN® Dy547) miRNA mimic based on the cel-miR-67 (Dharmacon, USA). 
This non-targetting miRNA transfection control was introduced to HKC-8 cells using the 
exact same protocol as was used to transfect the miRNA mimic/inhibitor of interest. The cells 
were transfected for 24 and 48-hour to capture intracellular uptake of miRNA mimic 
molecules. Visualisation of mimic delivery was performed by fluorescence microscopy at 
maximal absorbance/emission wavelengths of 557/570 nm. 
2.17.2.2. Expression of miR-21 after Transfection 
The level of expression of miR-21 after transfection of miR-21 mimic was used as an 
indicator of success of the transfection method. HKC-8 cells were transfected with miR-21 
mimic according to the protocol described in the previous section. After a 24-hour incubation, 
cells were harvested for RNA isolation. Expression analysis was performed by qPCR for 
miR-21. The expression level of miR-21 in mimic transfected HKC-8 cells was compared to 
miR-21 level in non-transfected HKC-8 cells and HKC-8 cells transfected with scrambled 
mimic control. 
2.18. Luciferase Reporter Assay to Assess TGF-b Activity 
To assess activation of TGF-β pathway, a clone of HKC-8 cell lines containing the 
SMAD3 luciferase reporter construct pCAGA12-luc was generated in our facility (see Figure 
2-19). The plasmid was a courtesy of Jean-Michel Gauthier (Dennler et al., 1998). This stably 
transfected cell line was maintained in full media for HKC-8 cells listed in Table 2-1 with the 
addition of 300 µg/mL Hygromycin B as a selection agent. The cells were used in the 
experiments to investigate the role of TGF-β1 in the PTEC response to IRI and the effect of 
miR-21 in modifying this response.  
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Figure 2-19 Plasmid map of SMAD3 luciferase reporter 
Plasmid map of SMAD3 luciferase reporter construct pCAGA12-luc which was stably transfected to 
HKC-8 cells to generate a clone of SMAD3-luciferase reporter HKC-8 clone. 
2.18.1. Determining the Effect miR-21 Over-expression in PTECs on TGF-β Signalling 
SMAD3-luciferase HKC-8 cells were seeded onto transfection complex containing 
miR-21 mimic or scrambled sequence miRNA mimic in 6-well plates. After 24-hour of 
incubation, transfection media was substituted with media containing 0, 0.1, 0.25, 0.5, 1, 2.5 
and 5 ng/mL TGF-β, and were incubated for another 24-hour. Cells were harvested and 
prepared for measurement of luciferase activity as described in section 2.7.1.     
2.18.2. Establishing the Role of IRI in TGF-β Activity in PTECs 
SMAD3-luciferase HKC-8 cells were transfected with miR-21 mimic and scrambled 
miRNA mimic control. Hypoxia was induced in these transfected cells by incubation in 1%O2 
for 12-hours. To induce reperfusion injury, cells were treated with 400 µM H2O2 for 4 hours, 
followed by incubation in normal growth medium for the remaining 24 hours. Cells were 
harvested and lysed in accordance to the luciferase assay measurement protocol described in 
section 2.7.1.     
2.18.3. Evaluating the effect of miR-21 over-expression in the post ischaemic response to 
TGF- β1 
SMAD3-luciferase HKC-8 cells were transfected with miR-21 mimic and scrambled 
miRNA mimic control. Hypoxia was induced in these transfected cells by incubation in 1% 
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O2 for 12-hours. TGF-β was introduced in several concentrations (0, 1, 5 and 10 ng/mL) after 
induction of hypoxia. Cells were harvested and lysed in accordance to the luciferase assay 
measurement protocol described in section 2.7.1. 
2.18.4. Evaluating the effect of miR-21 inhibition in ischaemic PTECs 
HKC-8 cells containing SMAD3-luciferase reporter gene were co-transfected with 
miR-21 mimic, miR-21 inhibitor and their respective scrambled control. The cells were 
subsequently exposed to 1%O2 to simulate hypoxia. Luciferase activity was measured as an 
indicator of TGF-β pathway activity.  
2.19. Protein Expression Studies to Assess the Link between TGF-b1, miR-21 and 
Ischaemia in PTECs 
Western blot and immunofluorescence were used to assess how TGF-β1 may alter 
PTEC morphology, and to evaluate the implication of over-expressing or inhibiting miR-21 
on the expression and distribution of SMAD3, SMAD7, epithelial marker proteins, such as E-
cadherin, and in mesenchymal marker proteins, such as a-SMA and Collagen I. Antibodies 
used against these proteins were listed in Table 2-10. These protein expression studies were 
undertaken to achieve the specific objectives summarised in 2.19.1 - 2.19.4.  
2.19.1. Assessing the Effect of TGF-β1 on PTEC Morphology 
An experiment to assess the effect of TGF-β1 treatment on PTEC phenotype was 
conducted. For this purpose, only HKC-8 cells were used. Cells were cultured in 6-well plate 
to 80% confluency. Growth medium was substituted with serum-free medium 24-hour prior 
to TGF-β treatment. Cells were incubated in 0, 0.1, 0.5, 1, 5 and 10 ng/mL of TGF-β. The 
effect of TGF-β to cellular expression of α-SMA and E-Cadherin was evaluated by 
immunofluorescence. 
2.19.2. The Effect of Ischaemia on the Expression of SMAD7 
HKC-8 cells were incubated in 1%O2 for 24 hours. Cells were harvested and protein 
lysates were prepared based on the method described in 2.8.2. SMAD7 expression level was 
determined by Western blotting.  
 
 
76 
2.19.3. Evaluating the Effect of miR-21 on the Expression of SMAD7 
Total protein was isolated from HKC-8 cells transfected with miR-21 mimic, miR-21 
inhibitor and their respective scrambled controls. Transfection of miR-21 mimic and inhibitor 
was performed on 6-well plates using reverse transfection procedure method described in 
section 2.17.1. Cells were harvested 24-hour after transfection, and protein lysates were 
obtained. The level of expression of SMAD7 was visualised by Western blotting.  
2.19.4. The Effect of miR-21 on Cellular Morphology  
To evaluate whether alteration in miR-21 expression level affects PTEC phenotype 
changes in response to TGF-b1, we quantified the expression of E-Cadherin, α-SMA and 
Collagen I in HKC-8 cells transfected with miR-21 mimic. Briefly, HKC-8 cells were seeded 
onto 6-well plates following the addition of transfection complex containing either miR-21 
mimic, srambled miRNA mimic control and transfection reagent only. Cells were incubated 
in 5% CO2 incubator for 24-hour to allow transfection of miRNA mimic before being treated 
with 1 ng/mL TGF-b1.    
2.20. Evaluating miR-21 Expression and Distribution in Renal Tissue 
2.20.1. Tissue origin and ethical approval 
Normal human kidney tissue was obtained from macroscopically normal poles of 
nephrectomy specimens removed for oncological indications. Ethical approval was obtained 
from National Research Ethics Committee, East Midland, UK for works on gene and protein 
expression in the kidney (REC reference number 13/EM/0311). Evaluation of ischaemic 
kidney tissue was carried out using sections from kidneys that are deemed unsuitable for 
transplantation, and was rejected by all UK centres due to various reasons. These organs have 
cold ischaemic time of more than 12-hour. Ischaemic kidney tissue was accessed through the 
Institute of Transplantation Tissue Biobank, Freeman Hospital, Newcastle upon Tyne, UK 
(REC reference number 11/NE/0352). 
2.20.2. qPCR to quantify miR-21 expression  
Tissue RNA was isolated from frozen ischaemic and non-ischaemic kidneys. Tissues 
were processed immediately after their removal from -80°C, without allowing tissue to thaw. 
600 µL of Cell Disruption buffer was added to each tissue sample in a RNAse-free 
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microcentrifuge tube. Tissue was mechanically homogenised using a Tissue Lyser II (Qiagen, 
USA). Denaturing solution was added once the sample was homogenised, and RNA isolation 
process was continued as described in the RNA isolation method in section 2.5.1. Mir-21 
expression in ischaemic and non-ischaemic tissue was quantified in accordance to the qPCR 
protocol mentioned in section 2.6.2.   
2.20.3. In situ hybridisation 
2.20.3.1. Assay principle 
In situ hybridisation (ISH) was used to visualise the expression and distribution of miR-
21 in renal tissues. ISH allows detection of a specific nucleic acid sequence (in this case miR-
21) in tissue samples using a labelled nucleic acid probe at a specific annealing temperature. 
In this experiment, ISH was performed using mirCURY LNA™ microRNA ISH kit for 
formalin-fixed paraffin embedded tissue (FFPE) (Exiqon, Denmark). Initially, the tissues 
were treated with Proteinase-K to facilitate hybridisation of a specific miRNA sequence by its 
complementary double-digoxigenin (DIG) labelled probes. The hybridised sequences marked 
by DIG-labelled probes were then detected using a specific anti-DIG antibody, which was 
coupled with the enzyme alkaline phosphatase (AP). To visualise, the substrate 4-nitro-blue 
tetrazolium (NBT) and 5-bromo-4-chloro-3’-indolylphosphate (BCIP) was used. Presence of 
the enzyme AP will precipitate NBT-BCIP, resulting in the formation of purple fine 
precipitates on the hybridised complexes. Finally, nuclear fast red staining was added to the 
slides to provide a better histological orientation. 
2.20.3.2. Assay optimisation 
ISH optimisation was performed to obtain the optimal conditions for the assay to 
produce strong and specific signal from the positive control miRNA probe, and minimal 
signal from the scrambled negative control miRNA probe. Assay parameters which needed 
optimisation included duration and concentration of Proteinase-K treatment, probe 
concentration and probe incubation time. 
2.20.3.3. Materials and assay protocol 
FFPE tissue samples were cut into three 3µm sections, designated for the detection of 
miR-21, positive control, and scrambled negative control. Residual paraffin was removed by 
immersing the slides in Xylene, 100% ethanol and 70% ethanol consecutively. This is 
followed by washing in PBS. The buffers shown in Table 2-13 were used for ISH.   
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Table 2-13 Buffers and reagents used in in situ hybridisation 
Buffers and Reagents Composition / Description Source 
Proteinase-K buffers 
5 mL of 1 M tris-HCl (pH 7.4) 
2 mL of 0.5 M EDTA 
0.2 mL of 5 M NaCl 
Add to 900 mL RNAse-free 
water, adjust volume to 1000 mL 
Sigma 
Sigma 
Sigma 
Sigma 
 
SSC Buffer concentrate 
(20X) 
0.3 M sodium citrate in 3M NaCl Sigma 
PBS 
1.15 gram Na2HPO4 
8.0 gram NaCl 
0.2 gram KCl 
0.2 gram KH2PO4 
in 1000 mL distilled water, pH 
adjusted to 7.4 
Sigma 
PBS-T (0.1%) 
1 mL of Tween-20 +  
1 L PBS (pH 7.4) 
Sigma 
Sigma 
KTBT solution 
7.9 gram Tris-HCl (50mM) 
8.7 gram NaCl (150mM) 
0.75 gram KCl (10mM) 
Add to 900 mL RNAse-free 
water, adjust volume to 1000 mL 
Sigma 
Sigma 
Sigma 
Sigma 
 
Proteinase-K reagent 
To make 15 µg/mL: 
Add 7.5 µL proteinase-K stock + 
10 mL proteinase-K buffer 
 
Exiqon 
Not applicable 
Hybridisation mix 
2x miRNA ISH buffer and 
RNAse-free water (1:1) 
Exiqo 
Antibody blocking solution 
10 mL PBS-T +  
200 µL sheep serum  + 
 330 µL 30% BSA 
Sigma 
Sigma 
Sigma 
Antibody dilutant 
10 mL PBS-T (0.05%) +  
100 µL sheep serum +  
330 µL 30% BSA 
Sigma 
Sigma 
Sigma 
Ant-DIG reagent 
Sheep-anti-DIG-AP antibody + 
antibody dilutant (1:800) 
Roche 
Not applicable 
AP substrate  
1 NBT-BCIP tablet + 
10 mL RNAse-free water +  
20 µL levamisol 
Roche 
Sigma 
Vector Laboratorie 
 
Slides were treated with 15 µg/mL of Proteinase-K at 37°C for 10 minutes. 
Hybridisation was performed using 80 nM of DIG-labelled miR-21 probe, positive control 
probe (miR-126) or scrambled negative control probe for 2 hours at 50°C. After hybridisation, 
slides were washed in 5X and 1x saline citrate buffers (SSC buffers) and PBS consequtively. 
Slides were incubated at room temperature for 15 minutes with blocking solution before the 
application of anti-DIG antibody for 60 minutes, after which the slides were washed with 
PBS-T. AP substrate was added to the sections and incubated for 2 hours at 30°C. The final 
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reaction was terminated using KTBT buffer followed by the addition of nuclear counter 
staining (nuclear fast red, Sigma, USA). Finally, slides were dehydrated and mounted using 
Eukitt (Sigma) mounting medium. 
Slides were visualised using a Nikon Eclipse microscope (Nikon, Japan). The same 
imaging parameters were applied to all samples. Images were taken to qualitatively 
demonstrate the location of miR-21 in renal tissues, as well as to observe differences in miR-
21 distribution between ischaemic and non-ischaemic kidneys. Staining was not quantified.          
2.21. Statistical Analyses 
All statistical analyses were performed using Prism 7.0 (Graph Pad, USA) statistical 
analysis software. Due to the limited number of samples in each experiment, no normalisation 
test was performed. Normal distribution was assumed prior to statistical analysis. Comparison 
of the means of two unmatched groups was performed using unpaired t-test. One-way 
ANOVA with the appropriate multiple comparison tests (Bonferoni, Dunnet or Tukey) were 
used to detect statistically significant differences between the means of more than two groups 
defined by one factor. To determine how a variable is affected by two factors, two-way 
ANOVA was used. Data was expressed as the mean ± the standard deviation (SD). p Value 
<0.05 was considered as statistically significant, which was classified into several categories 
as represented in form of the following symbols: * = p ≤0.05; ** = p ≤0.01; *** = p ≤0.001; 
**** p ≤0.0001.  
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Chapter 3. Isolation and Characterisation of Human Primary Tubular 
Epithelial Cell  
3.1. Introduction and Objectives 
Although immortalised cell lines are a useful model to validate miRNA targets, their 
response to IRI may be significantly distinct from human primary cells. Both HKC-8 and HK-
2 cells used in this study are among the most common cell lines used in the study of TECs. 
Nonetheless, several limitations in their use have been observed, including the lack of 
phenotypic resemblance to human primary PTECs (Sharpe and Dockrell, 2012). I 
hypothesised that IRI alters the profile of miRNAs in the PTECs, and these changes may be 
different across different PTEC cell types. Despite these differences, I predicted a set of 
miRNAs would still be altered in a similar pattern across the different cell types. This set of 
overlapping miRNAs would be an attractive candidate for further target prediction and 
validation, and thus would be the focus of my thesis. To achieve this, I generated human 
primary PTECs derived from normally functioning kidney.  
There are several methods described to isolate human PTECs. The initial isolation 
protocols almost uniformly included the use of mechanical and enzymatic digestion followed 
by cellular suspension using Percoll centrifugation (Baer et al., 1997; Qi et al., 2007; Brown 
et al., 2008; A.Vesey et al., 2009; Van der Hauwaert et al., 2013). As an alternative to Percoll 
centrifugation, the use of cell dissociation followed by cellular separation using anti-
Prominin-1 antibody (Legouis et al., 2015), and the consecutive sieving method using 125-
µm and 45-µm pores (Sharpe and Dockrell, 2012) have been proposed. Other authors 
suggested an additional immunogenic separation step following centrifugation of cells, 
mainly by utilising antibody against CD10 or CD13 (Baer et al., 1997; Van der Hauwaert et 
al., 2013).  
Most authors have documented that isolation of a relatively pure PTEC population is 
achievable using the Percoll gradient centrifugation method. In addition, this method is easy 
to learn and adapt, as it does not require additional immunology-based sorting. Based on its 
reported efficacy, cost-efficiency and practicality I decided to adapt the Percoll gradient 
method to isolate PTECs from non-ischaemic kidney tissue. The final cellular yield of this 
method is highly dependent upon the initial tissue dimension and weight. It was therefore 
crucial to evaluate the success of this technique in the tissue specimens available to our 
facility which are relatively small. Furthermore, the initial tissue weight may also affect the 
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final quality and purity of the isolated cells, especially if they were to be used at later 
passages.   
3.2. Results 
3.2.1. Light microscopic appearance of primary PTEC 
Under light microscope, the isolated cells showed distinct cobblestone-like appearance 
when a confluent monolayer was formed. This appearance is especially apparent during 
earlier passage number. Most cells are hexagonal in shape with distinct inter-cellular borders 
as seen in Figure 3-1. 
 
 
Figure 3-1 Light microscopic images of primary PTECs at passage 1  
Each picture (a-d) represents cells isolated from a different patient. Cells were grown in complete 
media to form a monolayer. Images were acquired at 200x magnification to demonstrate a typical 
epithelial cobblestone. 
Upon seeding, the cells grew in an island-like pattern or clusters, before consolidating 
to form a confluent monolayer. This characteristic was maintained throughout passage 2 
(Figure 3-2) and passage 3 (Figure 3-3), with a reasonably uniform appearance across 
different patients. On average, the isolated cells reach 80% confluency in 72 to 96 hours after 
initial seeding. 
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Figure 3-2 Light microscopic appearance of primary PTEC at passage 2  
Primary PTEC light microscopy images captured at 200x magnification showing prominent 
cobblestone appearance. Individual cells have a pentagonal/hexagonal morphology characteristic of 
epithelial cells. Each picture (a-d) represents cells isolated from a different patient 
 
 
Figure 3-3 Light microscopic appearance of primary PTEC at passage 3 
Primary PTEC isolated from four different patients (a-d) forming a monolayer at passage 3. Images 
were taken under light microscope at 200x magnification. No difference in cell morphology could be 
seen when compared to earlier passages. 
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At passage 4, more cells were identified to have a spindle-like shape, which is not a 
feature of epithelial cells. This characteristic became more prominent as the culture reached 
later passages. Cellular dedifferentiation started to occur at passage 4 in almost all isolates 
(Figure 3-4). Although the cells initially grew in clusters, their ability to maintain growth and 
form a confluent monolayer diminished markedly compared to passage 1 and 2. At passage 4, 
the cobblestone-like pattern was no longer prominent, and was replaced by an irregular and 
patchy growth pattern.  
 
 
Figure 3-4 Light microscopic appearance of primary PTEC at passage 4  
Primary PTEC isolated from four different patients were grown to a monolayer. Images were acquired 
using a light microscope at 200x magnification, which showed a loss in epithelial morphology. Each 
image (a-d) represents cells isolated form different patients.  
The development of senescence and cellular dedifferentiation were more notable at 
passage 5 (Figure 3-5). Cells obtained from different patients showed loss of features 
associated with normal epithelial cells, including change in the shape of cell from hexagonal 
to a more elongated shape. 
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Figure 3-5 Light microscopic appearance of primary PTEC at passage 5 
Primary PTEC at passage 5 under light microscopy (imaged at 200x magnification). Cellular 
arrangement was markedly different from passage 1-3. Each image (a-d) represents cells isolated from 
different patients. 
Furthermore, the formation of hemicysts or “domes” in some of the isolated cells was 
evident (Figure 3-6), which is indicative of active transcellular transport in these cells. These 
“domes” were only seen at earlier passage (passage 1-3), and not at later passages. 
 
 
Figure 3-6. Hemicysts formation in primary PTEC 
Primary PTEC at passage 2 showing “domes” formation or hemicysts when cells were grown to more 
than 80% confluency. Image was acquired using a light microscope at 200x magnification.  
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To evaluate the effect of cryopreservation to the cells, we recovered frozen cells and 
identified any morphological changes that may be present.  These thawed cells from four 
different isolates showed no morphological abnormality, compared to the freshly isolated 
cells (Figure 3-7).  
 
 
Figure 3-7 Appearance of primary PTEC grown after thawing    
Light microscopy images of cells which were frozen at passage 1. Images were taken at 200x 
magnification. Cobblestone arrangement was prominently shown in (a) passage 2 and (b) passage 3. 
Morphologic changes started to appear at (c) passage 4 and becoming more apparent at (d) passage 5. 
3.2.2. Immunofluorescent characterisation of primary PTEC 
Isolated cells were stained to determine the expression of proteins known to be 
expressed in epithelial cells and non-epithelial cells. Expression of ZO-1, as a tight junction 
protein, was prominent in almost all cells (Figure 3-8, panel a-c) with a ‘honeycomb’ 
appearance indicating the cells are epithelial in nature.  E-Cadherin staining was also positive, 
although was weaker in certain regions of the slides (Figure 3-8, panel d-f). K-Cadherin, a 
relatively specific marker of proximal tubular epithelial cells, was strongly expressed in 
almost all cells (Figure 3-8, panel g-i). Unlike E-Cadherin, K-Cadherin (also known as 
Cadherin-6) was not distinctly expressed on the cell surface, with previous reports describing 
a cytoplasmic distribution (Paul et al., 1997; Baer et al., 2006; Systems, 2015). Cytokeratin 
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has been widely used to characterise renal proximal tubular epithelial cells. It was strongly 
expressed in the cytoplasm of most of the primary PTECs isolated (Figure 3-8, panel j-l). In 
conclusion, all epithelial markers selected to characterise primary PTEC were consistently 
expressed across cells originating from different patients. 
 
 
Figure 3-8 Expression of various markers of epithelial cells in the isolated primary PTECs  
Immunofluorescent staining of proteins commonly expressed by tubular epithelial cells; (a-c) ZO-1, 
(d-f) E-cadherin, (g-i) K-cadherin and (j-l) Cytokeratin. Characterisation was made to primary PTEC 
at passage 2 or 3. Three images were displayed for each antibody (N=3), with each image representing 
a biological replicate.  Images were captured with fluorescence microscope at 200x magnification.  
Cells were also stained with non-epithelial markers to rule out possibility of a mixed 
population. Colagen-1, α-SMA and vimentin were used for this purpose. Our isolated primary 
PTEC did not show expression of these proteins (Figure 3-9, panel a-c). The results were 
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compared to primary human kidney fibroblasts isolated from the same tissue origin, which 
showed positive expression of these proteins (Figure 3-9, panel d-f). 
 
 
Figure 3-9. Expression of mesenchymal markers in primary PTECs and primary renal 
fibroblasts 
Immunofluorescent staining of mesenchymal markers; (a) Vimentin, (b) α-SMA and (c) Collagen-1 in 
the isolated primary PTECs. As positive controls, the same mesenchymal markers were applied to 
human primary fibroblasts isolated from similar tissue (d) Vimentin, (e) α-SMA and (f) Collagen-1. 
One image is a representation of an experiment conducted on biological duplicates (N=2). Images 
were acquired at 200x magnification.  
3.2.3. Scanning Electron Microscopy 
Scanning electron microscopy (SEM) images were taken on cells at passage 2, which 
highlight the round or hexagonal morphology common for PTEC (Figure 3-10 panel a). 
Higher SEM magnification showed presence of microvilli as a typical characteristic of 
epithelial cells (Figure 3-10 panel a-c). However, not all cells have these distinct microvilli on 
their surface. In a small area (as shown in Figure 3-10 panel b), some of these cells have very 
short villi. As expected, the isolated population contains some degree of contamination from 
other cell types (Figure 3-10 panel c), however, lower magnification (Figure 3-10 panel d), 
demonstrated that most cells were constituted by PTECs. An overview image of the slide also 
displayed distinct cobblestone-like conformation in a confluent monolayer (Figure 3-10 panel 
d). As comparison, fibroblasts isolated from similar samples were also imaged with SEM. 
This revealed a cell population with distinct morphology, mainly having a longer and spindle-
like appearance with no microvilli (Figure 3-11). 
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Figure 3-10 SEM images of human primary PTEC 
Scanning electron microscopy images of human primary PTECs at passage 3. Images a, b and c were 
captured at 5,000x magnification to show the presence of microvilli on the cell surface. Image d was 
taken at 500x magnification to provide an overview on how most area of the visual field was occupied 
by cells with microvilli.   
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Figure 3-11. SEM images of human primary fibroblasts 
Scanning electron microscopy images of human primary renal fibroblast at passage 2. Cells were 
isolated from tissue source similar to the tissues from which PTECs were isolated. Images a, b and c 
were acquired at 5,000x magnification to show the absence of microvilli on cell surface. Image d was 
captured at 500x magnification as an overview of a wider visual field.   
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3.3. Discussion 
Tubulointerstitial pathology has been frequently considered as the hallmark of various 
abnormalities in the kidney, including acute kidney injury due to IRI. PTEC is a key player in 
tubulo-interstitial pathology, thus has been the subject of numerous studies. In vitro studies 
using PTECs has been considered an important element of kidney research, as it is able to 
provide a well-controlled model to study renal response to a particular injury or disease. 
Despite the availability of animal primary PTECs and some immortalised PTEC cell lines, 
their genetic and biomolecular profile may not be an adequate representation of human 
primary PTECs. Establishing an effective and reproducible method to isolate human primary 
PTECs is therefore an important step in a kidney research.  
The most widely utilised method to isolate human primary proximal tubular cells is by 
Percoll density gradient centrifugation. Several adaptations of this technique have been 
reported in the literatures. Some authors used an ultracentrifuge to create the gradient density, 
while others performed collagenase digestion of renal tissue and mechanical sieving prior to 
the centrifugation step (Qi et al., 2007; Brown et al., 2008; A.Vesey et al., 2009; Sharpe and 
Dockrell, 2012). Despite being the most common method utilised, there are potential 
problems associated with this technique. One of the most common criticisms is the 
heterogeneity of the final product, which may contain not only proximal tubular cells, but also 
distal tubular cells, kidney fibroblasts and cellular debris. To overcome this problem, some 
authors reported the use of additional purification technique. This includes immune-magnetic 
separation technique using microbeads (Baer et al., 1997; Van der Hauwaert et al., 2013). 
Alternatively, others have proposed cellular sorting technique with the use of antibodies 
against prominin-1, a surface glycoprotein expressed in the brush border of proximal PTECs 
(Weigmann et al., 1997; Legouis et al., 2015) or by elimination of the contaminating distal 
convoluted tubular cells using anti-Tamm-Horsfall glycoprotein (Kamiyama et al., 2012). 
Despite their highly selective final product, the use of these additional immunogenic 
separation techniques is expensive, laborious, and are often associated with low cell yield and 
poor cell viability.  
Regardless of the criticism, several authors have evaluated the effectiveness of Percoll 
density gradient centrifugation protocol, especially when it was preceded with initial 
collagenase digestion and mechanical sieving steps. Cells characterisation performed by Qi et 
al. showed that the isolated cells have brush border enzyme activities (high gamma-glutamyl 
transpeptidase and alkaline phosphatase level) and transport activities indicative of PTEC (Qi 
et al., 2007). In our Institution, gradient centrifugation protocol with Percoll has been 
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established and applied to isolate primary PTECs from whole kidney, without the need to 
perform additional immunogenic separation steps. The isolated cells were mainly used for 
basic renal physiological experiments and drug transporter related research (Brown et al., 
2008).  
The use of higher collagenase concentration and longer collagenase exposure will result 
in less contamination of the final cell population; however, they are also associated with lower 
cell yield, thus lower cellular density, accelerated cellular dedifferentiation and earlier 
senescence. Deciding the most appropriate collagenase concentration and digestion time is 
therefore important to achieve the balance between reasonably pure culture and acceptable 
cellular yield. Initial optimisation steps to determine the appropriate concentration of 
collagenase, optimal enzymatic digestion and centrifugation time required, have been 
performed and reported previously (Brown et al., 2008). With this knowledge, I isolated 
PTECs from normal sections of human kidney, removed for oncological indications available 
to our facility using the already established protocol. It is important to mention that the 
original protocol was optimised for cell isolation from a larger section of renal tissue 
(approximately a quarter of the total minced cortical region of the whole kidney) compared to 
the tissues available to us (only sections of macroscopically normal kidney). Smaller tissue 
specimens were shown to yield cell populations with poorer quality and morphology. 
Moreover, smaller tissue specimens produced a very feint band of epithelial cells after 
gradient centrifugation. Manual aspiration of such a fine band is very likely to result in 
contamination by fibroblasts, erythrocytes or other cellular debris. Indeed, I found a visible 
contamination and poor growth capacity in cells isolated from tissue specimens that weighed 
below 1.5 gram. Brown et al. (Brown et al., 2008) documented the yield of around 3.5 million 
cells/gram wet weight kidney. Using the same collagenase concentration per gram weight of 
tissue, I have managed to achieve the yield of 1.5 to 2 million cells/gram wet weight of tissue 
specimen. 
Adequate characterisation of the isolated cells is necessary to ensure that the correct 
phenotype has been obtained in a reasonably pure culture. There are several characterisation 
methods that can be used. The simplest method is by examining the cell growth pattern and 
morphology by light microscopy. PTEC has a distinct hexagonal/round shape, initiates their 
growth in clusters, and when grown in high density, demonstrates the classic cobblestone-like 
appearance (Qi et al., 2007; A.Vesey et al., 2009). These features were easily identifiable in 
the cells that I isolated. Viable and functioning tubular cells have an intact cell-to-cell tight 
junction, and perform active cellular transport. This can be seen as accumulation of fluid 
between the cell monolayer and the solid growth surface of the culture vessels (Qi et al., 
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2007), which is often referred to as ‘domes’. Formation of ‘domes’ was also present in the 
PTECs populations I isolated.  
Presence of brush border is a typical feature of PTECs. To visualise this feature, I 
imaged the isolated cells using SEM. Microcillia were clearly present on the surface of most 
of the isolated cells. This strongly indicates that the majority of cells isolated have epithelial 
cell characteristics. However, the appearance of these microvilli appeared to be shorter than 
what normally seen on PTECs. It is highly likely that this was caused by the static (no 
continuous flow) environment in which the cells were cultured. Moreover, these primary cells 
were seeded directly on plastic surface, and not on a collagen matrix, which may affect the 
appearance of these villi. One other possible explanation is that the isolated cells were a mix 
population of cells consisting of distal TECs (DTECs) and not PTECs. DTECs are 
characterised by shorter villi compared to PTECs.  
Characterisation by immunofluorescence was performed to confirm that the isolated 
population are indeed epithelial cells, also to identify the extent of possible contamination by 
fibroblasts. For this purpose, several proteins, which are expressed in epithelial and mesangial 
cells, were selected. Zona Occludens-1 (ZO-1) is a tight junction protein presents on cellular 
membrane. ZO-1 is widely expressed on epithelial cells, but not specific to the renal tubular 
epithelial cells. This marker was selected to detect the proportion fibroblast contamination in 
the cultured population. Images from all our tissue samples showed that ZO-1 was strongly 
expressed in almost all regions of a slide, indicating negligible contamination from 
fibroblasts. Cytokeratin has been documented to be highly expressed in PTC culture (Qi et al., 
2007). In the isolated cells, prominent cytokeratin expression is uniformly identifiable, 
providing further support that the cells isolated are indeed PTECs.  
To further confirm, I decided to stain the cells for cadherins protein. The cadherins 
protein family are established markers of renal tubular epithelial cells. Their strong expression 
in the isolated cells clearly highlights the fact that renal tubular epithelial cells constituted 
majority, if not all, of the cultured cell population. Several papers have reported contradicting 
evidence of E-Cadherin, K-Cadherin or N-Cadherin expression in renal tubular epithelial cell 
sub-populations. It was previously accepted that generally E-Cadherin was highly expressed 
in renal proximal tubular epithelial cells. In contrast, some more recent authors documented 
that E-Cadherin was highly expressed in distal tubular cells and not as strongly expressed in 
proximal epithelial cells. K-Cadherin on the other hand was a prominent marker of proximal 
tubular cells. In a cultured proximal tubular cell population, however, both cadherins have 
been documented to be expressed equally strongly, as was also shown in the population I 
isolated. The immunofluorescence suggested stronger expression of K-Cadherin compared to 
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E-Cadherin, which is a consistent finding in proximal tubular epithelial cell population as 
documented by several authors (Paul et al., 1997; Baer et al., 2006; Systems, 2015). 
Mesangial and fibroblast markers, such as collagen-1, α-smooth muscle actin and vimentin 
were used to exclude cells of mesangial or fibroblast origin. These markers were not 
expressed in any of the isolated cells. 
Although primary culture of PTECs provides a better model to study the human kidney, 
their use has been restricted by the limited number of passages they could undergo. Some 
authors reported the end of mitotic lifespan of primary PTECs is reached after approximately 
8 to 10 passages, while others have only managed to successfully propagate primary PTECs 
for 5 passages (Qi et al., 2007; A.Vesey et al., 2009; Sharpe and Dockrell, 2012). Despite 
these differences, all authors have recommended only to use cells at passage 2 or 3 in 
experiments, to ensure unaltered characteristics of these cells. This agrees with my findings, 
which identified significant cellular morphological changes in these cells after four passages. I 
hypothesised that such an early change may be partly due to direct seeding of these cells to 
plastic surface with no collagen coating. However, I decided not to modify the seeding 
method since I was intending to use the cells only at passage 2 or 3 in my experiments.  
Taken into consideration the results of all characterisation methods used, I have satisfactorily 
proved that the isolated cells fulfil the characteristics of PTECs. Furthermore, I have also 
established a modified gradient centrifugation protocol to isolate PTECs from a relatively 
small kidney tissue, which has been shown to be relatively easy to perform as well as 
reproducible. This method also produces a pure final population of cells without the need to 
perform additional separation techniques. I could confidently conclude that the isolated 
population is representative of human primary PTECs. 
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Chapter 4. Effect of Ischaemia and Free Radicals in MicroRNA Profile of 
Tubular Epithelial Cell 
4.1. Introduction and Specific Objectives 
Ischaemia and reperfusion injury is one of the contributing factors to the progression of 
allograft damage after kidney transplantation. As to whether the injury induces reversible or 
irreversible tissue damage depends upon the duration of injury, frequency and degree of 
severity. There is substantial evidence available to support that IRI leaves signature miRNA 
changes, which vary between different organ and tissues. How these miRNA changes affect 
organ function at shorter or longer time points, however, remains to be comprehensively 
investigated. 
Proximal tubular epithelial cells have been identified as both the target and an active 
player in the renal response to IRI.  Identifying the signature changes in PTEC miRNA after 
IRI is the first step in selecting key miRNAs involved in the renal response to IRI.  The main 
objective of this part of the study is to create an optimal IRI model in vitro, and to further 
observe how IRI alters miRNA expression level in various types of renal PTECs. Prior to 
miRNA profiling, an optimal protocol to induce hypoxia and reperfusion in the various cell 
types used had to be established. An ideal ischaemia or reperfusion treatment should be 
adequate to induce detectable level of stress resulting in miRNA changes without 
compromising cellular viability. To determine these optimal treatment conditions, I set up a 
series of experiment to objectively measure each cell’s viability threshold and tolerability to 
either ischaemia or reperfusion injury.  
Profiling miRNA in only one cell type following a specific condition is not ideal, and is 
considered one of the factors contributing to the lack of overlapping results among existing 
data. This is an important factor to consider, especially if the profiling is based only on 
immortalised cell lines, which arguably possesses limited resemblance to primary human 
cells.  By using several cell types in this profiling step, we expect to see an overlapping set of 
miRNAs, which are consistently up/down-regulated following ischaemia or reperfusion.  
These miRNAs will be considered strong candidates to be explored and validated further.  
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4.2. Results: Simulating Ischaemia and Reperfusion Injury 
4.2.1. Assessment of the Effect of Hypoxia 
4.2.1.1. HIF-1a Nuclear Localisation  
After 12 hours of incubation with 1% O2, HKC-8 cells were stained with anti HIF-1α 
antibody to assess the response to hypoxia. HKC-8 cells treated with 100 µM CoCl2 for 72 
hours were used as a positive control (Figure 4-1 panel d-f).  Intra-nuclear staining of HIF-1α 
was visible in both positive control and HKC8 cells incubated in hypoxia chamber. (Figure 
4-1 panel a-f). Chemical stabilisation of HIF-1α by CoCl2 treatment resulted in more HIF-1α 
nuclear localisation compared to induction of hypoxia using a hypoxia chamber. Nevertheless, 
it is evident that there was a clear increase in cytoplasmic and intra-nuclear HIF-1α staining in 
the hypoxic cells compared to the normoxic cells.  
 
Figure 4-1 HIF-1α expression in HKC-8 cells in ischaemic condition 
HIF-1α expression in HKC-8 cells incubated in 1% O2 for 12 hours (a and b), CoCl2 for 72 hours (c 
and d), and in normoxia (e and f). Images were taken at 400x magnification using Zeiss Axio imaging 
unit. Images shown are the representative of images captured from two independent experiments 
(N=2). 
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4.2.1.2. HRE-Luciferase Activity 
Indirect measurement of hypoxia responsive element activation through luciferase 
activity enabled demonstration of a functional effect of hypoxia to HKC-8 cells. Incubation in 
1% O2 for 12 hours initiate a HRE activation. Interestingly, further incubation time resulted in 
less luciferase activity (Figure 4-2). At both time points, HKC-8 cells were clearly shown to 
be responding to hypoxia, indicated by the significance increase in luciferase activity 
compared to HKC-8 cells in normoxic environment. 
 
Figure 4-2 HRE luciferase activity following hypoxia 
Fold change in luciferase activity of hypoxia response elements (HRE)-transfected HKC-8 cells after 
12 and 24-hour incubation in 1% O2. Luciferase expression was compared to HRE-transfected HKC-8 
cells incubated in normoxia. Mean luciferase activity was normalised to the total protein. HKC-8 cells 
transfected with an empty plasmid (PGL3) were used as plasmid control. Data was presented as fold 
change of the mean of normalised luciferase activity + SD. One-way ANOVA test was used to detect 
significant difference between the means. Multiple comparisons between samples were performed 
using Bonferroni post-hoc analysis. (*** = p ≤0.001; **** p ≤0.0001) 
4.2.2. Assessment of Oxidative Stress 
4.2.2.1. Viability Assay 
To appropriately simulate reperfusion injury, cells should be stressed enough to induce 
gene expression changes without significant effects on cell viability. 80% viability was 
chosen as it is an arbitrary cut-off to demonstrate cell loss due to free radical injury, but with 
sufficient cell survival for analysis. Every cell type responded similarly to H2O2 treatment. 
Increasing concentration of H2O2 resulted in gradual cell death in all cells. In HKC-8 cells, the 
threshold concentration is 400 µM. HK-2 and primary PTECs were more sensitive to H2O2 
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treatment, with a H2O2 concentration of 200 µM and 300 µM, respectively sufficient to cause 
20% cell death (Figure 4-3).  
 
Figure 4-3 PTEC viability after induction of free radical 
Percentage viability of various types of cells: (a) HKC-8 cells; (b) HK-2 cells, and (c, d) primary 
PTEC from two different patients after exposure to short-term H2O2 treatment (4 hour in H2O2 
followed by incubation in fresh complete media for 20-hour). Percentage viability was measured by 
trypan blue dye exclusion assay. Data was presented as the mean of percentage viability + SD from 
three replicates (N=3).  
The initial phase of this experiment was performed in HKC-8 cells. A wider range of 
H2O2 concentration was used to define the concentrations to use for future experiments. For 
HKC-8 cells, 400 µM was chosen as the optimal concentration as it resulted in 80% cell 
viability. HK-2 and primary human cells were more susceptible to free radical injury. The 
same concentration used for HKC-8 markedly reduced HK-2 and primary human cell viability 
to 50% and 60% respectively. Therefore, lower concentrations of H2O2 were considered as 
optimal treatment conditions. As the origin of human primary cells varies in terms of patient 
clinical status, underlying renal disease, and other undefined factors, the response to free 
radical stress was assessed in cells isolated from each patient. The results suggested the same 
optimal concentration of H2O2. 
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4.2.2.2. Detection of Oxidative Stress 
Fluorescence-activated cell sorting (FACS) was used to detect oxidative activity in 
cells. Population gating was performed based on FSC (forward scatter) and SSC (side scatter) 
(Figure 4-4). Unstained cells emitted negligible degree of fluorescence, which was regarded 
as cell auto-fluorescence (Figure 4-4 panel A). Median intensity emission of CM-H2DCFDA 
was plotted against number of events recorded on histograms. Untreated cells stained with 
dye showed an increase in fluorescence emission compared to unstained cells. This was used 
as control. As shown in Figure 4-4, there was an increase in fluorescence with increasing 
hydrogen peroxide concentration up to 400µM. This is represented as shift of the peak to the 
right (Figure 4-4 panel C-F). 
 
Figure 4-4 ROS molecular probe activity after H2O2 treatment 
Population gating and fluorescence emission of CM-H2DCFDA in HKC-8 cells treated with various 
H2O2 concentrations. Cells were exposed to H2O2 for 4 hours before incubation in normal media for 20 
hours before staining with CM-H2DCFDA. Results were presented as follows; (A) no probe, no H2O2; 
(B) with probe, no H2O2; (C) with probe, 200 µM H2O2; (D) with probe, 400 µM H2O2; (E) with probe, 
600 µM H2O2; (F) with probe, 800 µM H2O2. 
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As illustrated in Figure 4-4 (panel D), 400 µM H2O2 induced the most ROS in HKC8 
cells. Further increases in H2O2 concentration resulted in a lower median intensity (Figure 4-4 
panel E and F). At 800 µM, generation of ROS fell almost to the level comparable to control. 
There were two peaks of intensity visible at this concentration (Figure 4-4 panel F). The lower 
intensity peak may represent unviable cells, as a consequence of higher H2O2 concentration. 
 
Figure 4-5 Summary of ROS probe activation in H2O2 treated PTECs 
Graph showing median intensity emission of CM2-H2DCFDA in HKC-8 cells treated with different 
H2O2 concentrations. Data is presented as median intensity + SD of three replicates (N=3). One-way 
ANOVA with Bonferroni post-hoc analysis was used analyse emission at 200 µM, 400 µM, 600 µM 
and 800 µM compared with emission at 0 µM. (*** = p ≤0.001; **** p ≤0.0001) 
4.3. Results; MicroRNA Profiling  
4.3.1. MicroRNA Selection Criteria 
A change in a miRNA level of expression by 2-fold or greater was considered 
significant. As different cell types were used, their genetic differences need to be appreciated, 
especially between cell line (HKC-8 and HK-2 cells) and the two primary PTECs used. 
Therefore, miRNA selection was not performed only based on the magnitude of change in the 
level of expression, but also based on the consistency of up or down-regulation. Subsequent 
analysis will only include miRNAs which were consistently up/down-regulated in either both 
cell lines (HKC-8 and HK-2 cells) or both primary PTECs. These miRNAs that fulfil the 
selection criteria were included in the subsequent functional analysis work. 
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4.3.2. Quality Control and Normalisation Methods 
Several quality control metrics were performed to ensure that all samples were 
correctly processed and captured. This include field of view (FOV) and binding density. The 
data did not show significant discrepancy between the FOV count and FOV counted; 
indicating that no technical issues related to imaging performance was encountered in the 
experiment. The image saturation of all lanes was also within the desired range of binding 
density, reflecting the integrity of probe counts produced. The quality control metrics verified 
that there was no quality control issue related to sample quality, sample processing and assay 
techniques.  
To assess the performance of ligation controls, positive and negative controls, a 
heatmap illustrating their expression level was generated (Figure 4-6). All ligation controls 
performed as expected, indicated by positive detection of positive ligation controls, and 
negative expression of negative ligation control. The codeset provides six positive controls, 
which were ligated and hybridised in the same way as an endogenous miRNA in the codeset. 
These positive controls should be in six decreasing concentrations after hybridisation process; 
128 fM, 32 fM, 8 fM, 2 fM, 0.5 fM and 0.12 fM. The expression of these positive controls 
were also appropriately visualised in the heatmap. In addition, the expression levels of a set of 
mRNAs used as reference genes were also displayed, which were shown to be relatively equal 
across different samples. 
To profile miRNAs expression after IRI, I utilised a human miRNA codeset containing 
800 miRNAs. Following the manufacturer’s recommendation, I chose to normalise the data 
readings using global normalisation method (using the 100 mostly expressed miRNAs in the 
dataset). Prior to applying this method, however, it was necessary to ascertain that the 
expression of these reporter probes did not vary significantly between different samples. 
Using one of the sample/lane as a reference point, I selected the 100 most highly expressed 
miRNAs across all samples. 
As an alternative to global normalisation method, Nanostring® recommends the use of 
a set of reference genes in the raw data normalisation process. To evaluate whether the 
selection of normalisation method has an impact on the detection of miRNA changes, I 
compared the analysis results of data normalised by global normalisation to the analysis result 
of data normalised by reference gene normalisation. For the purpose of illustrating the 
similarity or differences of the two methods, I performed the comparison in both ischaemic 
injury and reperfusion injury cells at 12-hour time point only. 
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Figure 4-6 Control probes expression 
Heatmap illustrating the expression level of ligation controls (3 negative and 3 positive), positive 
controls (6 probes), negative controls (8 probes) and reference mRNAs (B2M, GAPDH, RPL19, 
ACTB, RPLP0). Level of expression data was displayed in (log2) of molecule count standardised to 
the z-score of the probe.  
 
At 12 hour hypoxia, 87 miRNAs that fulfil the selection criteria were identified using 
reference gene normalisation method, whilst global normalisation method identified 58 
miRNAs. Out of these miRNAs, 50 were commonly identified by both methods (Figure 4-7). 
At 12 hour free radical exposure, reference gene normalisation identified 79 miRNAs that 
fulfil the selection criteria, whilst only 58 miRNAs were identified by the global 
normalisation method. 46 miRNAs were commonly identified by the two methods at 12 hour 
exposure to H2O2 (Figure 4-8). 
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Figure 4-7 Detection of miRNAs using top 100 miRNAs vs reference gene normalisation in hypoxic cells 
Heatmap illustrating differential expression of miRNAs in all cell types after 12-hour hypoxia. Detection of miRNA was performed using two different 
normalisation method; top 100 miRNA normalisation and reference gene normalisation. The latter method detected 50 out of 58 miRNAs detected by top 100 
miRNA normalisation method. 
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Figure 4-8 Detection of miRNAs using top 100 vs reference gene normalisation in cells exposed to H2O2 
Heatmap illustrating differential expression of miRNAs in all cell types after 12-hour exposure to free radical. Detection of miRNA was performed using two 
different normalisation method; top 100 miRNA normalisation and reference gene normalisation. The latter method detected 45 out of 58 miRNAs detected by top 
100 miRNA normalisation method. 
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4.3.3. Assessing Stability of Profile 
Alteration in miRNAs profile following IRI in PTECs was detected by calculating the 
ratio of expression of a miRNA in ischaemia or reperfusion injury to its expression in the non-
treated cells. To evaluate the effect of incubation alone (without induction of ischaemia or 
reperfusion) on the cells, I compared miRNA expression in non-treated cells at 0-hour and 12-
hour for every cell type used. The comparison showed that in every cell type, there were a 
small number of miRNAs which were differentially expressed at the two observation points. 
However, the expression of the majority of miRNAs in the codeset was not altered by 12-hour 
incubation alone. The comparison between the two time points was illustrated in Figure 4-9. 
Detailed analysis of the two primary PTECs showed that the pattern of expression of most 
miRNAs was similar, which confirms the reproducibility of cell isolation procedure and 
relatively stable miRNA profile.  
 
 
Figure 4-9 MiRNA expression in untreated cells at 0-hour and 12-hour 
Scatter plots illustrating miRNA expression in untreated PTECs. Data was displayed as (log2) count of 
each miRNA. Comparison was made between: (a) HK-2 cells at 12-hour and 0-hour, (b) HKC-8 cells 
at 12-hour and 0-hour, and (c, d) pPTECs isolated from two different patients at 12-hour and 0-hour.  
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4.3.4. MicroRNA Profile Following Hypoxia and Induction of Free Radical  
For further analysis, we decided to include only the miRNAs which met the selection 
criteria described in section 2.15.1. These are miRNAs with consistent up or down-regulation 
of 2-fold change or more, in either both cell lines (HKC-8 and HK-2 cells) or both primary 
PTECs following a given treatment. The nCounter® platform detected 168 out of 800 
miRNAs provided in the codeset fulfilled the selection criteria. The relationship of the 
number of miRNAs and the treatment condition in which their expression level was found to 
be significantly altered was illustrated in Figure 4-10.  
 
 
Figure 4-10 Summary of the number of miRNAs significantly altered at a given treatment 
condition 
Codeset miRNAs is the total number of miRNA probes provided in the assay kit. Only miRNAs that 
met selection criteria were included in this diagram.  
To evaluate whether different injury types altered miRNA profile differently, we 
clustered miRNAs, which fulfilled the selection criteria, based on the direction of their 
alteration in either ischaemia or reperfusion injury. This is illustrated in Figure 4-11 and 
Figure 4-12. Analysis of both the 2 and 12-hour time points showed that hypoxia alone or free 
radical exposure alone produced distinct miRNA signature in PTECs. At 2-hour, only 21 out 
of 120 miRNAs were identified in both ischaemic injury and reperfusion injury, while 23 out 
of 87 miRNAs were identified by both injuries at 12-hour. We have identified only three 
miRNAs that showed significant and consistent up/down-regulation in either all cells, both 
cell lines, or both primary cells after hypoxia and H2O2 treatment; miR-21, miR-376a and 
miR-190b.  
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To assess similarities or differences between miRNA profile in cell lines and PTECs, 
the miRNAs which fulfil the selection criteria were grouped into several categories, based on 
their pattern of up or down-regulation in either cell lines (HKC-8 and HK-2) or primary 
PTECs as described in Table 4-1. Expectedly, each cell type produced a unique miRNA 
signature in response to either ischaemia or reperfusion, highlighting differences in cellular 
genetic characteristics. These differences are especially apparent between the two primary 
PTECs and cell lines (HKC-8 and HK-2). This is reflected by the dominance of category 2 
and 3, which represent consistent up/down-regulation in either cell lines or primary PTECs at 
all time points (Table 4-1). 
Table 4-1 Categorisation of miRNA profile 
Category Number of altered miRNAs at 2 hour Number of altered miRNAs at 12 hour 
Hypoxia ROS Hypoxia ROS 
1 5 5 6 3 
2 39 24 23 20 
3 19 58 29 35 
4 0 0 0 1 
Category 1: consistent up/down-regulation in all cell types 
Category 2: consistent up/down-regulation in cell lines (HKC-8 and HK-2) 
Category 3: consistent up/down-regulation in both primary PTECs 
Category 4: opposite effect between cell lines (HKC-8, HK-2) and primary PTECs 
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Figure 4-11 MiRNAs profile in all cells at 2-hour time point 
Heatmap illustrating differential expression of miRNAs in all cell types after 2-hour hypoxia or free-radical exposure. Data was expressed as fold change of gene 
expression (ratio of gene expression between treated and non-treated cells at 2-hour). Only miRNAs that fulfil the selection criteria were included. MiRNA 
clustering was performed solely based on the selection criteria. 
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Figure 4-12 MiRNAs profile in all cells at 12-hour time point 
Heatmap illustrating differential expression of miRNAs in all cell types after 12-hour hypoxia or free-radical exposure. Data was expressed as fold change of gene 
expression (ratio of gene expression between treated and non-treated cells at 12-hour). Only miRNAs that fulfil the selection criteria were included. MiRNAs were 
clustered based on the selection criteria. There was no statistical method applied to rank the miRNAs. 
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The miRNA expression profile at 2-hour and 12-hour after the same type of injury were 
also different. Consistent up- or down-regulation of a miRNA at both time points by a given 
injury may reflect its particular importance in performing a specific cellular function. 
Therefore, I have listed several miRNAs with the same pattern of expression at both 2-hour 
and 12-hour in either hypoxia alone or exposure to H2O2 alone. This is shown in Figure 4-13. 
 
 
Figure 4-13 Expression pattern of selected miRNAs at 2 and 12-hour hypoxia or free-radical 
exposure 
Heatmap showing expression of miRNAs that were significantly and consistently up- or down-
regulated after ischaemia or reperfusion injury. Data was expressed as fold change of gene expression 
(ratio of gene expression between treated and non-treated cells at 12-hour). MiRNAs were clustered 
based on the selection criteria without performing a specific statistical analysis.  
 
For the purpose of this study, I focused on 12-hour time point. At this time point, I 
identified 35 miRNAs with miRNAs level of expression changes unique to ischaemia. 
Similarly, 12-hour of free-radical injury induced changes in 35 other miRNAs (Figure 4-14). 
The expression level of 23 miRNAs was significantly altered in both injuries. The magnitude 
of changes of these miRNAs is shown in Figure 4-15 and Figure 4-16. 
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Figure 4-14 Venn diagram showing significantly altered miRNA at 12-hour time point  
The diagram enlists selected miRNAs, which were altered after hypoxia only, after exposure to H2O2 
only, and after both injuries. MiRNAs which have been previously identified in the literature which 
focused on renal model of IRI (see Table 1.1) were printed in bold italic font 
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Figure 4-15 Detailed list of miRNAs that fulfil the selection criteria at 12-hour hypoxia 
List of miRNAs which were up/down-regulated by more than 2-fold in either the two cell lines (HKC-
8 and HK-2) or in the two primary PTECs after 12 hour hypoxia. MiRNA was categorised based on 
their patter of expression (category 1: up/down-regulation in all cells, category 2: up/down-regulation 
in cell lines only, category 3: up/down-regulation in primary cells only, category 4: opposite effect in 
cell lines vs primary cells). Data was presented as the mean of fold change of expression compared to 
normoxic cells. Magnitude of expression was calculated by averaging the fold change in the affected 
cells respective of their miRNA pattern categories).  MiRNAs were listed based on the mean of 
magnitude (from the greatest magnitude of up-regulation at the top of the list to the greatest magnitude 
of regulation on the bottom of the list).  
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Figure 4-16 Detailed list of miRNAs that fulfil the selection criteria at 12-hour after H2O2 
treatment  
List of miRNAs which were up/down-regulated by more than 2-fold in either the two cell lines (HKC-
8 and HK-2) or in the two primary PTECs at 12 hour after H2O2 treatment. MiRNA was categorised 
based on their patter of expression (category 1: up/down-regulation in all cells, category 2: up/down-
regulation in cell lines only, category 3: up/down-regulation in primary cells only, category 4: opposite 
effect in cell lines vs primary cells). Data was presented as the mean of fold change of expression 
compared to non-ischaemic cells. Magnitude of expression was calculated by averaging the fold 
change in the affected cells respective of their miRNA pattern categories).  MiRNAs were listed based 
on the mean of magnitude (from the greatest magnitude of up-regulation at the top of the list to the 
greatest magnitude of regulation on the bottom of the list).  
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To examine possible overlaps between my findings and the results from previous 
miRNAs profiling studies in kidney IRI, a heatmap illustrating the expression pattern of 
several miRNAs mentioned in the literatures was generated (Figure 4-17). I found several 
miRNAs with significant changes in their level of expression, which have also been identified 
in previous reports. These miRNAs include miR-18a, miR-21, miR-34a, miR-155, miR-194, 
miR-199a, miR-210, miR-214, miR-494, and miR-877.  
 
Figure 4-17 Expression of previously identified miRNAs from the literature, in our dataset 
Heatmap illustrating the differential expression of previously identified miRNAs from the literature. In 
our dataset, only a few of these miRNAs showed significant differential level of expression after 
hypoxia or free-radical exposure. MiRNAs were clustered based on the selection criteria without 
performing a specific statistical analysis. 
 
4.4. Validation of Profiling Results 
Microarray results were validated using real-time quantitative PCR. Several 
microRNAs were selected from a group of microRNAs that were consistently up/down-
regulated in all cells (HKC-8, HK-2 and primary PTECs) following either ischaemia or 
reperfusion. These include miRNAs which were consistently up/down-regulated following 
exposure to both injuries, such as miR-21-5p and miR-34a-5p; miRNAs which were 
consistently altered following ischaemic injury only, such as miR-210-5p and miR-363-3p, 
and miRNAs which were consistently altered following reperfusion injury only, such as miR-
130b-3p and miR-142-3p.  
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4.4.1. Up-regulation of miR-21 After Hypoxia 
Up-regulation of miR-21 was seen consistently in all cells at 12-hour after induction of 
ischaemia (Figure 4-18). Unlike the result from NanoString® profiling, miR-21 expression 
was not significant in HKC-8 and HK-2 cells after 2 hours (Figure 4-18; (a) and (b)). In both 
HKC-8 and HK-2 cells, up-regulation of miR-21 reached its peak at 12-hour following 
ischaemic injury. In two primary PTECs, miR-21 was significantly up-regulated at both 2 and 
12-hour. I later confirmed this up-regulation in two other primary PTECs isolated from 
different patients (Figure 4-19).  
 
 
Figure 4-18  MiR-21 expression in PTECs following hypoxia 
Expression of miR-21 by real-time qPCR in HKC-8, HK-2 and primary PTECs isolated from two 
patients, relative to the expression of a housekeeping gene, RNU48. Data was presented as the mean 
of fold change of relative expression compared to control at 0 hour. Each graph is the result of  an 
experiment performed in three technical replicates. Statistical significance was derived by comparing 
the mean expression of miR-21 of the treated groups to their respective control at 0-hour using one-
way ANOVA with Dunnett’s post-hoc analysis. Chart bars represent the mean of fold-change 
expression + SD (* = p ≤0.05; ** = p ≤0.01; *** = p ≤0.001; **** p ≤0.0001) 
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Figure 4-19 Compilation of miR-21 expression in all primary PTECs following hypoxia 
Combined analysis of miR-21 expression by real-time qPCR in primary PTECs isolated from four 
different patients (N=4), relative to the expression of RNU48. Data presented were the results of four 
independent experiments, each performed in three technical replicates. Results were presented as the 
mean of fold-change expression + SD compared to normoxic cells at 0 hour. One-way ANOVA with 
Dunnett’s post-hoc analysis was applied to measure existing statistical difference in treated samples 
compared to untreated samples at 0-hour (*** = p ≤0.001; **** p ≤0.0001) 
 
4.4.2. Up-regulation of miR-21 After Free-Radical Stress 
Generally, the level of expression of miR-21 showed a trend of up-regulation in all 
cells following treatment with H2O2 (Figure 4-20). However, the level of increase was not 
enough to reach statistical significance in HKC-8 cells and one of the primary PTECs (Figure 
4-20; (a) and (c)) at the 2-hour observation time-point. Similar to the result from miRNA 
profiling, 12-hour of H2O2 treatment significantly increased miR-21 level of expression in all 
PTECs. Despite being statistically significant, the fold change increase in miR-21 did not 
reach two-fold in one of the primary PTECs. Taking into consideration the pre-existing inter-
individual differences, the magnitude of changes is also expected to vary across primary cells 
isolated from different patients. To confirm this finding, the same validation experiment was 
conducted in additional primary PTECs isolated from two more patients. The combined result 
revealed a statistically significant increase in miR-21 expression at 12-hour (Figure 4-21). 
MiR-21 was up-regulated by an average of three folds in all primary PTECs after H2O2 
treatment, with peak up-regulation occurring at 12-hour after injury. 
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Figure 4-20 MiR-21 expression in PTECs after H2O2 treatment 
Expression of miR-21by real-time qPCR in HKC-8, HK-2 and two primary PTECs after 2 and 12-hour 
H2O2 treatment. Expression of miR-21 was measured relative to RNU48 expression. Data was 
presented as the mean + SD of fold-change expression. Each graph presented was the result of a single 
experiment performed in three technical replicates. One-way ANOVA with Dunnett’s post-hoc 
analysis was applied to detect statistical significance by comparing the mean expression of miR-21 at 
each time point to untreated cells at 0-hour (* = p ≤0.05; ** = p ≤0.01; *** = p ≤0.001; **** p 
≤0.0001) 
 
Figure 4-21 MiR-21 expression in all primary PTECs following H2O2 treatment  
Data showing the mean of fold-change in miR-21 expression at 2 and 12-hour following reperfusion 
injury, normalised to the expression of RNU48. Expression level of the treated cells at 2 and 12-hour 
were compared to untreated cells at 0-hour. Data presented were the results of four independent 
experiments using primary cells isolated from four different patients (N=4). Each experiment was 
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performed in three technical replicates. Statistical significance was obtained using one-way ANOVA 
with Dunnett’s post-hoc analysis (*** = p ≤0.001) 
4.4.3. Expression of miR-34a in hypoxic PTECs 
Nanostring profiling showed down-regulation of miR-34a in hypoxic PTECs. 
Validation with qPCR also detected decrease in miR-34a expression during ischaemia. 
However, at 2-hour time point, the changes were only found to be statistically significant in 
primary PTECs (Figure 4-22; (c) and (d)), but not in HKC-8 or HK-2 cells (Figure 4-22; (a) 
and (b)). The decrease in miR-34a expression persisted, and reached statistical significance in 
all cells at the 12-hour time point. Generally, 12-hour ischaemia reduced miR-34a expression 
by approximately 3-4fold in all PTECs. This decrease in miR-34a expression was also 
verified in two additional primary PTECs isolated from different patients (Figure 4-23).  
   
 
Figure 4-22. MiR-34a expression following hypoxia 
qPCR results showing miR-34a expression in HKC-8, HK-2, and two primary PTECs after hypoxia, 
relative to the expression of a reference gene, RNU48. Each graph was the result of a single 
experiment performed in three replicates. Data were presented as the mean of fold-change expression 
+ SD. Statistical significance was tested using one-way ANOVA with Dunnett’s post-hoc analysis by 
comparing the mean of fold-change expression in the hypoxic group to the normoxic cells at 0-hour. 
(** = p ≤0.01; *** = p ≤0.001; **** p ≤0.0001) 
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Figure 4-23 MiR-34a expressionin primary PTECs  following hypoxia 
qPCR results of miR-34a expression in HKC-8, HK-2, and two primary PTECs after hypoxia, relative 
to the expression of RNU48. Data presented was the result of four independent experiments (N=4), 
each performed in three technical replicates. Data were presented as fold-change expression compared 
to the respective control at 0-hour.  Statistical significance was tested using one-way ANOVA with 
Dunnett’s post-hoc analysis by comparing the mean miR-34a expression in the treatment group to the 
control group at 0-hour. (* = p ≤0.05; ** = p ≤0.01; *** = p ≤0.001; **** p ≤0.0001) 
 
4.4.4. Expression of miR-34a After H2O2 Treatment 
Similar to ischaemia, induction of free radicals in PTECs also decreased miR-34a 
expression in all PTECs. Again, qPCR did not detect statistically significant changes at the 2-
hour time point. The down-regulation of miR-34 was sustained and reached statistical 
significance at 12-hour after H2O2 treatment in all cells (Figure 4-24). Down-regulation was 
3-4 fold in HKC-8 and primary PTECs compared to untreated cells (Figure 4-24; (a), (c) and 
(d)). In HK-2 cells, the expression of miR-34a was only reduced by approximately half of its 
control level (Figure 4-24; (b)). This finding was further verified by conducting the same 
experiment in additional primary PTECs isolated from two additional patients. The overall 
findings concluded that in all primary PTECs, 2 and 12-hour H2O2 treatment caused 
significant down-regulation of miR-34a (Figure 4-25).   
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Figure 4-24 Mir-34a expression after H2O2 treatment  
Mean of fold-change expression of miR-34a by real time qPCR, relative to RNU48 expression, in 
HKC-8, HK-2, and primary PTECs isolated from two patients. Each graph showed the result of a 
single experiment performed in three technical replicates. Result was presented as mean + SD. One-
way ANOVA test with Dunnett’s multiple comparison analysis was applied to compare the mean of 
each treatment group to control group at 0-hour. (* = p ≤0.05; ** = p ≤0.01; *** = p ≤0.001; **** p 
≤0.0001)  
 
Figure 4-25 MiR-34a expression after H2O2 treatment in all primary PTECs  
MiR-34a relative expression to RNU48 by real-time qPCR in primary PTECs isolated from different 
patients. Data presented was the result of four independent experiments (N=4), each performed in 
three technical replicates Diagram represents the mean of fold-change expression + SD. Statistical 
significance was tested by comparing the mean of fold-change expression at 2 or 12-hour time points 
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to untreated cells at 0-hour. Statistical analysis was performed using one-way ANOVA followed by 
Dunnett’s multiple comparison analysis. (**** p ≤0.0001) 
4.4.5. Other miRNAs  
The expression level of miR-210 and miR-363 were increased in hypoxic primary 
PTECs, but not after H2O2 treatment. Using qPCR, I validated this increase, which showed a 
significant up-regulation of both miRNAs by 2-fold specifically in response to hypoxic injury 
(Figure 4-26). In contrast, the expression of miR-130b and miR-142 was increased in 
response to H2O2 treatment (Figure 4-26). 
 
 
Figure 4-26. Expression level of miR-210, miR-363, miR-130b and miR-142 in hypoxia or after 
free radical induction 
The expression of selected miRNAs in primary PTECs incubated in hypoxia or treated with H2O2 by 
real-time qPCR. Expression of miRNA was  normalised to the expression of RNU48 as the reference 
gene. For each miRNA, experiments were conducted in primary PTECs isolated from three different 
patients (N=3). Comparison was made between the expression of each miRNA in a treatment time-
point to its control at 0-hour. Bar chart represents the mean fold-change expression + SD of the 
investigated miRNA. One-way ANOVA was applied to detect variance across sample set. Difference 
in the mean between treatment groups at 2, 12-hour and untreated group at 0-hour were analysed using 
Dunnett’s multiple comparison test. (* = p ≤0.05; ** = p ≤0.01; *** = p ≤0.001; **** p ≤0.0001) 
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4.5. Functional Analysis and Target Prediction Results 
This step of the project was only applied to miRNAs which fulfilled the selection 
criteria (consistently up/down-regulated in cell lines or both primary PTECs by 2-fold) at 12-
hour time point. Firstly, I utilised miRPath to find a potential association between the 
miRNAs listed in Figure 4-14 to any known biological pathway listed in the KEGG database. 
MirPath was selected for its practicality, as it allows analysis of a large selection of miRNAs 
in a single search. Association between a miRNA and a KEGG biological pathway was 
detected by miRPath through three prediction softwares; Tarbase, microT-CDS and 
TargetScan. To detect all potential pathways in which a miRNA from our set is targeting, we 
opted to use genes union selection method. This method calculates the union of targeted genes 
by the selected miRNAs set, listing all genes targeted by at least one of the miRNAs in the 
set. MiRPath then identified pathways associated with these genes. With this method, I was 
able to list all pathways targeted by a single miRNA.  The pathways targeted include HIF-1a 
signalling pathway, regulation of actin cytoskeleton, mTOR signalling pathway and TGF-b 
signalling pathway.  I then selected the pathways which were considered relevant in cellular 
response to IRI.  
 From the pathways listed above, I selected the TGF-b signalling pathway which is 
involved in the cellular response to both ischaemia and reperfusion injury. I identified 45 
miRNAs from the dataset, which were predicted to be involved in the regulation of TGF-b 
signalling pathway. These miRNAs include miR-133a, miR-363, miR-376a, miR-21, 
miR124, miR34a and miR-142. 
4.5.1. Targets of miR-21 
 Mir-21 is one of the miRNAs which was up-regulated in all cell types. Based on this, I 
performed target validation and explored the role of miR-21 in the TGF-b signalling pathway 
in the kidney following IRI. The potential target genes of miR-21 in the TGF-b signalling 
pathway listed by miRPath can be seen in Figure 4-27. 
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Figure 4-27 Illustration of TGF-b signalling pathway and potential target genes of miR-21 
Predicted mRNA targets of miR-21 in the TGF-b signalling pathway. Target genes predicted by two 
prediction software (both micro-T-CDS and Tarbase) were highlighted in amber, and target genes 
predicted by only one software (either micro-T-CDS or Tarbase) were highlighted in yellow. Diagram 
was accessed through miRPath version 2.0 computational tool and KEGG pathway (Kanehisa 
Laboratories). 
As described in the introductory section, all prediction software performed 
identification of miRNA targets by matching the nucleotide sequence between the seed region 
of miR-21 (2-8 bases) and 3’ untranslated region (UTR) of a potential target mRNA. 
However, each computational tool utilises a different algorithm, and therefore, it is crucial to 
use more than one tool to ensure the accuracy of each algorithm. I used miRWalk prediction 
software as it allows this verification process using three or four available computational tools 
in parallel. The following mRNA targets from miRPath were also listed by four 
computational tools in miRWalk: STAT3, IL6R, SMAD7, TGFBR2, BMPR2, TGFB2, 
CREB5, CDK6 and FASLG (also listed in Table 4-2).  
4.5.2. Targets of other potential miRNAs 
In addition, I applied the same target prediction steps to other significantly altered 
miRNAs at 12-hour, which were considered relevant to tubular epithelial cell response to IRI. 
The result of this analysis is displayed in Table 4-2. 
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Table 4-2 Predicted mRNA targets of selected miRNAs 
miRNA +/- Condition Cells Pathway Genes 
miR-21-5p + Ischaemia and ROS All 
HIF-1 signalling STAT3, IL6R 
TGF-β signalling TGFBR2, TGFB2, SMAD7, BMPR2 
PI3K-Akt PTEN, CREB5, CDK6, FASLG, IL6R 
miR-30a-3p - Ischaemia pPTECs HIF-1 signalling ANGPT2, AKT3 TGF-β signalling CREBBP, PITX2 
miR-34a-5p - Ischaemia and ROS All 
HIF-1 signalling 
ERBB2, PIK3CB, BCL2, 
PGF, LDHA, PRKCB, 
MAP2K1, VEGFA, 
SERPINE1, IL6R 
EMT NOTCH1, NOTCH2, NOTCH4 
TGF-β signalling SMAD4, E2F5 
miR-363-3p + Ischaemia pPTECs 
Extra-cellular matrix 
receptor 
COL2A1, ITGB6, ITGA5, 
ITGAV, COL1A2, FST, 
BMPR2 
EMT SOX4 
TGF-β signalling FST, BMPR2 
HIF-1 signalling PIK3R3, PI3CA 
miR-376a-3p + Ischaemia and ROS pPTECs 
TGF-β signalling BMPR2 
HIF-1 signalling PIK3CB 
miR-190b + Ischaemia and ROS pPTEC 
NFK-B TAB2, BCL2L1 
TGF-β signalling ROCK1 
miR-200c-3p + Ischaemia HKC-8, HK-2 
HIF-1 signalling EGFR, TCEB1, FLT1, RPS6KB1, EGLN1 
TGF-β signalling SMAD5, EP300, RPS6KB1 
miR-142-3p + ROS All NFK-B TAB2, ERC1, IRAK1 TGF-β signalling TGFBR1 
miR-130b-3p + ROS pPTEC TGF-β signalling 
SMURF2, INHBA, SKP1, 
SMAD4, TGFB2, 
TGFBR2, BMPR2 
HIF-1 signalling EDN1 
miR-124-3p - Ischaemia pPTECs TGF-β signalling 
ROCK1, BMPR1B, 
ROCK2, BMP6, SMAD5, 
SP1 
HIF-1 signalling RPS6KB1 
miR-302a-5p + Ischaemia All 
TGF-β signalling INHBB, SMAD4 
HIF-1 signalling BCL2, IGF1R, PIK3R1, PRKCB 
miR-7-5p + ROS HKC-8, HK-2 
TGF-β signalling SP1, RPS6KB1 
HIF-1 signalling FIGF, IGF1R, EGFR, MTOR, RELA, RPS6KB1 
miR-155-5p + ROS pPTECs TGF-β signalling SMAD2, PPP2CA, GDF6, SP1, ACVR1C, RPS6KB1 
miR-18b- 
5p + 
Ischaemia 
ROS 
pPTECs 
HKC-8, 
HK-2 
TGF-β signalling THBS1 
Genes listed were selected from miRPath pathways, which overlap with genes obtained from multiple 
computational analysis performed using miRWalk database. The sign +/- represents direction of 
changes in the level of expression of a miRNA; (+) = up-regulation and (-) = down-regulation 
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4.6. Discussion 
4.6.1. Assessment of Treatment Effect  
4.6.1.1. Assessing the Effect of Hypoxia  
The literature suggests various ways of mimicking hypoxia. The most commonly used 
methods include chemically-induced hypoxia, cell-density mediated hypoxia generation, and 
by using a hypoxic chamber/incubator. Cell-density mediated hypoxia is generated through 
over-confluent growth of cells (Marsters et al., 2014). The degree of hypoxia induced by 
growth over-confluence may not be uniform across all cells within a vessel. Furthermore, 
over-confluency itself may induce cellular changes, which are difficult to control, in addition 
to hypoxia. Although relatively inexpensive, chemically mimicking hypoxia (using cobalt 
chloride or desferoxamine) only targets the HIF-1α downstream response (Triantafyllou et al., 
2006). HIF-1α plays an important role in the cellular response to hypoxia, however, it is only 
one pathway among many other equally important pathways, thus may not reflect the 
comprehensive picture of the overall cellular response to oxygen deprivation. The use of a 
hypoxic chamber enables a more physiological resemblance of the effects of hypoxia. A 
pitfall associated with this method is fluctuating oxygen concentrations due to chamber 
opening and closing. Although transient loss of the hypoxic environment may not be a major 
problem, a short period of oxygenation (reperfusion) may interact with the effect of 
ischaemia. In my experimental setting, the design of the chamber allowed the cells to be 
inserted and handled under anaerobic conditions, minimising potential exposure to normal 
oxygen pressure.  
Deprivation of oxygen will not immediately lead to cell death, especially in renal 
PTECs. The unique physiology of renal blood flow enables PTECs to be both accustomed to 
yet still sensitive to hypoxia. PTECs are able to adapt well to physiological state of hypoxia, 
due to their constant exposure to a border-line hypoxic environment within the kidney. 
Assessing the effect of hypoxia by determining cell viability is therefore not an ideal method. 
To confirm whether hypoxia stimulates changes to PTECs, I stained the cells for HIF-1α.  
As described in Chapter 1, HIF is an important transcription factor in determining 
cellular response to hypoxia. During hypoxia, HIF-1α degradation by PHDs is impaired, 
leading to the accumulation in HIF-1α. This is followed by dimerization of HIF-α to HIF-b, 
nuclear localisation and activation of cellular pathways involved in cell survival, apoptosis or 
fibrogenesis. Immunofluorescence staining of hypoxic HKC-8 cells clearly illustrated HIF-1α 
in the nucleus (Figure 4-1 panel d-f). Interestingly, intra-nuclear HIF-1α in CoCl2 treated cells 
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was more prominent compared to the cells treated in a hypoxic chamber for 24 hours. This 
may be due to the nature of the stabilisation of HIF by CoCl2. Introduction of Co replaces Fe 
in PHDs, which inhibits their ability to recognise HIF-1α. Therefore, the mechanism of CoCl2 
in mimicking the effect of hypoxia is specific and limited to HIF-1α activation, reflected in a 
strong HIF-1α staining. 24-hour oxygen deprivation does not induce such strong HIF 
expression. Although HIF is a very important pathway, it is only a part of a more global 
cellular response to hypoxia associated with numerous pathways and various feedback 
regulators, which act at multiple levels of HIF regulation; mRNA level, protein level, and 
transcriptional activity of HIF (Henze and Acker, 2010).  These regulators were mainly 
studied in relation to cancer biology, but may also be potentially important in progression of 
damage from acute hypoxia.  
Furthermore, HIF is a transcription factor that is rapidly degraded, even if the effect of 
hypoxia persists in the cell. It is possible that evaluation of HIF expression at 24-hour is not 
the most appropriate time-point to assess hypoxia in a cell. To resolve this, I designed another 
experiment to confirm that the method of hypoxia induction elicited a biologically significant 
response in the cell.  The effect of hypoxia was quantified using an HRE-luciferase reporter 
plasmid transfected to HKC-8 cells. Results from this experiment clearly showed that 24-hour 
incubation in 1%O2 increased HRE driven luciferase expression compared to normoxic cells. 
Interestingly, the peak luciferase activity was recorded at 12-hour after hypoxia induction and 
decreased to almost half of its initial increase at 24-hour. This suggests that the cellular 
response to hypoxia is a very dynamic process involving complex regulatory feedback. A 
decrease in HRE activity despite continued exposure to low oxygen level suggests a form of 
cellular adaptation to hypoxia or an attempt to normalise HRE activation. Nonetheless, the 
increased luciferase activity is evidence that the intervention successfully induced hypoxia in 
PTECs.  
Prior to profiling using NanoString platform, a series of experiments were conducted in 
HKC-8 and HK-2 cells to detect changes in miR-21 and miR-34 level at 2 hour interval for up 
to 24-hour, following hypoxic injury. The results of these experiments showed that miR-21 
was up-regulated following hypoxia starting at 2-hour, which was followed by a marked 
increase at 12-hour. Based on this, both 2 and 12-hour time points were selected as the time 
points for the experiments using NanoString platform.  
4.6.1.2. Assessing the Effect of H2O2 Treatment 
Cells should be stressed enough to induce gene expression changes without significant 
reduction in cell viability. In this experiment, the cells were treated in H2O2 for a maximum of 
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4 hours, as prolonged exposure to H2O2 will result in cell death. Whilst reduced viability 
demonstrates the effect of H2O2 exposure, it does not provide evidence of ROS generation 
intracellularly. Fluorescence activity of CM-H2DCFDA was used as a measure of oxidative 
activity within the cells. This fluorescence activity increased after treatment with 200µM 
H2O2. The emission increased further as H2O2 concentration was increased to 400µM. A 
further increase in H2O2 concentration, however, resulted in markedly reduced fluorescence. 
This may indicate significant cellular stress or even cellular death because of H2O2 exposure. 
At 800µM, the number of events captured by FACS fell to 50% of the original parent 
population. This suggests significantly compromised cellular viability, thus highlighting the 
injurious effect of high concentrations of H2O2. The flow cytometry result supports previous 
viability experiments, confirming the optimal concentration of H2O2 to be used in HKC-8 
experiment is 400µM. To decide the time points of observation for miRNA profiling using 
NanoString platform, a qPCR to detect changes in miR-21 and miR-34 were performed in 
HKC-8 and HK-2 cells treated with the specified concentration of H2O2. As was observed in 
hypoxic cells, the expression level of both miRNAs was found to be significantly altered after 
2-hour exposure to H2O2. The changes were further significantly detected at 12-hour. Based 
on these findings, 2 and 12-hour were selected as the observation time points in cells treated 
with H2O2. 
4.6.2. Global MicroRNA Profiling 
4.6.2.1. Assessment of the Technology and Data Analysis 
Profiling of miRNA expression in different cells, tissues, treatment conditions and 
disease processes is an important step in miRNA research. There are several commercial 
measurement platforms currently available, mainly based on three main technologies; RNA 
sequencing, reverse transcription-quantitative PCR (qPCR) and microarray hybridisation. 
Ideally, the platform which provides the best detection rate, should be selected. Detection rate 
is influenced by several factors, such as assay sensitivity, assay detection cut-off, and the 
number of probes available within the platform. Although the latter factor does not apply to 
sequencing-based technology, it is often the deciding factor in choosing between PCR based 
and microarray hybridisation methods. 
Several studies have used the Nanostring nCounter platform in their miRNA profiling 
method, and have shown excellent robustness and reproducibility. In addition, the fully 
automated process has allowed minimal manual handling time, which not only reduced the 
likelihood of user error, but also increased efficiency and practicality. 
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There are several normalisation methods recommended before changes in the level of 
miRNA expression could be analysed; (1) using a set of reference/housekeeping genes, (2) 
using total counts of expression within a sample, and (3) global normalisation method using 
the top 100 most highly expressed miRNAs. Typically, the first method relies on the selection 
of at least three reference genes, which are consistent in their expression across different cell 
types with different treatments. The choice of reference genes is therefore crucial, and the 
accuracy of the normalisation is highly determined by the number of genes included. With a 
codeset of approximately 800 miRNAs from different cell types, normalisation of raw data 
using only three or four genes may not be the best option. In addition, we also showed that the 
expression level of some of the provided reference mRNAs was significantly altered in the 
treated group (RPL0, RPL19 and GAPDH were significantly up-regulated in primary TECs 
following exposure of H2O2). Nevertheless, we have shown that the selection of normalisation 
method did not greatly affect the detection of changes in miRNA expression. 
Alternatively, the sum of all counts in each sample can be used to approximately 
determine the total nucleic acid expression within a sample. This total sum of a sample 
relative to the mean sum of all counts of each sample can be used to generate a scaling factor. 
However, this method is not suitable in comparing different cell types with different overall 
expression profiles, as it may skew the data inappropriately and not produce representative 
results. More appropriately, I opted to normalise the dataset using the global normalisation 
method. In a large codeset containing more than 300 probes, it is assumed that the level of 
expression of only a small portion of the targets assayed may fluctuate in any given sample, 
and that the level of expression of most will be the same. This method utilises much larger 
numbers of reporters, thus providing more accuracy. Nevertheless, it is crucial to determine 
that the fraction of probes used as reporters do not exhibit differential expression from sample 
to sample. My preliminary analysis showed no significant inter-sample variations exist across 
the top 100 mostly expressed miRNAs. In parallel, I also analysed the data using reference 
gene normalisation, to confirm whether the choice of normalisation method altered the 
findings significantly. The result of this parallel analysis showed reasonably similar findings 
to the result from global normalisation, especially in regards to the consistently up/down-
regulated miRNAs across all cell types. 
Assessment of background technical noise in the platform is important to determine 
background threshold and ascertain that all read-outs were indeed true signal. As mentioned 
previously, the assay employs negative control probes, in which no target transcripts were 
supplied. Positive signals coming from these probes can therefore be assumed as technical 
noise or background. The average expression of these negative controls in a specific sample 
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can therefore be used as background threshold for that lane. To avoid false discovery, I 
decided to use the average plus two standard deviation (mean + 2SD) of all negative control 
probe counts as the background threshold for all samples. This adds a level of stringency to 
ascertain that any reading above the threshold was a real signal.          
4.6.2.2. Ischaemia versus Reperfusion; Distinct but Linked 
Clinically, ischaemia and reperfusion injury is one continuous process. The severity of 
reperfusion injury is closely linked to the initial ischaemic insult, which will determine the 
total injury suffered by an organ/tissue. However, ischaemia or reperfusion injury involved 
different mechanistic pathways, and induce distinct effector cellular response. Kalogeris et al. 
stated that the onset of ischaemia triggers two separate pathologic processes (Kalogeris et al., 
2012). Firstly, there are processes which result from ischaemia per se, and secondly are 
biomolecular changes during ischaemia that contribute to the surge in generation of reactive 
oxygen species and subsequent activation of the immune system. The data analysis from this 
experiment showed distinct genetic regulation involved in the two processes, which indicates 
potential differences in effector pathways involved. However, there are also miRNAs which 
were commonly up/down-regulated during ischaemia as well as after free radical induction. 
The in vitro ischaemia model used in this experiment only allowed a very short normoxic 
recovery phase, and the reperfusion model was not preceded by any ischaemic injury. Thus, 
the altered miRNAs identified in both injuries were very likely to be induced separately by 
either ischaemia or the presence of free-radicals. 
4.6.2.3. Cell lines vs Primary Cells 
 The miRNA profiling analysis results showed that the expression of a miRNA in 
primary PTECs is not always similar to its expression in either HKC-8 or HK-2 cells. This is 
especially of importance in interpreting miRNA studies which base their findings on profiling 
miRNAs in cell lines only. In addition to differences in platform and technologies used, in my 
opinion, the genetic discrepancies between immortalised cell lines and primary cells is also a 
strong contributor to the lack of overlap in the results of currently available miRNA studies.  
To accommodate these differences in genetic characteristics, I modified the initial 
selection criteria for a miRNA of interest. Initially, I intended to include only those miRNAs 
with level of expression changes in all cells after a given treatment and at all observation 
points. However, this approach will exclude the majority of miRNAs from the codeset, and 
may overlook the potential biological importance of a miRNA. Hence, I decided to group the 
cells used into cell lines (HKC-8 and HK-2) and primary cells (pPTEC 1 and pPTEC 2). 
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Application of the modified selection criteria allowed more miRNAs to be included. These 
miRNAs showed similar pattern of up- or down-regulation in either the cell lines or primary 
PTECs. These are the best microRNA candidates to be analysed further for their involvement 
in the tubular epithelial cell response to IRI. The distinctly different response between cell 
lines and primary cells highlights the significance of including human primary cells in this 
study or any microRNA profiling study. 
4.6.3. MiR-21 
Due to its abundance in various organs and tissues, miR-21 has been the subject of 
many miRNA studies. Mir-21 has been linked with an array of biological functions and 
disease processes, including cancer, inflammation, cardiovascular diseases, various fibrotic 
processes and epithelial-to-mesenchymal transition. In kidney transplantation, up-regulation 
of miR-21 has been associated with poorer allograft function, delayed graft function, and 
development of interstitial fibrosis (Ben-Dov et al., 2012; Scian et al., 2013b; Khalid et al., 
2016). Furthermore, miR-21 has also been shown to be involved in various kidney 
pathologies, including renal cell carcinoma, development of renal fibrosis, and progression to 
chronic kidney disease  (Zhong et al., 2011; Li et al., 2013; Wang et al., 2014b; Zhou and 
Jiang, 2014; McClelland et al., 2015; Hennino et al., 2016). The precise role of miR-21 in the 
renal response to IRI, however, is less clear. Some studies suggested up-regulation of miR-21 
after IRI may have beneficial and pro-survival effect. In contrast, there is substantial evidence 
available to link miR-21 to activation of apoptosis, fibrosis and deleterious clinical outcome. 
In this study, miR-21 is the only miRNA, which was significantly altered in all PTEC 
types at all time points after both ischaemia and reperfusion injury. This result reiterates what 
has been reported by other authors. MiRNA profiling studies conducted in murine and human 
renal tubular cells also showed rapid up-regulation of miR-21 in hypoxic PTECs compared to 
normoxic controls (Goodwin et al., 2010; Shapiro et al., 2011). The same findings were also 
reported in studies using a mouse IRI model (Saikumar et al., 2012; Jia et al., 2013). The 
expression of miR-21 following free radical injury alone, however, has not been reported. 
Although all these findings suggest an important role that miR-21 after IRI, it is previously 
not known whether miR-21 up-regulation is involved in the molecular events following 
ischaemia per se, the events related to the surge in reactive oxygen species following 
reperfusion, or both. The design of this study allowed me to investigate these potential links 
individually. Our findings clearly showed that miR-21 was involved in the response to both 
ischaemia and free radical injuries. 
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In a study utilising mice IRI model, up-regulation of miR-21 was consistently detected 
at 24-, 72- and 120-hour (Saikumar et al., 2012). Interestingly, I found that the up-regulation 
of miR-21 was detectable at as early as 2-hour after injury by approximately 2-fold change, 
which continued to rise to approximately 3-4 fold change at 12-hour after injury. This finding 
suggests a role of miR-21 at a very early phase of injury. To my knowledge, there is currently 
no available data documenting the pattern of miR-21 expression at these early time points.  
Using multiple computational analysis software, I identified miR-21 targets, which 
were considered relevant to renal IRI. Data suggests that mir-21 interacts with the HIF 
pathway by targeting the gene phosphatase and tensin homology deleted on chromosome 10 
(PTEN), which indirectly activates the Akt pathway, leading to HIF stabilisation (Liu et al., 
2011). Expression of miR-21 is also activated by the pro-inflammatory cytokine, IL-6 through 
STAT3-dependent mechanism (Xu et al., 2014). Both IL-6 and STAT3 were also detected in 
my computational analysis result.  
I also identified several potential target genes of miR-21 in the TGF-β pathway, such as 
SMAD7 and TGFBR2. The interaction between miR-21 and TGF-β pathway is especially 
important to evaluate the mechanistic link between IRI, early up-regulation of miR-21 and the 
development of fibrosis as the main mechanism for deterioration in allograft function. This is 
the main objective and will be discussed in detail in the following chapter.    
4.6.4. Other Potential MiRNAs 
Akker et al. (van den Akker et al., 2015) highighted on the lack of overlapping results 
in currently available studies on miRNA in kidney transplantation. In order to find other 
potential miRNAs, I compared the expression pattern of selected miRNAs in my dataset to 
their expression reported in the literature. To maintain uniformity in study design and model, I 
only listed studies that use the ischaemia and reperfusion injury model. The comparison is 
summarised in Table 4-3. 
I observed a similar pattern of change in some of these miRNAs, such as miR-34a, 
miR-155, miR-194, miR-199 and miR-210. However, a significant proportion of these 
miRNAs were not significantly altered or were only altered in one type of cell, so were not 
included in the selection. These differences in findings may be attributed to several factors.  
Differences in detection platform technology utilised for miRNA profiling, sample types 
(cellular RNA vs tissue RNA vs body fluids; human vs murine; FFPE vs fresh frozen 
preparation) have been proposed as a main contributor to the lack of overlap miRNA studies. 
This could also be the main reason for the differences seen in our profiling result. As seen in 
Table 4-3, the majority of studies listed performed miRNA profiling in murine tissue.
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Table 4-3 Summary of the expression pattern of previously identified miRNAs in the literature compared to their expression pattern in the current dataset 
miRNA Current Dataset Literature References Expression Cell Type Condition Expression Model Specimen Platform 
miR-10a No significant changes detected Up-regulated within 1hr Rat IRI (45 min. bilateral pedicle clamping; 12hr reperfusion) 
Tissue  Microarray 
qPCR (Wang et al., 2014a) 
miR-18a No significant changes detected 
Tissue: Up-regulated 
Blood: Down-regulated 
Urine: Undetectable 
Rat IRI (30 min. bilateral pedicle 
clamping, 24, 72 and 120 hr 
reperfusion) 
Tissue, blood, 
urine 
Microarray (Saikumar et al., 
2012) 
miR-20a No significant changes detected Up-regulated at day 1 
Mice (30 min; unilateral pedicle 
clamping, 1, 3, 5, 7, 14, 21, 30-
day reperfusion) 
Tissue  Microarray 
qPCR (Goodwin et al., 2010) 
miR-21 Up-regulated All Ischaemia and ROS 
Up-regulated at day 1 
Mice (30 min; unilateral pedicle 
clamping, 1, 3, 5, 7, 14, 21, 30-
day reperfusion) 
Tissue  Microarray 
qPCR (Goodwin et al., 2010) 
Up-regulated Mice (30 min. unilateral pedicle clamping) 
Tissue Microarray (Chau et al., 2012) 
Tissue: Up-regulated at 24, 
72, 120-hr 
Blood: Down-regulated 
Urine: Down-regulated 
initially, modestly elevated 
within 72h  
Rat IRI (30 min. bilateral pedicle 
clamping, 24, 72 and 120 hr 
reperfusion) 
Tissue, blood, 
urine 
Microarray 
(Saikumar et al., 
2012) 
miR-24 No significant changes detected Up-regulated 
Mice IRI (30 min. unilateral 
pedicle clamping) 
Tissue qPCR 
(Lorenzen et al., 
2014) Chemical anoxia for 1hr + ATP 
repletion for 30min. 
HK-2 cells qPCR 
miR-34a Down-regulated All 
Ischaemia 
and ROS Down-regulated 
1% oxygen for 2,4, 6, 12, 24, 48, 
72 hr 
HK-2 cells Microarray 
qPCR (Du et al., 2012) 
miR-127 No significant changes detected Up-regulated 
Rat IRI (45 min. bilateral pedicle 
clamping, 0, 1, 3, 5, 7-day 
reperfusion) 
Tissue Microarray 
qPCR (Aguado-Fraile et 
al., 2012) 1% oxygen for 6 hours, re-
oxygenation for 1, 3, 6, 24 hr. 
HK-2 cells qPCR 
miR-
146a No significant changes detected Up-regulated after day 3 
Mice (30 min; unilateral pedicle 
clamping, 1, 3, 5, 7, 14, 21, 30-
day reperfusion) 
 
Tissue  Microarray 
qPCR (Goodwin et al., 
2010) 
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miR-155 Up-regulated pPTEC ROS 
Up-regulated in tissue 
Down-regulated in blood 
Unchanged (slight non-
significant decrease) in 
urine 
Rat IRI (30 min. bilateral pedicle 
clamping, 24, 72 and 120 hr 
reperfusion) 
Tissue, blood, 
urine 
Microarray 
(Saikumar et al., 
2012) 
miR-187 No significant changes detected Rapidly down-regulated, continue to decrease 
Mice (30 min; unilateral pedicle 
clamping; 1, 3, 5, 7, 14, 21, 30-
day reperfusion) 
Tissue  Microarray 
qPCR (Goodwin et al., 2010) 
miR-192 No significant changes detected 
Rapidly down-regulated, 
continue to decrease 
Mice (30 min; unilateral pedicle 
clamping; 1, 3, 5, 7, 14, 21, 30-
day reperfusion) 
Tissue  Microarray 
qPCR (Goodwin et al., 2010) 
Up-regulated after 6hr Rat IRI (45 min. bilateral pedicle clamping, 12hr reperfusion) 
Tissue  Microarray 
qPCR (Wang et al., 2014a) 
miR-194 Up-regulated pPTEC Ischaemia 
Down-regulated, remain at 
level ≈ control 
Mice (30 min; unilateral pedicle 
clamping, 1, 3, 5, 7, 14, 21, 30-
day reperfusion) 
Tissue  Microarray 
qPCR (Goodwin et al., 2010) 
Up-regulated after 6hr Rat IRI (45 min. bilateral pedicle clamping, 12hr reperfusion) 
Tissue  Microarray  
qPCR (Wang et al., 2014a) 
miR-
199a-3p Up-regulated pPTEC Ischaemia  Up-regulated after day 3  
Mice (30 min; unilateral pedicle 
clamping; 1, 3, 5, 7, 14, 21, 30-
day reperfusion) 
Tissue  Microarray 
qPCR (Goodwin et al., 2010) 
miR-210 Up-regulated All Ischaemia 
Up-regulated AKI patients vs healthy control Plasma qPCR (Lorenzen et al., 2011a) 
Up-regulated, most 
prominent at 4hr and 24hr 
after reperfusion 
Mice IRI (30min. bilateral 
pedicle clamping) 
Tissue Microarray 
(Liu et al., 2012) 
miR-214 No significant changes detected Up-regulated after day 3, wane by day 21 
Mice (30 min; unilateral pedicle 
clamping; 1, 3, 5, 7, 14, 21, 30-
day reperfusion) 
Tissue (fresh) Microarray 
qPCR (Goodwin et al., 2010) 
miR-494 No significant changes detected Up-regulated rapidly (within 1 hr) 
Mice IRI (45 min. bilateral 
pedicle clamping; 1, 3, 6, 12, 24 
48 hr reperfusion) 
Tissue qPCR 
(Lan et al., 2012b) 
miR-
877* No significant changes detected 
Up-regulated at 3, 6 and 
24hr. 
Mice IRI (27 min. bilateral renal 
pedicle clamping) 
Tissue 
Plasma 
qPCR (Bellinger et al., 
2014) 
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Previous studies have associated changes in expression of several miRNAs to a 
number of clinical events in kidney transplantation, including delayed graft function, 
interstitial fibrosis or tubular atrophy. The expression of these miRNAs, which fulfil the 
selection criteria in our dataset are summarised in Table 4-4.  
Table 4-4 MiRNAs associated with post-transplant clinical events relevant to IRI 
Clinical 
focus miRNAs 
Literatures Current Dataset 
+/- Specimen Reference +/- Cell Type Condition 
DGF 
miR-21 + Tissue 
(Wilflingseder et 
al., 2013) 
+ All 
Ischaemia 
and ROS 
miR-21 + Tissue, urine 
(Ben-Dov et al., 
2012) 
IF/TA 
miR-92a + Urine (Maluf et al., 2014) - pPTECs 
Ischaemia 
and ROS 
miR-345 + Urine (Maluf et al., 2014) - pPTECs ROS 
miR-142-
3p 
+ Tissue, urine 
(Scian et al., 2011; 
Ben-Dov et al., 
2012) 
+ pPTECs 
Ischaemia 
and ROS 
The sign +/- represents direction of changes in the level of expression of a miRNA; (+) = up-
regulation and (-) = down-regulation. DGF = delayed graft function; IF = interstitial fibrosis; TA = 
tubular atrophy  
  
4.6.4.1. MiR-34a 
The research on miR-34 has been gaining substantial interest since the discovery of its 
important role as a master regulator in tumour suppression. A long list of cancer types, which 
include lung, liver, prostate, colon, brain, skin and several haematological malignancies have 
been shown to down-regulate expression of miR-34 (Bader, 2012). Mir-34 is a miRNA family 
consisting of three family members; miR-34a, miR34b and miR34c. Mir-34a is identified as 
the most prevalent across all organs in physiological condition, whilst miR-34b and miR-34c 
are more specific to lung, ovary, testes and trachea (Bader, 2012). The miR-34 family has a 
very close homology (80-95%), enabling them to regulate similar target genes involved in 
tumour-related biological pathways, including cell cycle arrest, inhibition of proliferation, 
apoptosis, cellular differentiation, inhibition of WNT signalling and p53 activity (Chen and 
Hu, 2012; Agostini and Knight, 2014).  
The role of miR-34 in kidney pathologies has not been extensively studied. Several 
authors have reported the effect of miR-34 in renal cellular senescence and apoptosis. MiRNA 
profiling at ageing renal mesangial cells showed up-regulation of miR-34a, which was 
associated to the suppression of the anti-oxidant activity of thioredoxin reductase 2 (Txrnd2), 
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which in turn promotes renal senescence (Bai et al., 2011). In relation to ischaemic renal 
injury, Du et al. showed down-regulation of miR-34a after 24-hour of hypoxia in HK-2 cells 
(Du et al., 2012). Interestingly, I also observed this down-regulation in other human PTECs, 
including human primary PTECs after 12-hour of either ischaemia or free radical injury. The 
same author related post-ischaemic down-regulation of miR-34a to an increase in Notch1 and 
Notch2 expression, which promote EMT (Du et al., 2012). In contrast, induction of IRI in 
mice resulted in increased expression of miR-34a, which inhibited autophagic activity of renal 
TECs by direct binding to Atg4B mRNA (Liu et al., 2015). The gene Atg4B was also 
identified in our computational tool analysis result.   
4.6.4.2. MiR-363 
The role of miR-363 was found to be important in the progression of several 
malignancies. An association between high expression of miR-363 and increased 
proliferation, poorer prognosis and promotion of chemo-resistance in gastric cancer has been 
reported (Zhang et al., 2016). However, miR-363 was identified to have a tumour suppressive 
role in lower gastrointestinal tract malignancy. Down-regulation of miR-363 was linked with 
increased invasion and cell migration of colorectal cancer, primarily by allowing Sox4 gene to 
be over-expressed (Hu et al., 2016), a gene that contributes to cancer cell survival and 
metastasis. 
The link between miR-363 and IRI has not been well studied. To date, mir-363 has 
only been linked with the HIF-1a pathway in the regulation of haematopoiesis in human 
leukemic cell lines (Xie et al., 2016). In the kidney, miR-363 was identified as an inducer of 
EMT in human renal tubular epithelial cell lines by interacting with the TWIST pathway, 
thereby promoting EMT (Morizane et al., 2016). This data suggests that miR-363 exerts its 
effect through interaction with the inhibitors of the TWIST pathway. However, further 
validation to demonstrate that an increase in miR-363 reduces the levels of TWIST inhibitors 
has not been successful. Interestingly, a previous study in colorectal cancer cells showed that 
it is inhibition of miR-363 that promotes EMT, proven by reduction in E-cadherin expression 
(Hu et al., 2016). 
Computational analysis or the current dataset detected several target mRNAs of miR-
363. Some of which should be explored further. A possible interaction between miR-363 with 
genes encoding proteins involved in extra-cellular matrix formation, such as Collagen and 
Integrin-b6 is especially compelling, to relate IRI to subsequent fibrogenic processes within 
the kidney.  
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4.6.4.3. MiR-210 
MiR-210 has been identified as one of many miRNAs induced by hypoxia, and 
involved in the regulation of key pathophysiological aspects following hypoxia (also known 
as a hypoxamir). Its role has been investigated in relation to the progression of various 
malignant processes. The role of miR-210 in the progression of malignant cells is closely 
linked with HIF-1a stabilisation (McCormick et al., 2013). MiR-210 facilitates tumour 
progression through multiple synergistic pathways, such as by increasing the rate of cell cycle 
progression, interfering with normal DNA repair process, altering normal mitochondrial 
function and cellular metabolism, aiding malignant cells to evade apoptosis, and promoting 
angiogenesis and metastatic potential (Qin et al., 2014; Dang and Myers, 2015). MiR-210 is 
highly expressed in renal cancer cells compared to healthy normal kidney. It is also correlated 
with poorer prognosis in renal clear cell carcinoma patients (Samaan et al., 2015). In relation 
to IRI to the kidney, a higher plasma level of miR-210 is associated with activation of 
vascular endothelial growth factor (VEGF) and increased renal angiogenesis (Liu et al., 
2012). In critically ill patients with acute kidney injury, higher plasma levels of miR-210 has 
been shown to be a predictor of mortality (Lorenzen et al., 2011a). In a kidney transplant 
cohort, lower urinary level of miR-210 was associated with acute T-cell mediated rejection 
and more rapid decline in GFR 1-year after transplantation (Lorenzen et al., 2011b). 
As a hypoxamir, I expected miR-210 to be upregulated following ischaemia. At a very early 
time point, this up-regulation could only be seen in primary PTECs. At the 12-hour time 
point, however, miR-210 was significantly up-regulated across all cell types. This change was 
seen only in ischaemic PTECs, but not in H2O2 treated cells, indicating its close association 
with HIF-1a signalling. Interestingly, one report showed that even though miR-210 was up-
regulated in hypoxia, the majority of its target genes are not classical hypoxia inducible genes. 
The target genes of miR-210 are involved in regulating cellular metabolic processes and gene 
expression (Huang et al., 2009). It is hypothesised that miR-210 may act as a mediator of 
HIF-1a to indirectly switch-off unnecessary cellular function during hypoxia (Huang et al., 
2009). In accordance, the computational analysis of miR-210 targets that I performed also did 
not reveal any miR-210 target genes directly relevant to the renal response to IRI. 
 
 
 
136 
Chapter 5. The Role of miR-21 in Kidney Response to IRI 
5.1. Introduction and Objectives 
There are a number of reports describing the involvement of miR-21 in disease 
processes. MiR-21 has been identified as one of the miRNAs involved the regulation of 
cancer cells, thus recognised as an oncomir. High level of expression of miR-21 has been 
associated with various malignancies, including glioblastomas, cholangiocarcinoma, lung 
cancer, renal cancer, prostate cancer, and gastrointestinal cancer (Selcuklu et al., 2009; 
Jazbutyte and Thum, 2010). The involvement of miR-21 in this range of organ malignancies 
could be explained by the fact that miR-21 was ubiquitously expressed in different human 
organs, which is an uncommon feature for a miRNA. Furthermore, miR-21 has also been 
shown to play roles in several biological processes, including inflammation, cellular 
proliferation, cellular migration and apoptosis (Kumarswamy et al., 2011).  
The link between miR-21 and the renal response to IRI was established, largely based 
upon profiling urinary, plasma, or tissue miR-21 in relation to acute kidney injury (AKI). 
Although most studies agreed that miR-21 was up-regulated following IRI, data on the 
implications of this up-regulation for kidney function is still conflicting. Several authors 
documented the role of miR-21 in decreasing apoptosis and necrosis of tubular cells following 
IRI, which may have a protective capacity, and that knocking-down miR-21 resulted in cell 
death (Li et al., 2013; Hu et al., 2014; Xu et al., 2014). On the other hand, others have shown 
that high expression of miR-21 did not prevent cellular death after an ischaemic insult 
(Goodwin et al., 2010). These findings suggest that fine-tuning miR-21 levels in response to 
an injury is essential for cell survival. More importantly, the molecular mechanism on how an 
increase of miR-21 level after IRI influences cellular function still requires investigation. 
In this part of the project, I am interested in investigating the association of higher 
expression of miR-21 following IRI with changes in PTEC phenotype, and how this may 
affect kidney function in the longer term. To control biological variation across different 
PTEC types, only HKC-8 cells were used in the experiments described in this chapter. The 
main objective of this chapter is to verify known miR-21 mRNA targets, and to assess the 
relationship of miR-21 to the pathways involved in kidney response to IRI; the TGF-b 
signalling pathway and HIF-1a signalling pathway. To provide a more complete overview of 
the role of miR-21 in renal response to IRI, the distribution and quantification of miR-21 in 
ischaemic and non-ischaemic renal tissue were also assessed. 
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5.2. Results 
5.2.1. Qualitative Assessment of MicroRNA Mimic Transfection 
The experiments included in this chapter involved transfection of either miRNA mimic 
or inhibitor to simulate conditions of a high-level or an absence of miR-21. A method to 
evaluate successful transfection protocol was therefore needed. Fluorescent-labelled miRNA 
mimic was utilised to visualise the miRNA transfected into the cells. Incubation of 24-hour 
with miRNA mimic and transfection reagent was adequate to introduce miRNA mimic 
molecule into HKC-8 cells. At 24-hour, the delivery of miRNA mimic was visible in almost 
all cells as shown in Figure 5-1.  
To assess the result of the transfection process, miR-21 expression following miR-21 
mimic transfection was quantified, and compared to its expression in non-transfected HKC-8 
cells and in HKC-8 cells transfected with miRNA mimic with scrambled sequence. MiRNA 
probe for mature miR-21 sequence as described in Chapter 2 was used in this experiment. The 
result showed that 24-hour incubation of HKC-8 cells in the transfection complex containing 
miR-21 mimic molecule increased mature miR-21 expression to more than 80-fold compared 
to transfection with scrambled miRNA mimic sequence (Figure 5-2). As expected, HKC-8 
cells incubated in media only, or addition of transfection reagent to the media did not increase 
the expression of miR-21. 
In summary, the result of transfection procedure applied to HKC-8 cells was 
qualitatively visible from tracking the incorporation of immunofluorescent-labelled miRNA 
as well as semi-quantitatively evident in the increase of miR-21 expression following 
transfection. Taking these factors into consideration, mimic transfection procedure was 
decided to be performed by incubating HKC-8 cells in the transfection complex containing 
miRNA mimic or inhibitor for 24-hour. 
The objective of over-expressing miR-21 in PTEC in the experiments described in this 
chapter is to elucidate the molecular mechanism of miR-21 in renal response to IRI. For this 
purpose, all experiments were performed using HKC-8 cell line, as this cell could be 
transfected easily and relatively tolerant to the use of transfection reagent. However, the 
transfection of miR-21 mimic to primary PTECs may be of importance to assess how 
alteration in miR-21 may affect the viability of primary cells. This could be evaluated by 
calculating the transfection efficiency of miR-21 mimic in primary cells, which will determine 
the number of viable cells that uptake miR-21 mimic molecule in relation to varying 
concentration of the miRNA mimic molecule and the transfection reagent.  
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Figure 5-1 Fluorescent-labelled miRNA mimic in HKC-8 cells 
Incorporation of fluorescent-labelled miRNA mimic into HKC-8 cells following incubation in 
transfection complex containing the miRNA mimic and transfection reagent for 24-hour. DAPI was 
applied for nuclear counter-staining. Slides were visualised at 557/570nm in (a) 100x magnification 
and (b) in 200x magnification. Non-transfected HKC-8 cells and HKC-8 cells incubated in 
transfection reagent only for 24-hour were used as comparison (image c and d).   
 
Figure 5-2 MiR-21 Expression after miR-21 mimic transfection 
Expression of miR-21 in HKC-8 cells, relative to the expression of RNU48. MiR-21 expression was 
measured following miR-21 mimic transfection using qPCR. miRNA probe used was specific for 
mature miR-21 sequence. Samples were incubated for 24-hour in; media only (No TFX), media with 
transfection reagent only (TFX Reagent), or media with transfection complex containing either 
scrambled miRNA mimic or miR-21 mimic. Each bar represents the mean of three replicates + SD. 
Statistical significance was indicated by **** p ≤0.0001, and was calculated using one-way ANOVA 
test followed by Bonferroni multiple comparison analysis.  
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5.2.2. SMAD7 is a target of miR-21 
The result of computational analysis showed that SMAD7 is a potential target of miR-
21. Over-expression of miR-21, therefore, was expected to supress the expression level of 
SMAD7 level in HKC-8 cells. An experiment comparing the expression of SMAD7 in miR-
21 mimic treated cells to non-transfected cells was conducted to verify this assumption. As 
shown in Figure 5-3, the intensity of SMAD7 was significantly reduced in miR-21 mimic 
transfected cells, which indicate suppression of SMAD7 by miR-21 over-expression.  
 
 
Figure 5-3 SMAD7 expression following miR-21 over-expression 
Expression of SMAD7 in miR-21 mimic transfected HKC-8 cells, compared to non-transfected HKC-
8 cells (No TFX), and HKC-8 cells transfected with scrambled miRNA mimic control. Each group 
represents three independent experiments (N=3). SMAD7 expression was quantified by measuring its 
band intensity in each sample, relative to the band intensity of loading control protein (GAPDH). Data 
was presented as the mean + SD of band intensity, as measured using ImageJ imaging analysis 
software. Statistical significance was indicated by * = p ≤0.05, and was calculated using one-way 
ANOVA test followed by Bonferroni multiple comparison analysis.  
5.2.3. MiR-21 over-expression facilitates nuclear translocation of SMAD complexes 
SMAD7 is an inhibitory SMAD that functions to block SMAD2/3 activation. Hence, 
inhibition of SMAD7 by miR-21 would favour SMAD2/3 activation, leading to translocation 
of SMAD complex into the nucleus. To assess this, antibody against SMAD3 was used to 
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detect SMAD3 localisation following transfection with miR-21 mimic, in the absence of 
exogenous TGF-β. 
Figure 5-4 showed that transfection of miR-21 induced translocation of SMAD 
complexes into the nucleus. This is indicated by detection of SMAD3 inside the nuclei in a 
punctate pattern. This appearance was not observed in non-transfected cells and in cells 
transfected with scrambled sequence miRNA mimic.   
 
Figure 5-4 Intra-nuclear localisation of SMAD3 in HKC-8 cells over-expressing miR-21 
Nuclear translocation of SMAD complexes were detected by applying primary antibody against 
SMAD3 in HKC-8 cells transfected with miR-21 mimic. Alexa Fluor 546 secondary antibody was 
used to visualise SMAD3. HKC-8 cells which were not transfected, and cells transfected with 
scrambled sequence miRNA mimic control were used as comparison. Nuclei were counter-stained 
using DAPI. Images were captured using fluorescent microscope under 400x magnification. Images 
displayed were representative of three independent experiments (N=3). 
 
 
141 
5.2.4. In the absence of TGF-b1, miR-21 did not cause significant increase in SMAD3 
activity  
To assess whether the observed SMAD3 translocation had any effect on SMAD3 
activity, HKC-8 cells containing SMAD3-luciferase reporter plasmid was used. These cells 
were transfected with miR-21 mimic and were incubated for 24 hour. In the absence of TGF-
b1, transfection of miR-21 mimic to HKC-8 cells did not significantly increase SMAD3 
activity. Mir-21 mimic transfected cells showed more luciferase activity compared to control 
groups (Figure 5-5). However, the increase was not enough to reach statistical significance.  
 
 
Figure 5-5 The effect of miR-21 over-expression in SMAD3-luciferase activity without TGF-b1 
HKC8-cells containing SMAD3-luciferase reporter plasmid were transfected with miR-21 mimic 
before the measurement of luciferase activity. Data was presented as the mean + SD of fold change in 
luciferase activity compared to non-coding miRNA mimic-transfected (NC-mimic) cells. Non-
transfected group was denoted as No TFX. Statistical analysis was performed with three replicates 
using One-way ANOVA test, which revealed no statistically significant different between the groups.  
5.2.5. MiR-21 sensitised the HKC-8 cell response to TGF-b1 
Addition of TGF-b1 after miR-21 transfection resulted in a marked elevation in fold-
change increase of SMAD3 activity (Figure 5-6). TGF-b1 at a concentration of 0.1ng/mL was 
sufficient to induce SMAD3 activity significantly from its activity in the scrambled miRNA 
mimic transfected cells or in non-transfected cells. A further increase in TGF-b1 
concentration increased SMAD3-luciferase activity, creating an even bigger difference 
between miR-21 transfected cells and the control groups. Differences of luciferase activity 
between these groups were found to be statistically significant for every concentration of 
TGF-b1 used.  
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TGF-b1 Groups pValue TGF-b1 Groups pValue 
0 miR-21 vs Scrambled ns 1.0 miR-21 vs Scrambled ≤0.0001 
miR-21 vs No TFX ns miR-21 vs No TFX ≤0.0001 
Scrambled vs No TFX ns Scrambled vs No TFX ns 
0.1 miR-21 vs Scrambled ≤0.0001 2.5 miR-21 vs Scrambled ≤0.0001 
miR-21 vs No TFX ≤0.0001 miR-21 vs No TFX ≤0.0001 
Scrambled vs No TFX ns Scrambled vs No TFX ns 
0.25 miR-21 vs Scrambled ≤0.0001 5.0 miR-21 vs Scrambled ≤0.0001 
miR-21 vs No TFX ≤0.0001 miR-21 vs No TFX ≤0.0001 
Scrambled vs No TFX ns Scrambled vs No TFX ns 
0.5 miR-21 vs Scrambled ≤0.0001    
miR-21 vs No TFX ≤0.0001    
Scrambled vs No TFX ns    
Figure 5-6 The effect of miR-21 over-expression and TGF-b1 in SMAD3-luciferase activity 
TGF-b1 was added in a range of concentrations (0.1-5ng/mL) to miR-21 mimic-transfected HKC-8 
cells. The same treatment was also given to non-transfected HKC-8 cells (No TFX), and cells 
transfected with scrambled miRNA mimic. Luciferase activity was measured and normalised to the 
total protein from each sample. Fold-change of luciferase activity was calculated from the ratio of 
luciferase activity of a sample in each TGF-b1 concentration to its luciferase activity without TGF-b1 
(e.g. miR-21 mimic transfected cells at 0.1ng/mL / miR-21 mimic transfected cells at 0 ng/mL).   Data 
was presented as the mean of fold-change + SD. Each value was generated from three experiments 
(N=3). Data was analysed using Two-way ANOVA followed by comparison of the mean within each 
concentration (simple effects within the rows) using Tukey’s multiple comparison test. (ns = not 
significant) 
 
5.2.6. Determining TGF-β1 Concentration that Induces a Change in Cellular Morphology 
I hypothesised that miR-21 may require the presence of TGF-b1, in order for it to have 
an effect on PTEC morphology. However, the addition of exogenous TGF-b1 alone has been 
documented to cause PTEC phenotypic changes. Therefore, it was crucial to identify a 
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concentration of TGF-b1 that does not elicit a marked change in PTEC. To do this, HKC-8 
cells were treated with serial concentration of TGF-b1. The upper limit of TGF-b1 
concentration was set at 10ng/mL, as this is the most widely used concentration to induce 
changes in PTEC morphology documented in the literature.  
As expected, normal HKC-8 cells (with no TGF-b1 treatment) expressed E-cadherin, 
without any evidence of a-SMA expression. Down-regulation of E-cadherin was detectable 
when TGF-b1 concentration was increased to 0.5ng/mL. Expression of a-SMA started to be 
detected when HKC-8 cells were treated with 1ng/ml of TGF-b1, which was also 
accompanied by further decrease in E-cadherin expression. This pattern of an increase in a-
SMA expression and decrease in E-cadherin down-regulation became clearer as the TGF-b1 
concentration was increased to 5 and 10ng/mL (Figure 5-7). The area of fluorescence of E-
cadherin and a-SMA were quantified and plotted against serial concentration of TGF-b1 to 
obtain pattern of E-cadherin and a-SMA expression changes following TGF-b1 treatment 
(Figure 5-8).  Based on this, 1ng/mL was chosen as the concentration of TGF-b1 to be used in 
future experiments. This concentration was considered adequate to induce a modification in 
cellular phenotype without changing the morphological characteristic of PTECs completely.   
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Figure 5-7 The effect of TGF-b1 on the expression of E-cadherin and a-SMA in HKC-8 cells 
Expression of E-cadherin and a-SMA following addition of TGF-b1 at the concentrations shown. 
Proteins of interest were probed using Alexa fluor 488 secondary antibody following incubation with 
primary antibodies against E-cadherin and a-SMA. DAPI was applied for nuclear staining. Images 
were captured at 100x magnification. Images displayed were representative of three technical 
replicates.  
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Figure 5-8 Quantification of fluorescence area of E-cadherin and a-SMA in TGF-b1-treated 
HKC-8 cells 
Area of fluorescence of E-cadherin and a-SMA in relation to TGF-b1 treatment at increasing 
concentrations. Data was presented as the mean of total area of fluorescence in µm2 per field of view + 
SD. Analysed images were captured from three different area of a slide. Three slides were analysed for 
each concentration.   
5.2.7. The effect of miR-21 over-expression and TGF-b1 on PTEC morphology 
The following experiments were designed to evaluate the effect of the modification of 
TGF-b1 signalling pathway by miR-21 over-expression in PTEC. Immunofluorescent and 
Western blot techniques were used to assess changes in PTEC and to quantify protein changes 
in miR-21 mimic-transfected HKC-8 cells, which were treated with 1ng/mL of TGF-b1. The 
investigation was focused on the alteration of E-cadherin, as a marker of epithelial cells, and 
Collagen type 1 and a-SMA as markers of fibrosis.  
Figure 5-9 and Figure 5-10 showed down-regulation of E-cadherin expression in HKC-
8 cells transfected with miR-21 mimic, and treated with 1ng/mL of TGF-b1. This pattern of 
down-regulation was detected by two techniques, both of which showed a statistically 
significant effect. HKC-8 cells transfected with scrambled miRNA mimic and non-transfected 
cells, and then treated with TGF-b1 were used as controls.  
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Figure 5-9 Visualisation of E-cadherin expression following miR-21 over-expression and TGF-b1 
treatment  
E-cadherin expression was assessed in miR-21 mimic transfected HKC-8 cells, non-transfected cells, 
and HKC-8 cells transfected with scrambled miRNA mimic. Cells were treated with 1ng/mL TGF-b1 
for 24 hour prior to analysis. Cells were probed with primary antibody against E-cadherin, followed by 
AlexaFluor 488 secondary antibody. Total area of fluorescence per field of view was measured from 
three independent experiments (N=3). Data was presented as the mean of total area of fluorescence in 
log2 format + SD from three fields of view. Images were captured at 400x magnification, and image 
analysis were performed using ImageJ software. One-way ANOVA was used to detect statistically 
significant changes between the groups, followed by Bonferroni post-hoc analysis. (*** = p ≤0.001) 
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Figure 5-10 Western blot analysis of E-cadherin in HKC-8 cells over-expressing miR-21 treated 
with TGF-b1  
Western blotting was used to detect E-cadherin expression in miR-21 mimic-transfected cells, 
scrambled miRNA mimic-transfected cells, and non-transfected cells.  Band intensity was analysed 
and measured using ImageJ analysis software. Band intensity of a sample reflects E-cadherin quantity 
in that sample, relative to the amount of total protein loaded, which was shown by GAPDH 
expression.  Each band represents an independent experiment. Data was presented as the mean of 
relative intensity + SD of the three bands displayed. Statistical analysis was performed using One-way 
ANOVA with Bonferroni post-hoc analysis. (** = p ≤0.01)  
The expression of a-SMA was markedly increased in cells transfected with miR-21 
mimic. Immunofluorescent staining of miR-21 mimic-transfected cells showed prominent 
development of actin stress-fibres in HKC-8 cells. Without miR-21 mimic, treatment of 
1ng/mL of TGF-b1 resulted in less expression of a-SMA in HKC-8 cells. The up-regulation 
of a-SMA due to miR-21 over-expression in these cells was found to be statistically 
significant. Western blotting also showed that a-SMA expression in HKC-8 cell lysates after 
miR-21 mimic transfection was significantly increased.  
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Figure 5-11 The effect of miR-21 over-expression on a-SMA expression in TGF-b1-treated 
HKC-8 cells  
After transfection of miR-21 mimic, HKC-8 cells were treated with 1ng/mL TGF-b1. A primary 
antibody against a-SMA was used. AlexaFluor 488 was used as secondary antibody, followed by 
DAPI nuclear counter-staining. Images were viewed at 400x magnification to capture total area of 
fluorescence per visual field. Experiments were conducted in three independent times (N=3). Data was 
presented as the mean of total area of fluorescence in log2 format + SD. Image analysis was performed 
using ImageJ software. One-way ANOVA was used to detect statistically significant changes between 
the groups, followed by Bonferroni post-hoc analysis. (*** = p ≤0.001) 
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Figure 5-12 a-SMA expression by Western blotting in HKC-8 cells following transfection with 
miR-21 mimic and TGF-b1 treatment 
Evaluation of a-SMA expression by Western blotting. Scrambled miRNA mimic-transfected cells, 
and non-transfected cells were used as controls. ImageJ analysis software was used to quantify and 
analyse the a-SMA band intensity relative to GAPDH. Each band represents an independent 
experiment. Data was presented as the mean of relative intensity + SD of the three bands displayed. 
Statistical analysis was performed using One-way ANOVA with Bonferroni multiple comparison test. 
(**** = p ≤0.0001) 
Unlike a-SMA, the expression of Collagen type 1 did not show any notable increase by 
immunofluorescent staining. There was only a very faint increase in Collagen type 1 
expression seen in HKC-8 cells transfected with miR-21 mimic compared to the control 
groups. Quantification of Collagen type 1 using Western blot technique, however, showed 
that over-expression of miR-21 induced Collagen type 1 protein synthesis.  
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Figure 5-13 Immunofluorescent staining for Collagen-1 following miR-21 over-expression and 
TGF-b1 treatment  
Collagen-1 staining in miR-21 mimic transfected HKC-8 cells, non-transfected cells, and HKC-8 cells 
treated with scrambled miRNA mimic following treatment with 1ng/mL TGF-b1. AlexaFluor 488 was 
used as secondary antibody. Images were representative of three independent experiments (N=3). The 
mean of total area of fluorescence per field of view + SD was analysed. Images were captured under 
400x magnification, and image analysis were performed using ImageJ software. One-way ANOVA 
was applied to detect statistically significant changes between the groups, followed by Bonferroni 
post-hoc analysis. 
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Figure 5-14 Collagen-1 expression by Western blotting in miR-21 mimic transfected-HKC-8 
cells 
Western blotting for Collagen-1 using lysates from HKC-8 cells transfected with miR-21 mimic, 
scrambled miRNA mimic, and non-transfected cells. Band intensity was measured by ImageJ 
software. The mean of band intensity relative to the band intensity of loading control protein, GAPDH 
was compared between the groups. Comparison of the means between the groups was performed with 
One-way ANOVA with Bonferroni multiple comparison test. Each band represents an independent 
experiment. Data was presented as the mean of relative intensity + SD of the three bands displayed. 
(*** = p ≤0.001) 
5.2.8. Hypoxia leads to increase in miR-21 and SMAD7 suppression  
Previous experiments have established the relationship between miR-21 up-regulation 
and SMAD7 inhibition, which was followed by activation of TGF-b1 signalling. To assess 
whether ischaemia alone can lead to these series of event, the level of expression of miR-21, 
SMAD7 and SMAD3 activity were measured in hypoxic cells. For this purpose, hypoxia was 
simulated in HKC-8 cells using several validated methods; by transfection with HIF-1a 
plasmid, thus increasing HIF-1a expression, by stabilisation of intra-cellular HIF-1a using 
CoCl2, and incubation in 1%O2 for 24 hours. To confirm if these methods of inducing or 
mimicking hypoxia resulted in equal miR-21 up-regulation, qPCR was utilised to detect 
changes in miR-21 following a given treatment.  
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Figure 5-15 MiR-21 level following different methods of inducing hypoxia  
Changes in miR-21 level of expression after induction of hypoxia by HIF-1a plasmid transfection, 
CoCl2 treatment, and incubation in 1%O2, as quantified by real-time PCR. Mir-21 expression was 
normalised to the reference gene RNU48. Each bar represents the mean of fold-change of expression + 
SD from three replicates in a single experiment. To detect significant variation, comparison of the 
means was performed with One-way ANOVA. Multiple comparison test using Bonferroni method was 
then applied to test the difference of the means between specified groups for statistical significance. (* 
= p ≤0.05) 
 
Based on my observations using miR-21 mimic, I hypothesise that the increase in miR-
21 induced by hypoxia will reduce SMAD7 levels. To test this, Western blotting was used to 
visualise SMAD7 expression from cell lysates of hypoxic, CoCl2 treated and HIF-1α 
transfected HKC-8 cells. Figure 5-16 showed that SMAD7 levels were reduced in conditions 
mimicking hypoxia. Although incubating the cells in 1%O2 for 24-hour led to a reduction in 
SMAD7 levels, stabilisation of HIF-1a through transfection of HIF-1a plasmid or CoCl2 
treatment showed a greater reduction in SMAD7.  
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Figure 5-16 SMAD7 expression in hypoxic HKC-8 cells  
Western blot results of SMAD7 expression. Hypoxic-like conditions were induced by transfection of 
HIF-1a plasmid, CoCl2 treatment, and 24-hour incubation in 1%O2. SMAD7 expression in these cells 
were compared to normoxic non-transfected HKC-8 cells, and normoxic HKC-8 cells transfected with 
pCDNA control plasmid. Band intensity was quantified with ImageJ software. Data was presented as 
the mean of band intensity relative to the intensity of the loading control protein, GAPDH. Each bar 
represents the mean of 2 samples (N=2) in each group. One-way ANOVA test was used to compare 
the means. To test for statistical significance between the groups, Bonferroni post-hoc analysis was 
used. (* = p ≤0.05; ** = p ≤0.01). 
  
The effect of hypoxia to SMAD3 activation was also investigated. To do this, I used a 
clone of HKC-8 cells stably transfected with SMAD3-luciferase reporter plasmid, which was 
cultured in conditions to mimic hypoxia as described previously. Compared to HKC-8 cell 
grown in a normoxic environment, hypoxia induced by 1% O2 incubation increased SMAD3 
reporter activity by approximately 30-fold (Figure 5-17). This increase in SMAD3 reporter 
activity was even greater when there was an increase in intra-cellular HIF-1a expression, or 
when HIF-1a was stabilised. The activity of SMAD3 reporter induced by HIF-1a plasmid 
transfection or CoCl2 were statistically different from the increase of SMAD3 reporter 
activity induced by 1%O2. The same clone of HKC-8 cells incubated in the transfection 
reagent in normoxia was used as controls for HIF-1a plasmid transfection. SMAD3 reporter 
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activity in this group was no different form the other control groups, ensuring that the 
transfection process did not affect the observed findings.  
 
 
Figure 5-17 SMAD3-luciferase activity in hypoxia or conditions mimicking hypoxia 
Measurement of luciferase activity in a SMAD3-luciferase transfected HKC-8 cells. To simulate the 
effect of hypoxia, cells were cultured for 24-hour in 1% O2, transiently transfected with HIF-1a 
plasmid, or treated with CoCl2. The same clone of HKC-8 cells incubated in a normoxic environment 
were used as control for 1%O2 and CoCl2 treated groups, whilst cells transfected with pCDNA control 
plasmid was used as a comparison for HIF-1a-transfected cells. HKC-8 cells incubated with 
transfection reagent only (denoted as TFX Reagent) were also assessed. Luciferase activity was 
normalised to the total protein for each sample. Each bar represents the mean + SD of fold change in 
luciferase activity in three replicates from a single experiment. One-way ANOVA test was used to test 
for existing statistical significant difference between the means. Multiple comparison test between 
groups was performed using Bonferroni post-hoc analysis. (** = p ≤0.01; *** = p ≤0.001; **** p 
≤0.0001). 
As hypoxia led to an increase in miR-21 expression and a subsequent reduction in 
SMAD7, I hypothesised that hypoxia would make cells more responsive to TGF-b1. To test 
this hypothesis, I evaluated whether hypoxia increased SMAD3-luciferase reporter gene 
activity in HKC-8 cells treated with exogenous TGF-b1. To achieve this, the same 
experimental design was applied with the additional treatment of cells with increasing 
concentrations of TGF-b1. The results showed that hypoxia or augmentation of HIF-1a 
concentration significantly increased SMAD3 reporter gene activity in HKC-8 cells (Figure 
5-18). HIF-1a stabilisation by CoCl2 caused the greatest change in SMAD3 activity compared 
to the other hypoxic groups.     
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TGF-b1 Groups pValue 
0 Normoxia vs 1%O2 ns 
Normoxia vs CoCl2 ns 
Control plasmid vs HIF-1a ns 
1 Normoxia vs 1%O2 p ≤0.01 
Normoxia vs CoCl2 p ≤0.001 
Control plasmid vs HIF-1a p ≤0.01 
5 Normoxia vs 1%O2 p ≤0.01 
Normoxia vs CoCl2 p ≤0.0001 
Control plasmid vs HIF-1a p ≤0.0001 
10 Normoxia vs 1%O2 p ≤0.0001 
Normoxia vs CoCl2 p ≤0.0001 
Control plasmid vs HIF-1a p ≤0.0001 
Figure 5-18 SMAD3-luciferase activity in conditions that simulate hypoxia in the presence of 
exogenous TGF-b1 
Experiment was conducted in a clone of HKC-8 cells containing SMAD3-luciferase reporter plasmid. 
SMAD3-luciferase activity in HKC-8 cells transfected with HIF-1a plasmid, HKC-8 cells treated with 
CoCl2, and HKC-8 cells incubated in 1% O2 for 24-hour is shown. Non-transfected normoxic HKC-8 
cells, HKC-8 cells containing the control plasmid pCDNA and HKC-8 cells incubated in transfection 
reagent only were used as controls. All cells were also treated with 0, 1, 5 and 10ng/mL of TGF-b1. 
Luciferase activity was normalised to the total protein for the respective samples. Each measurement 
point represents the mean of fold change + SD of luciferase activity compared to non-transfected, 
normoxic HKC-8 cells without TGF-b1 treatment. Two-way ANOVA was used to detect difference in 
the means across all groups. Further multiple comparison was performed using Bonferroni post-hoc 
analysis to test for statistical significant difference between groups. 
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5.2.9. Inhibition of miR-21 prevents SMAD7 suppression 
I have provided evidence establishing a link between ischaemia, miR-21 up-regulation, 
SMAD7 down-regulation, and subsequent sensitivity of TGF-b1 signalling pathways. Firstly, 
the effect of miR-21 inhibition on SMAD7 was investigated by transfecting HKC-8 cells with 
anti-miR-21, and compare the result of transfecting the cell with miR-21 mimic. As shown 
previously, over-expression of miR-21 lead to suppression of SMAD7. Expectedly, this was 
not seen in cells treated with anti-miR-21. Inhibition of miR-21 did not result in an increase of 
SMAD7 expression (see Figure 5-19).  
 
Figure 5-19 The effect of miR-21 inhibition on SMAD7 expression in normoxic HKC-8 cells  
Western blot for SMAD7 in normoxic HKC-8 cells. Cells were transfected with miR-21 inhibitor 
(anti-miR-21) and compared to SMAD7 expression in cells transfected with miR-21 mimic. MiRNA 
inhibitor with non-coding nucleotide sequence (NC-anti) and scrambled sequence miRNA mimic 
(NC-mimic) were used as controls. The band intensity was quantified using ImageJ software. 
Experiment were performed using lysates from three different cells (N=3), except for NC-mimic cells 
(N=2). Each bar illustrates the quantified intensity of SMAD7 band relative to the intensity of 
GAPDH. Data was displayed as the mean of relative intensity + SD. Comparison of the means 
between treatment groups was performed using one-way ANOVA followed by Bonferroni post-hoc 
analysis (* = p ≤0.05; ** = p ≤0.01; ns = no significant difference detected) 
To assess whether inhibition of miR-21 would prevent post-ischaemic SMAD7 down-
regulation, HKC-8 cells transfected with miR-21 inhibitor (anti-miR-21) followed by 
incubation in 1% O2 for 24-hour to simulate hypoxia. Without anti-miR-21, hypoxia 
supressed SMAD7 expression. This down-regulation of SMAD7 was not observed in the cells 
transfected with anti-miR-21 (Figure 5-20).  
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Figure 5-20 The effect of miR-21 inhibition on SMAD7 expression in hypoxic HKC-8 cells  
Western blot for SMAD7 in hypoxic HKC-8 cells. Cells were transfected with either miR-21 inhibitor 
or miRNA inhibitor with non-coding nucleotide sequence (denoted as NC-anti). Band intensity was 
quantified using ImageJ software. SMAD7 expression in cells with miR-21 inhibitor of each treatment 
group was compared to SMAD7 expression of its respective non-coding antimiR control. Experiment 
were performed using lysates from three different cells (N=3). Each bar illustrates the quantified 
intensity of SMAD7 band relative to the intensity of GAPDH. One-tailed t-test was used to compare 
the means in each treatment group (** = p ≤0.01) 
 
The same experiment was repeated with the addition of lysates of HKC8 cells 
transfected with non-coding miRNA inhibitor incubated in normoxic condition to compare 
the expression of SMAD7 after anti-miR-21 treatment following hypoxia to the basal level of 
SMAD7 at normoxic condition. The results showed that treating hypoxic TECs with anti-
miR-21 brought the level of SMAD7 expression back to its basal level at normoxia (see 
Figure 5-21). 
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Figure 5-21 SMAD7 expression in hypoxic cells treated with anti-miR-21 and in normoxic cells 
Western blot for SMAD7 in hypoxic HKC-8 cells treated with anti-miR-21 (denoted as antimiR-
21+hypoxia). Expression level was compared to hypoxic HKC-8 cells transfected with non-coding 
miRNA inhibitor (denoted as NC-anti+hypoxia). Hypoxia was simulated by incubating the cells in 
1%O2 for 24-hour. Basal SMAD7 level during normoxia was represented by HKC-8 cell transfected 
with non-coding miRNA inhibitor (denoted as NC-anti+normoxia). Each band represents protein 
lysate prepared in an independent experiment (N=2 for NC-anti+normoxia and N=3 for other 
treatment groups). Band intensity was measured using ImageJ software, relative to the expression of 
GAPDH. Data was presented as the mean of relative intensity + SD. One-way ANOVA test with 
Bonferroni multiple comparison test was used to detect statistical significance (* = p ≤0.05; ns = no 
significant difference detected) 
5.2.10. Inhibition of miR-21 prevents post-ischaemic SMAD3 activation 
The effect of miR-21 inhibition in preventing hypoxia-induced down-regulation of 
SMAD7 has been shown in the previous section. The next objective was to test whether miR-
21 inhibition also resulted in decreased activation of SMAD3. For this purpose, I used HKC-8 
cells stably transfected with SMAD3-luciferase reporter plasmid. These cells were co-
transfected with anti-miR-21, miR-21 mimic, non-coding antimiR, and miRNA mimic with 
scrambled nucleotide sequence. The transfected cells were incubated in 1% O2 to simulate 
hypoxia, or co-transfected with HIF-1a plasmid to resemble post-ischaemic increase in HIF-
1a.  
Previous experiments showed that hypoxia alone increased SMAD3-luciferase activity 
in HKC-8 cells, and the addition of miR-21 mimic was shown to further increase SMAD3 
activation. Introduction of anti-miR-21 to hypoxic cells showed the opposite effect, lowering 
SMAD3-luciferase activity by approximately 2-fold (Figure 5-22). The effect of modifying 
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miR-21 activity was also assessed using HKC-8 cells containing SMAD3-luciferase reporter 
gene, which were co-transfected with HIF-1a plasmid. Cells over-expressing miR-21 led to 
higher SMAD3-luciferase activity compared to scrambled mimic miRNA-transfected cells. 
Similarly, inhibiting miR-21 reduced SMAD3 activity compared to transfecting the cells with 
non-coding miRNA inhibitor (Figure 5-23).  
The effect of miR-21 mimic or inhibitor transfection was insignificant in the absence of 
hypoxic injury or HIF-1a over-expression. This is the finding from experiments using the 
same clone of HKC-8 cells incubated in normoxia for 24-hour, and by transfecting the cells 
with control plasmid, pCDNA. Although miR-21 mimic increased SMAD3-luciferase 
activity, and its inhibition reduced SMAD3 activity in normoxic cells, the magnitude of their 
changes was not statistically significant (Figure 5-24).     
 
 
Figure 5-22 The effect of modifying miR-21 function on SMAD3 activity in hypoxic HKC-8 cells  
SMAD-3 luciferase activity in HKC-8 cells incubated in 1% O2 for 24-hour. Cells were transiently 
transfected with either miR-21 mimic or anti-miR-21 prior to induction of hypoxia. Cells transfected 
with non-coding sequence antimiR (denoted as NC-anti) and non-coding miRNA mimic (denoted as 
NC-mimic) were used as controls respectively. Luciferase activity for each group was normalised to 
protein concentration. Data was presented as the mean fold change of luciferase activity + SD from 
three replicates. Result presented is from a single experiment representatives of N=3.  To test for 
statistically significant difference between the means, One-way ANOVA test was used, followed by 
Bonferroni post-hoc analysis. (** = p ≤0.01; **** p ≤0.0001) 
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Figure 5-23 The effect of miR-21 inhibition on SMAD3 activity in HIF-1a-transfected HKC-8 
cells  
SMAD-3 luciferase activity was measured in HKC-8 cells over-expressing HIF-1a following 
transfection of these cells with miR-21 inhibitor and miR-21 mimic. Luciferase activity was compared 
to the luciferase activity of cells containing HIF-1a plasmid, which were transfected with non-coding 
sequence antimiR (denoted as NC-antimiR+HIF) and non-coding miRNA mimic (denoted as NC-
mimic+HIF). Luciferase reading for each group was normalised to the total protein concentration 
quantified in the sample. Data was presented as the mean fold change of luciferase activity + SD from 
three replicates. Result presented is from a single experiment representatives of N=3.  One-way 
ANOVA and subsequent Bonferroni multiple comparison tests were used to test for statistically 
significant difference between the means (** = p ≤0.01; **** p ≤0.0001).  
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Figure 5-24 The effect of miR-21 inhibition on SMAD3 activity in normoxic HKC-8 cells  
The mean fold change of luciferase activity + SD from SMAD-3 luciferase HKC-8 cells grown in 
normoxic conditions (top), and SMAD-3 luciferase HKC-8 cells transfected with pCDNA as control 
plasmid (bottom). Data was the result of three replicates. Result presented is from a single experiment 
representatives of N=3.   Cells were transiently transfected with either miR-21 mimic, anti-miR-21, 
non-coding mimic (denoted as NC-mimic) or non-coding anti-miR (NC-antimiR). One-way ANOVA 
test was applied, followed by Bonferroni post-hoc analysis, which showed no statistical significant 
difference between the groups 
 
 
162 
5.2.11. Tissue Expression and Distribution of miR-21 
Evaluation of miR-21 distribution and level of expression in ischaemic renal tissue is 
essential to verify the in vitro findings. To achieve this objective, I compared miR-21 
expression using real-time qPCR using RNA isolated from ischaemic and non-ischaemic 
renal tissue. The range of miR-21 expression was considerably wide in both groups, 
especially in the ischaemic group. Nevertheless, it was obvious that miR-21 expression level 
was significantly higher in ischaemic tissue compared to miR-21 expression in non-ischaemic 
renal tissue (Figure 5-25).   
 
 
Figure 5-25 Mir-21 expression in ischaemic and non-ischaemic renal tissue 
Expression level of miR-21 as measured using real-time qPCR. The unaffected part of kidneys 
removed for oncological indication was used for non-ischaemic tissues, whilst ischaemic tissues were 
derived from kidneys deemed unsuitable for transplantation with cold ischaemia time of more than 24-
hour. Data was presented as the mean relative expression of miR-21 (2-ΔCT) to the reference gene 
RNU48. There were 10 kidneys included in non-ischaemia group (N=10), and ten kidneys included in 
ischaemia group (N=10). To test for statistical significance, comparison of the means was performed 
using one-tailed t-test. (**** =  p ≤0.0001) 
Qualitative assessment of miR-21 distribution in renal tissue was performed using in 
situ hybridisation (ISH). Three specimens were randomly selected from each ischaemic and 
non-ischaemic kidney group. The tissues were incubated in hybridisation mixture containing 
DIG-labelled miRNA probe for miR-21or DIG-labelled probe with random sequence. I 
presented the results as individual comparison of three paired specimens (Figure 5-26, Figure 
5-27, Figure 5-28). The pairing between a sample from ischaemic kidney group and a sample 
from non-ischaemic kidney group was performed randomly.  Thus, any sample from the 
ischaemic kidney was eligible to be paired with any of the non-ischaemic kidney samples.   
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Figure 5-26 and Figure 5-27 show that the expression of miR-21 was stronger in 
ischaemic renal tissue. It was also shown that miR-21 was predominantly detected in tubular 
cells. In both figures, miR-21 was undetectable in the non-ischaemic renal tissues. As 
expected, there was no staining using for scrambled miRNA sequence, indicating no non-
specific binding of the probes. Figure 5-28 also showed marked miR-21 expression in the 
ischaemic tissue. However, this figure showed that miR-21 staining was also observed in the 
non-ischaemic tissue. MiR-21 expression in Figure 5-28 was also shown to be limited to 
tubular cells.  
 
 
Figure 5-26 Distribution of miR-21 in ischaemic and non-ischaemic renal tissue – comparison 1 
MiR-21 distribution in human renal tissue by in situ hybridisation. Ischaemic and non-ischaemic renal 
tissues were incubated in hybridisation mixture containing 80nM of DIG-labelled ISH probe for miR-
21 sequence, or 80nm of DIG-labelled probe with scrambled nucleotide sequence. Anti-DIG antibody 
conjugated with Alkaline Phosphatase (AP) was subsequently applied, followed by the addition of 
NBT-BCIP substrate to allow visualisation of miRNAs. Nuclei were stained using nuclear fast red 
staining. Images were captured at 200x magnification.  
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Figure 5-27 Distribution of miR-21 in ischaemic and non-ischaemic renal tissue – comparison 2 
In situ hybridisation for miR-21 in ischaemic and non-ischaemic renal tissue. Hybridisation mixture 
containing DIG-labelled miRNA probe for miR-21 and DIG-labelled scrambled sequence miRNA 
probe were applied to both tissues. Anti-DIG antibody coupled with AP was applied following probe 
incubation. To visualise miRNA, NBT-BCIP substrates was added. Nuclei were counter-stained using 
fast red nuclear staining.  Images were captured at 200x magnification. 
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Figure 5-28 Distribution of miR-21 in ischaemic and non-ischaemic renal tissue – comparison 3 
In situ hybridisation to detect the presence of miR-21. DIG-labelled probe for scrambled miRNA 
sequence was used as comparison. Probe bound to miRNA of interest were visualised by adding anti-
DIG antibody conjugated to AP followed by the addition of NBT-BCIP substrate. Fast red nuclear 
staining was used. Slides were visualised at 200x magnification. 
 
5.3. Discussion 
5.3.1. Establishing the miR-21 – SMAD7 – SMAD3 axis in the renal response to ischaemia 
The involvement of miR-21 in the renal response to IRI has been suggested from the 
miRNA profiling results. Computational prediction of miRNA targets has also identified 
various pathways and genes, which may be regulated by miR-21. Ideally, it will be possible to 
investigate miR-21 involvement in all the pathways relevant to the renal response to IRI, such 
as PI3K-Akt, HIF-1a signalling and TGF-b signalling pathways. Previous studies performed 
in our laboratory have shown that hypoxia is associated with changes in cell phenotype, 
potentially contributing to the progression of injury, and deterioration in renal function. These 
post-ischaemic morphological changes were closely associated with activation of the TGF-b 
signalling pathway. Several publications have reported that SMAD3 may regulate the 
expression of miR-21 (Zhong et al., 2011).  In addition, studies on diabetic nephropathy have 
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described how miR-21 can target SMAD7, and that this is correlated with worse renal 
structure and function (Wang et al., 2014b; McClelland et al., 2015). However, there is no 
data on the effect of miR-21 changes following ischaemia on the activity of TGF-b signalling, 
and how this may affect cellular phenotype. This was the main reason for focusing this part of 
the study on elucidating the link between miR-21 up-regulation after IRI to alteration in TGF-
b signalling activity, and potentially subsequent tubular cell morphological changes.  
The TargetScan database predicted a near-perfect complementary interaction between 
miR-21 and its predicted target site in the 3’ UTR of SMAD7 mRNA, suggesting a potentially 
strong inhibitory effect on SMAD7 function by miR-21. This inhibition of SMAD7 by miR-
21 in renal tubular epithelial cells was previously documented by Lin et. al. (Lin et al., 2014). 
Using rat tubular epithelial cell line, Lin et. al showed inhibition of SMAD7 protein following 
transfection with lentivirus over-expressing miR-21. I verified this finding in a human tubular 
epithelial cell line, HKC-8, using a different transfection method. The expression of SMAD7 
was lower in human tubular epithelial cells over-expressing miR-21. The implication of lower 
SMAD7 levels in renal tubular cell, however, has not been well described. Rat tubular cells 
with miR-21 over-expression and low SMAD7 protein levels showed inhibited proliferation 
compared to normal cells (Lin et al., 2014). In a high glucose environment rodent tubular 
epithelial cells, inhibition of SMAD7 by miR-21 enhanced TGF-b1 activity (McClelland et 
al., 2015). I tested whether this link between miR-21, SMAD7 and activation of TGF-b 
pathways was also present in an in vitro model of IRI using human tubular epithelial cell 
lines. Using immunofluorescence, I showed that intra-nuclear localisation of SMAD3 
occurred in cells over-expressing miR-21. This complements the findings observed by 
McClelland et. al., which showed increased phosphorylation of SMAD3 in miR-21 mimic 
transfected rat tubular epithelial cells.  
Further, I also explored whether SMAD3 translocation into the nucleus resulted in an 
increase in the SMAD3/TGF-b activity. In the absence of exogenous TGF-b, miR-21 
transfected cells did not show significantly more SMAD3-luciferase activity compared to the 
control groups. Addition of even very low concentration of TGF-b, however, caused a 
significant increase in SMAD3-luciferase activity in miR-21 mimic-transfected cells, but not 
in cells transfected with scrambled miRNA mimic or non-transfected cells. Interestingly, 
TGF-b has also been shown to play role in the regulation of miR-21. In a breast carcinoma 
cell line, mutation in the kinase domain of the TGF-b receptor type 1, which inhibits TGF-b 
signalling, has been shown to reduce pre-miR-21 expression, but not pri-miR-21. This 
suggests the contribution of TGF-b in maintaining high miR-21 levels in tumour cells in an 
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autocrine fashion (Davis et al., 2008). SMAD proteins have also been shown to interact with 
RNA helicase p68, which is a critical sub-unit of the DROSHA microprocessor complex. In 
addition, SMAD3 knock-out mice also showed reduced miR-21 expression, again suggesting 
the involvement of SMAD3 in the up-regulation of miR-21.  
In a normoxic environment, inhibition of SMAD7 by miR-21 alone was not enough to 
cause significant alteration to TGF-b activity. The presence of an injury, such as ischaemia, 
plays a major role in determining if miR-21 up-regulation resulting in an increase in TGF-b 
activity. The results showed that simulation of hypoxia by 24-hour incubation in hypoxic 
chamber, or conditions mimicking hypoxia by CoCl2 treatment, or transfection of HIF-1a 
plasmid, also led to inhibition of SMAD7 and sensitisation of HKC-8 cells to TGF-b. This 
finding establishes that post-ischaemic miR-21 up-regulation inhibits SMAD7, which has the 
potential to relieve the inhibition of TGF-b activity. However, the interaction between 
ischaemia, miR-21 and TGF-b/SMADs activation is more complex, and may involve 
numerous feedback auto-regulatory mechanisms (Figure 5-29). Several reports have 
suggested inter-dependence between HIF-1α and SMAD3. Some authors have documented 
that HIF-1α induced by hypoxia activates the TGF-b/SMAD3 pathway, which may up-
regulate genes related to fibrosis (Kimura et al., 2008; Kushida et al., 2016). In contrast, other 
reports have not found that hypoxia alone activates SMAD3, but instead showed that SMAD3 
plays a role in stabilising HIF-1α (Basu et al., 2011). In addition, HIF-1a has also been 
suggested to occupy direct binding sites on the miR-21 promoter (Liu et al., 2014), which in 
part also lead to an increase in HIF-1α. MiR-21 has been also shown to regulate PTEN, a 
suppressor of Akt pathway (Liu et al., 2014; McClelland et al., 2015). Inhibition of PTEN 
will increase Akt pathway activity, leading to an increase in its down-stream products, such as 
HIF-1α. Available evidence, therefore suggests that there is an established link between 
ischaemia, miR-21 and SMADs signalling. In ischaemia, SMAD7 is down-regulated leading 
to an increase in SMAD3 activity. In addition, the increase in SMAD3 activity will directly 
up-regulate miR-21, completing a positive feedback system which makes the injured cell 
more sensitive to TGF-b. 
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Figure 5-29 The proposed link between ischaemia, miR-21 and TGF-β 
 
The role miR-21 in TGF-β pathway and hypoxia was further confirmed in the 
experiments using miR-21 inhibitor. Inhibiting miR-21 was shown to prevent the down-
regulation of SMAD7 following exposure to either TGF-β or hypoxia. In hypoxia, 
stabilisation of HIF-1α may lead to increased SMAD3 activity, due to the interdependence of 
HIF-1α and TGF-β pathways (Basu et al., 2011). The addition of miR-21 inhibitor in these 
cells significantly reduced SMAD3 activity. In normoxic cells, this significant reduction in 
SMAD3 activity was not seen, primarily due to the absence of an injury to elevate the 
baseline SMAD3 activity level. In the mouse model of diabetic nephropathy, the introduction 
of miR-21 inhibitor has been shown to increase E-cadherin expression and lower α-SMA 
level (Wang et al., 2014b). 
5.3.2. Modification of MiR-21 Expression in Normal vs Disease 
The results from experiments using miR-21 mimic or inhibitor during normoxia and 
hypoxia showed that the effect of modifying miR-21 expression is especially greater when the 
cells were under stress. This has also been documented in an in vivo mouse model. Microarray 
analysis of healthy kidneys from miR-21 knocked-out mice showed similar genetic 
expression of predicted miR-21 targets to wild-type mouse. However, differences were only 
seen after obstruction of the ureter or after induction of IRI (Chau et al., 2012). This is further 
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supported by Androsavich et al., which showed that miR-21 strongly degraded its mRNA 
targets in cancer cells, but not in healthy mouse liver (Androsavich et al., 2012). Although 
there has been no satisfactory explanation for this, it has been proposed that the difference in 
miR-21 activity in normal and disease condition may be closely related to its low 
thermodynamic stability and low abundance of its target genes (Androsavich et al., 2012).  
Specifically, for the experiments in this study, the differences in miR-21 effect in 
hypoxic and normoxic conditions may also be related to the level of pre-existing endogenous 
TGF-β1 induced during hypoxia. The results suggest that miR-21 was not the initiator of 
injury progression, but rather, act as a mediator which sensitised cells to TGF-β1. The higher 
level of pre-existing TGF-β1 is, therefore, associated with greater changes facilitated by miR-
21. 
5.3.3. MiR-21 and changes in TEC morphology 
Changes in epithelial cells morphology has been identified as a contributing factor in 
the progression and deterioration of function in various kidney pathologies. Tissue analysis 
from diabetic nephropathy rat models showed increased in miR-21 expression, which was 
associated with increased in Collagen type 1, fibronectin, α-SMA, and decreased in E-
cadherin expression in renal epithelial cells (Zhong et al., 2011; McClelland et al., 2015). 
Similarly, this was also observed in tissue and cells isolated after unilateral ureteric 
obstruction (UUO). Increased miR-21 expression was detected in the ligated mouse kidney, 
which was also shown to have higher expression of α-SMA, fibronectin, and collagen type I 
and IV (Zhong et al., 2011). Furthermore, introducing miR-21 inhibitor agent to the 
obstructed kidney was shown to reduce the level of TGF-β1, as well as the expression of 
fibrotic markers, such as α-SMA, fibronectin, and collagen type I (Zarjou et al., 2011). 
In the absence of any pathology, such as high glucose level, or artificially-induced 
interstitial fibrosis, the effect of miR-21 expression on tubular cell morphology has not been 
described previously. My initial experiment using miR-21 mimic-transfected cells without the 
addition of exogenous TGF-b revealed no changes in the expression of E-cadherin and α-
SMA. Thus, as suggested by the result of SMAD3-luciferase experiment, it appeared that 
addition of TGF-b was required to induce potentially detectable changes. For this purpose, a 
low concentration of TGF-β was used, which was sufficient to initiate some phenotypic 
changes, but not completely alter the normal cellular morphology. In the presence of 
exogenous TGF-β, the expression of fibrotic markers represented by α-SMA and Collagen 
type 1 were significantly increased by over-expressing miR-21. This was accompanied by 
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down-regulation of the epithelial marker E-cadherin. These findings strengthen the argument 
that miR-21 may have a deleterious effect in renal tubular cells, particularly in combination 
with an increased level of TGF-β or in the presence of an injury, such as hypoxia.   
5.3.4. Post-ischaemic miR-21 expression and distribution in cellular sub-population of the 
kidney 
So far, in vitro results have shown that miR-21 level of expression was higher in 
ischaemic PTECs than in normal PTECs. To validate whether this also occurred in vivo, 
comparison was made between severely hypoxic renal tissue and non-ischaemic tissue. The 
severely ischaemic tissues were obtained from kidneys which were deemed unsuitable for 
transplantation for various reasons, and had been in cold ischaemia for more than 12 hours. 
Despite being grouped under ‘non-ischaemic tissues’, the kidney tissues used as comparison 
were obtained from macroscopically normal section of kidneys removed for oncological 
indications, thus will to have experienced a brief period of ischaemia. This could explain the 
result in comparison 3 (Figure 5-28), which detected miR-21 in the non-ischaemic kidney. In 
addition, miR-21 has also been linked with malignancy in the kidney, such as renal cell 
carcinoma. This could also explain the detection of miR-21, even in the non-ischaemic 
kidney. Nevertheless, real-time qPCR results still showed significant difference in miR-21 
expression between the two-groups, which clearly suggests that ischaemic injury increases 
miR-21 expression.   
Most miRNA profiling studies in the kidney focused their investigation primarily on 
tubular epithelial cells of the kidney, and indeed documented high level of miR-21 expression 
in this sub-population of cells. The results of miR-21 in situ hybridisation presented in this 
chapter also showed that miR-21 was detected mainly in tubular cells, and not in the 
glomerulus. Moreover, the result of several studies focusing on the role of miRNAs in 
glomerular injury did not detect significantly levels of miR-21 in the glomerulus (Kato et al., 
2012; Trionfini and Benigni, 2017). This does not imply that miR-21 has no regulatory 
function in other cell populations within the kidney. In fact, miR-21 has been shown to 
repress pro-apoptotic activity, resulting in inhibition of podocyte loss following TGF-β 
stimulation or in hyperglycaemic glomerular injury. This in part suggests that the effect of 
miR-21 in the glomerulus is the opposite of its effect in tubulo-interstitial cells (Lai et al., 
2015).  
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In conclusion, I have shown that post-ischaemic miR-21 lead to PTEC sensitisation to 
TGF-β through a complex regulatory feedback involving SMAD7, SMAD3 and HIF1-α. In a 
relatively physiological state, or when an injury was transient and tolerable, this is expected to 
facilitate cellular recovery and survival. When the injury was repetitive or severe, the 
interaction between miR-21, SMADs signalling and HIF may contribute to the worsening of 
the effect of the initial injury, resulting in the changes of cellular morphology and 
fibrogenesis. In kidney transplant settings, the outcome of this interaction becomes more 
complex and harder to predict, as the organ is more susceptible to injury due to various 
contributing factors, such as pre-existing morbidities, the use of nephrotoxic medications and 
the degree of ischaemic and reperfusion injury. 
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Chapter 6. Thesis Summary 
6.1. Summary of Aims and Outcomes 
6.1.1. Profiling and Identifying Key MiRNAs Involved in the Renal Response to IRI 
In this study, I have identified that ischaemia (induced by treating the cells in 1% O2 
incubator for 12-hour) or ROS treatment (given in the form of H2O2 treatment) induced 
changes in miRNA expression on PTECs. The changes in miRNA expression were detected 
using a microarray platform, NanoString, and was validated using real-time PCR.  
Using different tubular epithelial cell types, I have shown that these changes were 
unique to different cell types, and especially distinct between cell lines and human primary 
cells. This is evident from the analysis of the pattern of changes, which showed that most 
detectable changes in miRNA occurred only in cell line, but not in primary cells, or only in 
primary cells, but not in cell lines. The findings have also shown that different type of injury 
left distinct pattern of miRNA changes in cells.  Despite the difference in miRNAs pattern in 
different cells or different injury, a number of miRNAs were found to be consistently up- or 
down-regulated in all cells at a given time point, suggesting their common involvement in 
renal response to IRI. These identified miRNAs include miR-21, miR-34a, miR-363, miR-
210, miR-142 and miR-130b. These miRNAs were considered as key miRNA candidates to 
be explored and validated further.  
Multiple computational miRNA target prediction databases were used to predict the 
target of these miRNAs, which highlighted their involvement in pathways related to the renal 
response to IRI, such as HIF-signalling pathway and TGF-b signalling pathway. The potential 
role of miR-21 and miR-34a are especially of interest, as the change of expression in both 
miRNAs were shared consistently by all cell types used in this study. Interestingly, other 
authors have also reported the involvement of miR-21 and miR-34a in various disease 
processes in the kidney, unrelated to IRI or kidney transplant setting. This indicates that both 
miR-21 and miR-34a play essential roles in various cell regulatory mechanisms and function 
in the kidney.   
6.1.2. Functional Analysis of miR-21 
MiR-21 was selected to be the focus of this project due to its expression profile pattern 
in all PTEC types used in this study. Furthermore, despite being frequently investigated for its 
role in various kidney pathologies, lack of overlap and conflicting research findings has 
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limited the potential utilisation of miR-21. I was particularly interested in the consequence of 
miR-21 up-regulation following ischaemia or ROS treatment. The literature has reported that 
an association between high miR-21 expression with biopsy proven interstitial fibrosis/tubular 
atrophy (Ben-Dov et al., 2012; Wilflingseder et al., 2013). Others have also associated miR-
21 increase to kidney pathologies resulting from a relatively long-term exposure to injury, 
such as chronic hypoxia or diabetic nephropathy (McClelland et al., 2015).  
The change in miR-21 level of expression in this study was detected after exposure to a 
short-term and transient injury, indicating its role, even in early renal response to injury. The 
effect of miR-21 up-regulation was then investigated in vitro using miR-21 mimic 
transfection to over-express mature miR-21, or by transfection of anti-miR-21 to inhibit miR-
21 production. The link between ischaemia, miR-21 and TGF-b signalling pathway was 
especially interesting, as previous work by our group has shown that ischaemia may lead to 
modification in PTEC phenotype through TGF-b pathway activity. SMAD7 was predicted 
and validated as the target for miR-21. In this study, I observed that up-regulation in miR-21 
after ischaemia has led to suppression of SMAD7 and an increase in SMAD3 activity in a 
renal PTEC cell line. However, the effect of miR-21 up-regulation did not have a significantly 
detectable consequence in a physiological setting, or in the absence of additional injury, such 
as ischaemia. In hypoxic cells, over-expression of miR-21 in PTEC showed significantly 
higher SMAD3-luciferase activity compared to cells with no miR-21 over-expression. Over-
expression of miR-21 in PTEC appeared to have sensitised the cells to exogenous TGF-b1, 
indicated by significantly higher SMAD3-luciferase activity in these cells compared to the 
cells transfected with non-coding miRNA mimic or the non-transfected cells.  
Furthermore, this study has also shown that changes in PTEC phenotype was also 
exaggerated when miR-21 was over-expressed in PTEC. Treatment with 1ng/mL of TGF-b1 
resulted in a reduced E-cadherin expression and an increase in a-SMA and Collagen type 1 
expression in PTEC. When this was combined with miR-21 over-expression, the reduction of 
E-cadherin and the increase in a-SMA and Collagen type 1 were shown to be more obvious.  
The link between ischaemia, miR-21 and SMADs activity was further established by 
the results from experiments using hypoxic PTEC or by simulating the effect of hypoxia using 
HIF-1a transfection or CoCl2 treatment. These cells showed higher miR-21 level, lower 
SMAD7 expression and a significant increase in SMAD3-luciferase activity compared to their 
normoxic controls. These consequences of hypoxia or mimicking hypoxia effect were 
prevented by transfecting the cells with anti-miR-21.  
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6.1.3. In vivo Validation 
Post-ischaemic increase in miR-21 was validated in this study using real-time PCR and 
ISH in non-hypoxic and severely hypoxic renal tissues. The expression of miR-21 was 
significantly higher in hypoxic renal tissues. ISH results further confirmed that miR-21 was 
selectively distributed in the tubular cells of the kidney. Overall, the objectives and results of 
the study is summarised in Figure 6-1 . 
 
 
Figure 6-1 Project summary 
Schematic illustration of the objectives, steps, and results obtained in this study. 
6.2. Overall Discussion 
6.2.1. Study Implications 
This study has highlighted that short-term and transient ischaemic injury or induction 
of free-radicals has a clear effect in altering miRNA profile in different types of PTECs. To 
my knowledge, this is the only study available, which compared the expression of miRNAs in 
different PTEC cell types following IRI. Significant differences in miRNA profiles following 
IRI in cell line and PTECs implies that relying on cell lines alone may not be an ideal method 
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to perform a miRNA profiling study. Thus, careful measures should be taken when 
extrapolating miRNA profile in immortalised cell lines to human primary cells. The use of 
four different types of cells has enabled a selective inclusion of candidate miRNAs for further 
validation and functional analysis. Consistent detection of changes in a miRNA in four 
different cell type, as was seen for miR-21 in this study, is a strong supporting evidence to 
highlight the role of that particular miRNA in renal response to IRI.    
Biologically, changes in miRNA level indicate activation of pathways, which serves as 
an effector component of renal response to IRI. In this case, this study has established the 
association between post-ischaemic miR-21 up-regulation to suppression in the activity of an 
inhibitory SMAD7, and subsequent increase in SMAD3 activity. This may serve as a crucial 
response by which PTECs make themselves more sensitive to the presence of growth factor 
(i.e. TGF-b1). This may be aimed to promote repair and facilitate cell survival. However, 
when the injury is repetitive, or when the degree of injury is severe, this may lead to 
continuous activation of a positive feedback mechanism, causing an exaggerated response and 
uncontrolled repair process, which may be detrimental to long-term organ renal function. 
Furthermore, this study adds to the knowledge that the link between miR-21 and TGF-b 
pathway is not only limited to the direct miR-21 regulation by SMAD3. Indeed, this study has 
shown that miR-21 has an important role in regulating TGF-b signalling through SMAD7. 
Moreover, this study has also shown that the interaction between miR-21 and TGF-b in the 
kidney was not only limited to chronic injury or diabetic nephropathy, but also in an IRI 
model.  
6.2.2. Study Limitations 
Although the use of four different cell types has added a different perspective to the 
miRNA profiling results, it must be carefully approached and interpreted. Limitation in time 
and resources have only allowed the use of 24 samples in the initial profiling using 
NanoString. This means that only the primary PTECs could only be run in duplicates. 
Profiling of miRNAs in cell lines (i.e. HK-2 and HKC-8) had to rely only on a single 
experiment. Regardless, validation of the expression of selected key miRNAs using real-time 
PCR has shown consistent results in cell lines, which demonstrated the reproducibility of the 
profiling technique.  
The use of H2O2 in mimicking reperfusion injury has been reported in many studies. 
However, induction of free-radical using H2O2 only simulated a component of reperfusion 
injury. Comprehensively, reperfusion injury consists of other equally important components, 
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such as activation of the immune system. The interaction between tubular cells and the 
immune system is an important determinant of successful renal recovery or progression of 
injury, resulting in deterioration in function. This element of reperfusion has not been 
addressed by the model of reperfusion injury used in this study. This was accepted as the 
consequence of achieving the aim of profiling miRNA profile in PTECs as two separate 
injuries, in order to discover the potentially unique miRNA signature changes.      
In vivo validation of miR-21 expression in this study was performed on tissues 
originated from severely ischaemic kidney rejected for transplant, which were compared to 
the non-ischaemic tissues taken from the normal poles of kidney removed for oncological 
reasons. Although the expression of miR-21 was significantly different between these tissues, 
it would be more ideal to use a relatively healthy renal tissue for control, such as tissues from 
living donor. As has been reported, miR-21 may also be up-regulated in renal cell carcinoma, 
which could be a potential confounding factor.  
6.2.3. Challenges in microRNA Research 
The discovery of miRNAs has opened a rapidly growing research field. Initial technical 
challenges have been overcome by novel methodologies or modifications of existing 
technologies. Despite these efforts, miRNA research still faces significant obstacles. 
Increasing number of miRNA research has identified the complexity of miRNA biology, their 
regulatory roles and the intricate nature of miRNA-mRNA interaction. This complexity will 
influence the way we interpret, translate and apply available research findings. 
Despite the abundance of miRNA profiling studies and mechanistic experiments 
linking miRNAs to certain disease processes, little progress has been made in understanding 
the biology of miRNAs themselves. MiRNAs have been shown to be modified and interact 
with other epigenetic events, which will affect their capability to bind with mRNA (Kim et 
al., 2010; Yu and Chen, 2010; Singh and Campbell, 2013).  Moreover, it is becoming more 
widely accepted that the regulation of miRNA biogenesis does not take place by a single 
universal mechanism. Instead, different classes of miRNAs may undergo different processing, 
regulation and turnover (Davis and Hata, 2009). The details of these mechanisms and their 
biological consequences remain largely unknown. 
A published work on oncogenes by Poliseno et al. described functional role of 
pseudogenes, which were previously thought to be redundant (Poliseno et al., 2010). 
Pseudogenes are the transcripts of protein-coding genes, which are highly homologous to 
their cognate genes, except for several base pairs mismatches. Given this homology, 
pseudogenes compete with their respective mRNA for miRNA binding, acting as a ‘miRNA 
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decoy’, thus may be involved in disease pathogenesis (Poliseno et al., 2010; Bernardo et al., 
2012). This miRNA-pseudogene interaction complicates our attempt to translate the profile of 
a miRNA of interest to its actual biological role. 
Furthermore, different miRNAs may undergo maturation through different pathways. 
In contrast to the general miRNA maturation process, some miRNAs undergo maturation 
independent of Drosha or Dicer (Suzuki and Miyazono, 2011; Ha and Kim, 2014). As 
discussed previously, several authors have also documented interaction between miRNA 
maturation pathways and intracellular signalling molecules, nuclear genetic machinery and 
RNA binding proteins (Suzuki and Miyazono, 2011). These complicated interactions should 
be taken into consideration in the interpretation of profiling results or in drawing conclusion 
from an experimental model.    
It has been proven very difficult to assess the influence of a single miRNA to a 
particular cellular process or disease pathway. A cellular biological response or a disease 
process is a result of an orchestrated interaction of many genes requiring fine-tuning by many 
miRNAs. Theoretically, the different miRNAs may be up- or down-regulated to produce a 
synchronised biological effect. In reality, however, detection of such up- or down-regulation 
is not always simple, as the expression of some miRNAs may be altered below a detectable 
threshold, and yet still contributes to a biologically significant effect. Even if the alteration is 
detectable, experimental validation of only a single miRNA will only provide a partial picture 
of an overall biological response. It is almost impossible to design an experimental study that 
can evaluate a net result of numerous miRNAs interacting together to generate a fine-tuned 
cellular response.   
Another level of complexity in miRNA research is added by the discovery made by 
Vasudevan et al. on how miRNA may directly up-regulate gene expression during cell 
quiescence. Quiescence is stimulated by several factors, such as contact inhibition, loss of 
adhesion or serum starvation (Vasudevan et al., 2007). Initially, Vasudevan et al. identified 
two proteins required for translational up-regulation during serum starvation; argonaute 2 
(Ago 2) and fragile-X-mental retardation related protein (FXR1). These two key components 
need to bind to A+U-rich elements (AREs) in the 3’ UTR of TNF-α mRNA to increase its 
translation. The hypothesis that miRNAs may mediate this binding was tested using a 
computational prediction approach, which identified several miRNAs having seed regions 
complementary to TNF-α AREs. Hsa-miR-369-3 was found to be necessary for translational 
up-regulation of the ARE reporter, and that miR-369-3 was reduced in non-quiescent 
HEK293 cells. Whether this is specific to miRNAs targeting only TNF-α mRNA, or in fact 
also takes place in other miRNA-mRNA interaction still requires investigation. However, 
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further observation by the same author on other miRNAs; let7-a and miRcxcr4, showed 
translational down-regulation of their respective target mRNAs only in proliferating cells, but 
not in serum starved milieu (Vasudevan et al., 2007; Rusk, 2008). This finding notably adds a 
different dimension in the design and analysis of miRNA research, but more importantly to 
how miRNAs can be exploited in a specific cellular condition. 
To complicate the matter even further, technological variation in existing profiling 
platforms, differences in bioinformatics criteria and diversity in experimental design used also 
affect the result of different studies addressing the same research question. This is evident in 
the lack of overlapping results shown by many studies performed to investigate the role of 
miRNAs in kidney transplantation and kidney IRI. 
6.2.4. Future Directions 
The miRNA profiling results from this study have nominated several miRNAs with the 
potential to be validated further. The role of a hypoxamiR, miR-210, which can be indirectly 
involved in HIF-1a activity following ischaemia has not been well documented in kidney 
transplant setting, especially in its relation to IRI. Other potential candidates are miR-34a and 
miR-363. The link between miR-34a and the initiation of EMT process after ischaemia can be 
explored further. The role of miR-363 is especially interesting, due to its interaction with 
TWIST pathway and subsequent down-regulation in E-cadherin expression. Interestingly, 
miR-363 has also been linked with genes encoding Collagen and Integrin-b6. Therefore, over-
expression of miR-363 is expected to inhibit the expression of both Collagen and Integrin-b6. 
The resulting effect of this interaction also has the potential to be elucidated further. 
MiR-21 is an important player in renal response to IRI and other renal pathologies. This 
has been documented in vitro as well as in vivo. There are several literatures, which have 
already established an association between the higher expression of miR-21 in tissue or 
plasma to post-transplant graft function. Although these studies are valuable, in my 
perspective, the level of miR-21 in urine appeared to be especially attractive to be used as 
potential biomarker and predictor of graft function. Currently available literatures have 
highlighted the potential use of urinary miR-21 as a biomarker.  They detected that miR-21 is 
up-regulated in mouse hypertensive kidney injury model (Chen et al., 2017), mouse kidney 
fibrosis model (Chen et al., 2017), human renal interstitial fibrosis/tubular atrophy (IF/TA) 
(Wang et al., 2012; Maluf et al., 2014; Zununi Vahed et al., 2017), and in acute kidney injury 
(Saikumar et al., 2012; Du et al., 2013). However, not many studies have documented the use 
of miR-21 as a predictor of graft function in the context of kidney transplant. A report by 
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Maluf et al. (Maluf et al., 2014) did not detect miR-21 to be differentially expressed in urine 
of patients with IF/TA and in patients with normally functioning graft. The other closest 
available data is reported by Khalid et al. (Khalid et al., 2016), which showed significant 
correlation between miR-21 level in hypothermic machine perfusate to graft function at 6 and 
12 months after transplant. Future studies correlating miR-21 level in the urine or plasma 
immediately after transplant to graft function will be important if miR-21 is to be adapted as a 
potential biomarker or predictor.  
6.3. Study Conclusion 
Ischaemia and reperfusion injury induced changes in miRNA profile in renal proximal 
tubular epithelial cells, which is involved in the renal response to IRI. One of the miRNAs 
detected is miR-21, which is involved in the regulation of SMAD signalling following 
ischaemia. Through its interaction with SMAD7 and SMAD3, miR-21 was shown to make 
PTEC more sensitive to TGF-b1, which may be essential in cellular repair process and 
cellular survival. Mir-21 is highly expressed in tubular cells of ischaemic kidneys, further 
emphasising its role in the renal response to IRI. 
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Appendix – NanoString Sample Preparation Protocol 
The following sections describe materials and methods used in the preparation of samples to 
be profiled with NanoString platform, as adapted from the NanoString nCounter miRNA 
Expression Assay Manual. 
 
Materials Required 
1. nCounter miRNA Expression Assay Kit (NanoString Technologies, USA) 
2. DEPC-treated (or RNASse-free) water 
3. 100ng total RNA per sampe, normalised to 33 ng/µl 
4. Spectrophotometer (NanoDrop Technologies, USA) 
5. Micropipettes (0.5-10µl; 2.0-20µl; 20-200µl) 
6. Picofuge with strip-tube adaptor (Applied Biosystem, USA) 
7. Thermocycler (Applied Biosystem, USA) 
8. nCounter Prep Station (NanoString Technologies, USA) 
9. nCounter Digital Analyser (NanoString Technologies, USA) 
 
Thermocycler Protocols 
1. Annealing Protocol 
Temperature :  94°C – 1 minute 
    65°C – 2 minute 
    45°C – 10 minute 
    48°C – hold  
Total time :   13 minute 
2. Ligation Protocol 
Temperature :  48°C – 3 minute 
    47°C – 3 minute 
    46°C – 3 minute 
    45°C – 5 minute 
    65°C – 10 minute 
      4°C – hold 
Total time :   24 minute 
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3. Purification Protocol 
Temperature :  37°C – 2 hours 
    70°C – 10 minute 
      4°C – hold 
Total time :   2 hours 10 minute 
 
Sample Preparation Protocol 
1. RNA sample was normalised to 33 ng/µl using RNAse-free water. 
2. 499 µl RNAse-free water was added to 1 µl of the miRNA Assay Controls provided in 
the kit, in a sterile microcentrifuge tube. Solutions were mixed by vortexing and 
centrifugation at 1,000G for 30 second. The tube was stored on ice. 
3. Annealing master mix was prepared by combining 13 µl of Annealing Buffer, 26 µl of 
nCounter miRNA Tag Reagent and 6.5 µl of the diluted Assay Controls prepared in 
Step 2. Solutions were mixed well by pipetting up and down. 
4. 3.5 µl of the annealing master mix prepared in Step 3 was aliquoted into each tube of a 
12 x 0.2 ml strip tube. 
5. 3 µl (100ng) of RNA sample was added to each tube. The tubes were capped and 
gently flicked to ensure that the solutions were thoroughly mixed. Tubes were 
centrifuged at 1,000G for 30 second. 
6. The tubes strip was placed in a thermocycler and Annealing Protocol (as described in 
Thermocycler Protocol point 1) was initiated. 
7. Ligation master mix was prepared by combining 19.5 µl PEG and 13 µl Ligation 
Buffer. It was important to pipette PEG slowly to ensure accurate transfer of volume 
into the mix, as PEG is viscous. The solutions were mixed well by pipetting up and 
down.  
8. Following completion of the Annealing protocol, when the thermocycler has reached 
48°C, 2.5 µl of the ligation master mix was added to each tube. Thorough mixing of 
the solutions was ensured by flicking the tubes gently, which was followed by 
centrifugation at 1,000G for 30 second. Thermocycler was maintained at 48°C during 
this process. 
9. Tubes were returned to 48°C thermocycler, and were incubated for 5 minute. 
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10. With the tubes still in place in the heating block, 1 µl of Ligase was added directly to 
each tube. Incubation temperature was maintained at 48°C. No mixing required at this 
stage. 
11. Immediately after addition of Ligase to the final tube, tubes were recapped and 
Ligation Protocol (as described in Thermocycler protocol section point 2) was 
initiated.  
12. After Ligation protocol is completed, the tubes were removed from the heat block, and 
1 µl Ligation Clean-Up Enzyme was added into each reaction. To mix, tubes were 
gently flicked followed by centrifugation at 1,000G for 30 second. 
13. Tubes were returned into the thermocycler and Purification Protocol (as described in 
Thermocycler Protocol section point 3) was initiated. 
14. After completion of Purification Protocol, 40 µl of RNAse-free water was added to 
each sample. Ensure samples were thoroughly mixed by pipetting up and down 
followed by centrifugation at 1,000G for 30 second. 
15. Samples were immediately used for miRNA CodeSet hybridisation. 
 
Sample Preparation Protocol 
The final hybridisation reaction contained the following component: 10 µl Reporter CodeSet, 
10 µl hybridisation buffer, a 5 µl aliquot from the miRNA Sample Preparation protocol, and 5 
µl capture ProbeSet. The hybridisation reaction was prepared as follows: 
1. Aliquots of both Reporter CodeSet and Capture ProbeSet reagent were thawed on ice.  
To ensure aliquots were mixed well, the tubes were inverted several times, followed 
by centrifugation at 1,000G for 15 second. 
2. 130 µl of hybridisation buffer was added to the tube containing the Reporter CodeSet 
to create a master mix containing 130 µl of the Reporter CodeSet and 130 µl of 
hybridisation buffer. Tuber were inverted several times to mix, followed by 
centrifugation at 1,000G for 15 second. 
3. A 12-tube strip provided in the kit was labelled and cut in half to fit in a picofuge. 
4. 20 µl of master mix prepared in Step 2 was added into each of the 12 tubes. 
5. Samples from the miRNA Sample Preparation Protocol were denatured by incubation 
at 85°C for 5 minutes and were quickly stored on ice. 5 µl aliquot from the miRNA 
Sample Preparation protocol was added to each tube. 
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6. Thermocycler was pre-heated to 65°C and programmed for 30 µl volume and heated 
lid option. Time setting was programmed to infinite to ensure that the thermocycler 
temperature did not change to 4°C at the end of the run.  
7. 5 µl of Capture ProbeSet was added to each tube immediately prior to placing the tube 
at 65°C. To mix, strip tubes were inverted several times and gently flicked, followed 
by centrifugation at 1,000G for 15 second. It was important that this step was 
performed as quickly as possible, as minimising the time between the addition of the 
Capture ProbeSet and the placement of the reaction at 65°C will increase the 
sensitivity of the assay.  
8. Hybridisation assays were incubated for 16 hours, and left at 65°C until ready for 
further processing in nCounter Prep Station. 
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